CURRICULUM VITAE:

NAME: Christopher John McDougle, M.D.

BORN: Baltimore, MD, February 12, 1959

CHILDREN: Daughters - Meghan and Erin

MAILING ADDRESS: Work: Department of Psychiatry
Indiana University School of Medicine
Institute of Psychiatric Research
791 Union Drive, PR 113
Indianapolis, IN 46202-4887

WORK PHONE: (317) 274-4012

WORK FAX: (317) 278-3762

E-MAIL: cmcdougl@iupui.edu

EDUCATION: 1981 Valparaiso University, Valparaiso, IN, B.A. (Chemistry) (With Highest Distinction)

1986 Indiana University School of Medicine, Indianapolis, IN, M.D. (Medicine) (With Highest Distinction)

CAREER: **Past**:

1986-1987 Intern in Internal Medicine, Norwalk Hospital (in affiliation with the Yale University School of Medicine), Norwalk, CT

1987-1990 Postdoctoral Fellow (Resident) in Psychiatry, Yale University School of Medicine, New Haven, CT

1990-1996 Assistant Professor of Psychiatry, Yale University School of Medicine, New Haven, CT

1990-1997 Chief, Adult Pervasive Developmental Disorders (Autism) Clinic, Clinical Neuroscience Research Unit, Connecticut Mental Health Center, New Haven, CT

1992-1995 Postdoctoral Fellow (Resident) in Child and Adolescent Psychiatry, Yale Child Study Center, New Haven, CT

1994-1997 Chief, Obsessive Compulsive Disorders Clinic, Clinical Neuroscience Research Unit, Connecticut Mental Health Center,

New Haven, CT

1995-1996 Assistant Professor of Child and Adolescent Psychiatry, Child Study Center, Yale University School of Medicine, New Haven, CT

1996-1997 Associate Professor of Psychiatry and Child and Adolescent Psychiatry, Departments of Psychiatry and Child Study Center, Yale University School of Medicine, New Haven, CT

1996-1997 Director, Clinical Neuroscience Research Unit, Connecticut Mental Health Center, New Haven, CT

1997-2000 Raymond E. Houk Professor of Psychiatry (With Tenure), Indiana University School of Medicine

1997-2000 Assistant Chairman for Clinical Services, Department of Psychiatry, Indiana University School of Medicine

Current:

2000- Chairman, Department of Psychiatry, Indiana University School of Medicine

2000- Albert Eugene Sterne Professor of Psychiatry (With Tenure), Indiana University School of Medicine

2000- Executive Director, Institutue of Psychiatric Research, Indiana University School of Medicine

1997- Director, Section of Child and Adolescent Psychiatry, Department of Psychiatry, Indiana University School of Medicine

PROFESSIONAL HONORS:

COLLEGE/MEDICAL SCHOOL:

1979 Alpha Epsilon Delta Pre-Medical Honor Society

1982-1986 Student Research Fellowship in Academic Medicine, Indiana University School of Medicine

1985 Alpha Omega Alpha Honor Medical Society

1985-1986 Arthur B. Richter Scholarship in Child Psychiatry, Indiana

University School of Medicine

1986 John I. Nurnberger, Sr., M.D. Award, Department of Psychiatry, Indiana University School of Medicine (Top Graduating Medical Student in Psychiatry)

1986 Academic Achievement Award, Honors Program in Academic Medicine, Indiana University School of Medicine

RESIDENCY TRAINING:

1987 Samuel Floch Award (Outstanding Intern), Norwalk Hospital

1988-1990 Postdoctoral Fellow, Psychiatry, Biological Sciences Training Program, NIMH

1989 Seymour L. Lustman Research Award, Department of Psychiatry, Yale University School of Medicine

1990 Seymour L. Lustman Research Award, Department of Psychiatry, Yale University School of Medicine

RESEARCH:

1990-1991 Lilly Psychiatric Research Fellowship

1990-1992 NARSAD Young Investigator Award

1991 1st Prize, Research Poster Competition, Destructive Drives and Impulse Control, Fourth International Symposium, Amsterdam, The Netherlands

1992 1st Prize, Obsessive Compulsive Foundation Young Investigator's Award

1994-1996 NARSAD Young Investigator Award (Seaver Investigator Award)

1994 The American Academy of Child and Adolescent Psychiatry Presidential Scholar Award for Research

1997-1999 Theodore and Vada Stanley Foundation Research Award

1997-1999 NARSAD Independent Investigator Award (Seaver Investigator Award)

EDUCATION:

1992	Teacher of the Year, Yale Psychiatry Residents' Annual Award
1997	Teacher of the Year, Yale Psychiatry Residents' Annual Award
2002	Twelfth Annual Nancy C.A. Roeske, M.D., Certificate of Recognition for Excellence in Medical Student Education, American Psychiatric Association
2003	Trustee Teaching Award, Indiana University
2003	Teaching Achievement Award, Department of Psychiatry, Indiana University School of Medicine
2007	Annual Irma Bland Award for Excellence in Teaching Residents, American Psychiatric Association

OTHER:

1994	American Association on Mental Retardation, Region X - Connecticut Chapter, Outstanding Medical Personnel
1995-1999	American College of Neuropsychopharmacology, Associate Member
2001-2009	American College of Neuropsychopharmacology, Member
2005	American Psychiatric Association, Fellow
2009	Frank J. Menolascino Award for Psychiatric Services for Persons With Mental Retardation/Developmental Disabilities, American Psychiatric Association
2010	Distinguished Alumnus Award, Valparaiso University Alumni Association Annual Award, Valparaiso University
2010-	American College of Neuropsychopharmacology, Fellow

HONORARY LECTURESHIPS:

2004	Willard D. Boaz, M.D., Honorary Lecture, Department of Psychiatry, Case Western Reserve University School of Medicine, Cleveland, OH, April 23, 2004

2006	Glenwood Honorary Lectureship on Mental Health, University of Alabama at Birmingham, School of Public Health, Birmingham, AL, April 11-12, 2006.
2008	Distinguished Lecturer Series, University of California Davis, M.I.N.D. Institute, Sacramento, CA, May 20-22, 2008.
2008	Inaugural Daniel X. and Mary Freedman Fellowship Commemorative Lectureship in Academic Psychiatry, Department of Psychiatry, Yale University School of Medicine, New Haven, CT, October 17, 2008.
2009	Distinguished Lecture Series, University of California Los Angeles, Center for Autism Research and Treatment, Los Angeles, CA, June 5, 2009.

PROFESSIONAL LICENSURE:

1987	Diplomate, National Board of Medical Examiners
1988-1998	Licensed Medical Doctor, Connecticut Medical Examining Board, State of Connecticut, License No. 029205
1992	Diplomate, American Board of Psychiatry and Neurology - Psychiatry (No. 036303)
1996	Diplomate, American Board of Psychiatry and Neurology – Child and Adolescent Psychiatry (No. 4102)
2006	Diplomate, American Board of Psychiatry and Neurology – Child and Adolescent Psychiatry (No. 4102) - Recertification
1997-	Licensed Medical Doctor, Health Professionals Bureau, State of Indiana (No. 01047650)

MEMBERSHIP IN PROFESSIONAL SOCIETIES:

Alpha Omega Alpha Honor Medical Society
American Academy of Child and Adolescent Psychiatry
American Association of Chairs of Departments of Psychiatry
American College of Neuropsychopharmacology
American Psychiatric Association
Association for Academic Psychiatry
Indiana Psychiatric Society
Society for Neuroscience
Society of Biological Psychiatry
Society of Professors of Child and Adolescent Psychiatry

JOURNAL REFEREE:

Acta Psychiatrica Scandinavica
Adolescent Health, Medicine and Therapeutics
American Journal of Psychiatry
American Journal on Mental Retardation
Archives of General Psychiatry
Archives of Pediatrics & Adolescent Medicine
Biological Psychiatry
Bipolar Disorders
Brain & Development
Child and Adolescent Psychiatry and Mental Health
Clinical Drug Investigations
Clinical Medicine & Research
Clinical Schizophrenia & Related Psychoses
CNS Drugs
CNS Spectrums
Current Opinion in Investigational Drugs
Current Psychiatry
Depression and Anxiety
Developmental Medicine and Child Neurology
Experimental and Clinical Psychopharmacology
Expert Opinion on Emerging Drugs
Expert Opinion on Pharmacotherapy
Harvard Review of Psychiatry
International Clinical Psychopharmacology
International Journal of Neuropsychopharmacology
Journal of the American Academy of Child and Adolescent Psychiatry
Journal of the American Medical Association
Journal of Autism and Developmental Disorders
Journal of Child and Adolescent Psychopharmacology
Journal of Clinical Psychiatry
Journal of Clinical Psychopharmacology
Journal of Neurochemistry
Journal of Psychiatry and Neuroscience
Journal of Psychiatric Research
Journal of Psychopharmacology
Lancet
Life Sciences
Molecular Psychiatry
Neuropsychopharmacology
New England Journal of Medicine
Pediatrics
Pediatric Drugs
Pharmacogenomics Journal
Progress in Neuro-Psychopharmacology and Biological Psychiatry
Psychiatric Genetics
Psychiatric Times
Psychiatry Research
Psychological Medicine
Psychopharmacology
Psychosomatics

SERVICE TO THE DISCIPLINE:

EDITORIAL POSITIONS:

1997- Member, Editorial Advisory Board, Psychopharm Review (formerly International Drug Therapy Newsletter)

1997- Member, Editorial Board, Biological Psychiatry

1998- Member, Editorial Board, Psychopharmacology

1999-2003 Member, Editorial Board, Journal of Autism and Developmental Disorders

2001- Member, Editorial Board, Journal of Child and Adolescent Psychopharmacology

2002- Member, Editorial Board, The Brown University Psychopharmacology Update

2003- Associate Editor, Journal of Autism and Developmental Disorders

ADVISORY POSITIONS:

1997- Member, Autism Society of America Foundation Advisory Board

2000-2008 Member, Scientific Advisory Board, Anxiety Disorders Association of America

2001-2005 Member, Anxiety Disorders Association of America, Trainee Travel Awards Selection Committee

2003 Member, Anxiety Disorders Association of America, Poster Abstract Review Committee

2004-2005 Member, Indiana Medicaid Mental Health Pharmacy Partnership Advisory Board

2006-2008 Member, Anxiety Disorders of America, Junior Faculty Research Grant Selection Committee

GRANT REVIEWS:

2001 Member, Development of Innovative Treatment Approaches to Autism RFA ZRGI SSS-C 01 Ad Hoc Scientific Review Group, National Institutes of Health, July 24, 2001.

2001 Member, Behavioral Science Track Award for Rapid Transition (B/START) Program PA: MH 00-119 Ad Hoc Scientific Review Group, National Institute of Mental Health, July 31, 2001.

2002 Member, Interventions Review Committee, Special Emphasis Panel, ZMHI ITV-D015, National Institute of Mental Health, June 4, 2002.

2003 Member, Interventions Review Committee, Special Emphasis Panel, ZMHI ITV-D 01 S, Women's Mental Health, National Institute of Mental Health, June 10, 2003.

2003-2007 Member, Interventions Research Review Committee (ITV), National Institute of Mental Health.

2003- Member, Internal Advisory Committee, Pediatrics T32 Clinician-Scientist

Training Grant, NIH-National Institute of Child Health and Human Development, Department of Pediatrics, Indiana University School of Medicine.

2006 Member, Evaluating Progress on the Interagency Autism Coordinating Committee (IACC) Autism Research Matrix, National Institutes of Health.

2008 Member, Loan Repayment Program Review Committee, ZMH1 ERB-1 (C1)S, National Institute of Mental Health, March 24, 2008.

2009 Member, Loan Repayment Program Review Committee, ZMH1 ERB-1 (C3)1, National Institute of Mental Health, April 15, 2009.

2009 Member, ARRA Autism Review Committee #1, ZMH1 ERB-S (A1) R, National Institute of Mental Health, June 1, 2009.

2009 Member, ARRA Autism Review Committee #2, ZMH1 ERB-C (A1) R, National Institute of Mental Health, June 1, 2009.

2009 Member, ARRA Autism Review Committee #3, ZMH1 ERB-B (A1) R, National Institute of Mental Health, June 1, 2009.

2009 Member, RFA-OD-09-003: Challenge Grants Panel 5, ZRG1 BBBP-J (58) R, National Institute of Mental Health, June 6, 2009.

2009 Member, Special Emphasis Panel, ZRG1 BBBP-L (58) R, National Institute of Mental Health, June 6, 2009.

2010 Member, Loan Repayment Program Review Committee, ZMH1 ERB-1 (C1)S, National Institute of Mental Health, April 5, 2010.

INDIANA UNIVERSITY/DEPARTMENTAL ACTIVITIES:

1997-2000 Member, Psychiatry Research Committee, Department of Psychiatry

1997- Member, Executive/Institutional Committee, Department of Psychiatry

1997-2000 Member, Residency Training Committee, Department of Psychiatry

1997- Member, Alliance of Distinguished Rank Professors, Indiana University

1997-2000 Member, Riley Medical Care Committee, Riley Hospital for Children
1997-2000 Member, Board of Directors, Indiana University Psychiatric Associates, Inc.

1997-	Member, Compensation Committee, Department of Psychiatry
1997-1999	Co-Moderator, Collaborative Office Rounds Project, Maternal and Child Health Bureau, Indiana University School of Medicine site
1997-2000	Member, External Advisory Board, Department of Psychiatry
1997-2000	Member, Clinical Services Committee, Department of Psychiatry
1997-2000	Member, Budget Committee, Department of Psychiatry
1999-2000	Member, Tenure and Promotions Committee, Department of Psychiatry
1999-	Member, Clarian Behavioral Health Steering Committee
1999-2002	Member, Search and Screen Committee, Director – Stark Neurosciences Research Institute
2000-	President, Indiana University Psychiatric Associates, Inc.
2000-2003	Member, Board of Directors, Indiana University Psychiatric Management
2000-2001	Member, Search and Screen Committee, Chief - Psychiatry Service, Roudebush Veterans Administration Medical Center
2000-	Member, Executive Committee, Indiana University School of Medicine
2000-	Member, Clinical Chairs Committee, Indiana University School of Medicine
2000-2009	Member, Board of Directors, Indiana University Medical Group - Specialty Care
2001-2004	Member, Pharmacy and Therapeutics Committee, Wishard Memorial Hospital
2002-2009	Member, Finance Committee, Indiana University Medical Group - Specialty Care
2002-2010	Co-Facilitator, Medical Student Vertical Mentoring Program, Indiana University School of Medicine
2002-	Co-Chief (IU/Riley), Clarian Behavioral Health
2003-2004	Chair, Search and Screen Committee, Director, Midtown Mental Health

Center

2003- Member, Paul & Carole Stark Neurosciences Research Institute, Indiana University School of Medicine

2003- Member, Central Indiana Life Sciences Initiative, Neuroscience Target Team

2004-2005 Member, Search and Screen Committee, Associate Dean for Clinical Research, Indiana University School of Medicine

2004- Member, Data-Driven Decisions Steering Committee, Indiana University School of Medicine

2004- Member, Indiana University School of Medicine Peer Assessment Program for Medical Students

2004-2005 Co-Chair, Clarian/Indiana University School of Medicine/Health and Hospital Mental Health Cluster Workgroup

2005 Member, Search and Screen Committee, Director of Neuroimaging Center, Indiana University School of Medicine

2005- Member, Riley Hospital for Children Strategic Planning – Research Subcommittee

2005- Member, Indiana Alzheimer Disease Center (IADC), Internal Advisory Committee, Indiana University School of Medicine

2006 Participant, IUPUI Hiring/Employment Practices Review (Diversity)

2010 Member, Search and Screen Committee, Director-Section of Developmental Pediatrics, Department of Pediatrics, Indiana University School of Medicine

2010 Member, Search and Screen Committee, Associate Chief Operating Officer, Dean's Office, Indiana University School of Medicine

2010-2011 Participant, Workforce Development: Implementation and Evaluation of Formal Training for Mentors of K-Series Mentored Career Awards, NCRR University of Wisconsin (PI), Administrative Supplement

BIBLIOGRAPHY:

Original Articles:

1. **McDougle**, C.J., Goodman, W.K., Price, L.H., Delgado, P.L., Krystal, J.H., Charney, D.S., Heninger, G.R.: Neuroleptic addition in fluvoxamine-refractory obsessive compulsive disorder. Am J Psychiatry 147:652-654, 1990.

2. Goodman, W.K., **McDougle, C.J.**, Price, L.H., Riddle, M.A., Pauls, D.L., Leckman, J.F.: Beyond the serotonin hypothesis: A role for dopamine in some forms of obsessive compulsive disorder? J Clin Psychiatry 51:36-43, (Suppl.), 1990.

3. **McDougle**, C.J., Price, L.H., Goodman, W.K., Charney, D.S., Heninger, G.R.: A controlled trial of lithium augmentation in fluvoxamine-refractory obsessive compulsive disorder: Lack of efficacy. J Clin Psychopharm 11:175-184, 1991.

4. Kosten, T.R., Frank, J.B., Dan, E., **McDougle, C.J.**, Giller, E.L.: Pharmacotherapy for post-traumatic stress disorder using phenelzine or imipramine. J Nerv Ment Dis 179:366-370, 1991.

5. Satel, S.L., Price, L.H., Palumbo, J.M., **McDougle, C.J.**, Krystal, J.H., Gawin, F., Charney, D.S., Heninger, G.R., Kleber, H.D.: The clinical phenomenology and neurobiology of cocaine abstinence: A prospective inpatient study. Am J Psychiatry 148:1712-1716, 1991.

6. **McDougle, C.J.**, Southwick, S.M., St. James, R. L., Charney, D.S.: An open trial of fluoxetine in the treatment of post traumatic stress disorder. J Clin Psychopharmacol 11:325-327, 1991.

7. Woods, S.W., O'Malley, S.S., Martini, B.L., **McDougle, C.J.**, Price, L.H., Krystal, J.H., Hoffer, P.B., Kosten, T.R.: SPECT regional cerebral blood flow and neuropsychological testing in non-demented HIV-positive drug abusers: Preliminary results. Prog Neuro-Psychopharmacol & Biol Psychiatry 15:649-662, 1991.

8. Krystal, J.H., **McDougle, C.J.**, Kosten, T.R., Price, L.H., Aghajanian, G.K., Charney, D.S.: Baclofen-assisted detoxification from opiates: A pilot study. Journal of Substance Abuse Treatment 9:139:142, 1992.

9. Krystal, J.H., **McDougle, C.J.**, Woods, S.W., Price, L.H., Heninger, G.R., Charney, D.S.: Dose-response relationship for oral Idazoxan effects in healthy human subjects: Comparison with oral yohimbine. Psychopharmacology 108:313-319, 1992.

10. **McDougle,** C.J., Price, L.H., Palumbo, J.M., Kosten, T.R., Kleber, H.D., Heninger, G.R.: Dopaminergic responsivity during cocaine abstinence: A pilot study. Psychiatry Research 43:77-85, 1992.

11. **McDougle**, C.J., Price, L.H., Volkmar, F.R., Goodman, W.K., Ward-O'Brien, D., Nielson, J., Bregman, J., Cohen, D.J.: Clomipramine in autism: Preliminary evidence of efficacy. J Am Acad Child Adolesc Psychiatry 31:746-750, 1992.

12. Marek, G.J., **McDougle, C.J.**, Price, L.H., Seiden, L.S.: A comparison of trazodone and fluoxetine: Implications for a serotonergic mechanism of antidepressant action. Psychopharmacology 109:2-11, 1992.

13. Barr, L.C., Goodman, W.K., Price, L.H., **McDougle, C.J.**, Charney, D.S.: The serotonin hypothesis of obsessive compulsive disorder: Implications of pharmacologic challenge studies. J Clin Psychiatry 53[4,suppl]:17-28,1992.

14. **McDougle,** C.J., Goodman, W.K., Leckman, J.F., Holzer, J.C., Barr, L.C., McCance-Katz, E., Heninger, G.R., Price, L.H.: Limited therapeutic effect of addition of buspirone in fluvoxamine-refractory obsessive compulsive disorder. Am J Psychiatry 150:647-649, 1993.

15. McCance-Katz, E.F., Price, L.H., **McDougle, C.J.**, Kosten, T.R., Black, J.E., Jatlow, P.I.: Concurrent cocaine-ethanol ingestion in humans: Pharmacology, physiology, behavior, and the role of cocaethylene-A preliminary report. Psychopharmacology 111:39-46, 1993.

16. Rosen, M.I., Pearsall, H.R., Price, L.H., **McDougle, C.J.**, Woods, S.W., Kosten, T.R.: Carbamazepine vs. oxazepam for benzodiazepine detoxification in methadone-maintained patients: A pilot study. Am J Addictions 2(2):1-4, 1993.

17. Zimmermann, R.C., **McDougle, C.J.**, Schumacher, M., Olcese, J., Mason, J.W., Heninger, G.R., Price, L.H.: Effects of acute tryptophan depletion on nocturnal melatonin secretion in humans. J Clin Endocrin Metab 76:1160-1164, 1993.

18. Rosen, M.I., Pearsall, H.R., **McDougle, C.J.**, Price, L.H., Woods, S.W., Kosten, T.R.: Effects of acute buprenorphine on responses to intranasal cocaine: A pilot study. Am J Drug Alcohol Abuse 19(4):451-464, 1993.

19. **McDougle, C.J.**, Goodman, W.K., Leckman, J.F., Barr, L.C., Heninger, G.R., Price, L.H.: The efficacy of fluvoxamine in obsessive compulsive disorder: Effects of comorbid chronic tic disorder. J Clin Psychopharm 13(5):354-358, 1993.

20. Calvocoressi, L., **McDougle, C.J.**, Wasylink, S., Goodman, W.K., Trufan, S.J., Price, L.H.: Hospital treatment of patients with severe obsessive compulsive disorder. Hosp Comm Psychiatry 44(12):1150-1154, 1993.

21. Zimmermann, R.C., **McDougle, C.J.**, Schumacher, M., Olcese, J., Heninger, G.R., Price, L.H.: Urinary 6-hydroxymelatonin sulfate as a measure of melatonin secretion during acute tryptophan depletion. Psychoneuroendocrinology 18(8):567-578, 1993.

22. **McDougle, C.J.**, Goodman, W.K., Leckman, J.F., Lee, N.C., Heninger, G.R., Price, L.H.: Haloperidol addition in fluvoxamine-refractory obsessive compulsive disorder: A double-blind, placebo-controlled study in patients with and without tics. Arch Gen Psychiatry

51:302-308, 1994.

23. Barr, L.C., Goodman, W.K., **McDougle, C.J.**, Delgado, P.L., Heninger, G.R., Charney, D.S., Price, L.H.: Tryptophan depletion in patients with obsessive compulsive disorder who respond to serotonin reuptake inhibitors. Arch Gen Psychiatry 51:309-317, 1994.

24. Holzer, J.C., Goodman, W.K., **McDougle, C.J.**, Boyarsky, B.K., Leckman, J.F., Price, L.H.: Differential symptoms in obsessive compulsive disorder with and without a chronic tic disorder. British Journal of Psychiatry 164:469-473, 1994.

25. **McDougle, C.J.**, Black, J.E., Malison, R.T., Zimmermann, R.C., Heninger, G.R., Kosten, T.R., Price, L.H.: Noradrenergic dysregulation during discontinuation of cocaine use in addicts: Biochemical, behavioral, and cardiovascular correlates. Arch Gen Psychiatry 51:713-719, 1994.

26. Leckman, J.F., Goodman, W.K., North, W.G., Chappell, P.B., Price, L.H., Pauls, D.L., Anderson, G.M., Riddle, M.A., Hardin, M.T., **McDougle, C.J.**, Barr, L.C., Cohen, D.J.: The role of central oxytocin in obsessive compulsive disorder and related normal behavior. Psychoneuroendocrinology 19(8):723-749, 1994.

27. Anand, A., Charney, D.S., Delgado, P.L., **McDougle, C.J.**, Heninger, G.R., Price, L.H.: Neuroendocrine and behavioral responses to intravenous m-chlorophenylpiperazine (mCPP) in depressed patients and healthy comparison subjects. Am J Psychiatry 151:1626-1630, 1994.

28. Leckman, J.F., North, W., Price, L.H., Chappell, P.B., Anderson, G.M., Riddle, M.A., McSwiggan-Hardin, M., **McDougle, C.J.**, Barr, L.C., Pauls, D.L., Cohen, D.J., Goodman, W.K: Elevated levels of CSF oxytocin in obsessive compulsive disorder patients without a personal or family history of tics. Arch Gen Psychiatry 51:782-792, 1994.

29. Calvocoressi, L., Lewis, B., Kennedy, M., Goodman, W.K., Trufan, S.J., **McDougle, C.J.**, Price, L.H.: Family response to obsessive compulsive disorder. Am J Psychiatry 152:441-443, 1995.

30. Leckman, J.F., Goodman, W.K., Anderson, G.M., Riddle, M.A., Chappell, P.B., McSwiggan-Hardin, M.T., **McDougle, C.J.**, Scahill, L.D., Ort, S.I., Pauls, D.L., Cohen, D.J., Price, L.H.: CSF biogenic amines in obsessive compulsive disorder, Tourette's syndrome, and healthy controls. Neuropsychopharmacology 12:73-86, 1995.

31. **McDougle**, C.J., Krystal, J.H., Price, L.H., Heninger, G.R., Charney, D.S.: Noradrenergic response to acute ethanol administration in healthy subjects: Comparison with intravenous yohimbine. Psychopharmacology 118:127-135, 1995.

32. **McDougle, C.J.**, Kresch, L.E., Goodman, W.K., Naylor, S.T., Volkmar, F.R., Cohen, D.J., Price, L.H.: A case-controlled study of repetitive thoughts and behavior in adults with

autistic disorder and obsessive-compulsive disorder. Am J Psychiatry 152:772-777, 1995.

33. Aronson, S.C., Black, J.E., **McDougle, C.J.**, Scanley, B.E., Jatlow, P., Kosten, T.R., Heninger, G.R., Price, L.H.: Serotonergic mechanisms of cocaine effects in humans. Psychopharmacology 119:179-185, 1995.

34. Leckman, J.F., Grice, D.E., Barr, L.C., de Vries, A.L.C., Martin, C. Cohen, D.J., **McDougle, C.J.**, Goodman, W.K., Rasmussen, S.A.: Tic-related vs. non-tic-related obsessive compulsive disorder. Anxiety 1:208-215, 1994/1995.

35. Lombroso, P.J., Scahill, L., King, R.A., Lynch, K.A., Chappell, P.B., Peterson, B.S., **McDougle, C.J.**, Leckman, J.F.: Risperidone treatment of children and adolescents with chronic tic disorders: A preliminary report. J Am Acad Child Adolesc Psychiatry 34(9):1147-1152, 1995.

36. Malison, R.T., **McDougle, C.J.**, van Dyck, C.H., Scahill, L., Baldwin, R.M., Seibyl, J.P., Price, L.H., Leckman, J.F., Innis, R.B.: [^{123}I]B-CIT SPECT imaging demonstrates increased striatal dopamine transporter binding in Tourette's syndrome. Am J Psychiatry 152:1359-1361, 1995.

37. **McDougle, C.J.**, Barr, L.C., Goodman, W.K., Pelton, G.H., Aronson, S.C., Anand, A., Price, L.H.: Lack of efficacy of clozapine monotherapy in refractory obsessive compulsive disorder. Am J Psychiatry 152:1812-1814, 1995.

38. **McDougle, C.J.**, Fleischmann, R.L., Epperson, C.N., Wasylink, S., Leckman, J.F., Price, L.H.: Risperidone addition in fluvoxamine-refractory obsessive compulsive disorder: Three cases. J Clin Psychiatry 56:526-528, 1995.

39. Goodman, W.K., **McDougle, C.J.**, Price, L.H., Barr, L.C., Hills, O.F., Caplik, J.F., Charney, D.S., Heninger, G.R.: M-Chlorophenylpiperazine in patients with obsessive compulsive disorder: Absence of symptom exacerbation. Biol Psychiatry 38:138-149, 1995.

40. Cappiello, A., **McDougle, C.J.**, Malison, R.T., Heninger, G.R., Price, L.H.: Yohimbine augmentation of fluvoxamine in refractory depression: A single-blind study. Biol Psychiatry 38:765-767, 1995.

41. **McDougle, C.J.**, Brodkin, E.S., Yeung, P.P., Naylor, S.T., Cohen, D.J., Price, L.H: Risperidone in adults with autism or pervasive developmental disorder. J Child Adolesc Psychopharmacol 5(4):273-282, 1995.

42. Kosten, T.R., Kosten, T.A., **McDougle, C.J.**, Hameedi, F.A., Rosen, M.I., Oliveto, A.H., Price, L.H.: Gender differences in response to intranasal cocaine administration to humans. Biol Psychiatry 39:147-148, 1996.

43. Chappell, P.B., Leckman, J.F., Goodman, W.K., Bissette, G., Pauls, D.L., Anderson, G.M., Riddle, M.A., Scahill, L.D., **McDougle, C.J.**, Cohen, D.J.: Elevated CSF corticotropin-releasing factor in Tourette syndrome: Comparison to obsessive compulsive disorder and normal controls. Biol Psychiatry 39:776-783, 1996.

44. Epperson, C.N., **McDougle, C.J.**, Price, L.H.: Intranasal oxytocin in obsessive compulsive disorder. Biol Psychiatry 40:547-549, 1996.

45. Cappiello, A., Malison, R.T., **McDougle, C.J.**, Vegso, S.J., Charney, D.S., Heninger, G.R., Price, L.H.: Seasonal variation in neuroendocrine and mood responses to I.V. L-tryptophan in depressed patients and healthy subjects. Neuropsychopharmacology 15:475-483, 1996.

46. **McDougle, C.J.**, Naylor, S.T., Cohen, D.J., Aghajanian, G.K., Heninger, G.R., Price, L.H.: Effects of tryptophan depletion in drug-free adults with autistic disorder. Arch Gen Psychiatry 53:993-1000, 1996.

47. **McDougle, C.J.**, Naylor, S.T., Cohen, D.J., Volkmar, F.R., Heninger, G.R., Price, L.H.: A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder. Arch Gen Psychiatry 53:1001-1008, 1996.

48. Epperson, C.N., **McDougle, C.J.**, Price, L.H.: Intranasal oxytocin in trichotillomania. Biol Psychiatry 40:559-560, 1996.

49. Price, L.H., Malison, R.T., **McDougle, C.J.**, Pelton, G.H.: Antiglucocorticoids as treatments for depression: Rationale for use and therapeutic potential. CNS Drugs 5(5):311-320, 1996.

50. Kirwin, P.D., Anderson, G.M., Chappell, P.B., Saberski, L., Leckman, J.F., Geracioti, T.D., Heninger, G.R., Price, L.H., **McDougle, C.J.**: Assessment of diurnal variation of cerebrospinal fluid tryptophan and 5-hydroxyindoleacetic acid concentrations in healthy human females. Life Sci 60(12):899-907, 1997.

51. **McDougle, C.J.**, Holmes, J.P., Bronson, M.R., Anderson, G.M., Volkmar, F.R., Price, L.H., Cohen, D.J.: Risperidone treatment of children and adolescents with pervasive developmental disorders: A prospective open-label study. J Am Acad Child Adolesc Psychiatry 36(5):685-693, 1997.

52. Leckman, J.F., Grice, D.E., Boardman, J., Zhang, H., Vitale, A., Bondi, C., Alsobrook, J., Peterson, B.S., Cohen, D.J., Rasmussen, S.A., Goodman, W.K., **McDougle, C.J.**, Pauls, D.L.: Symptoms of obsessive compulsive disorder. Am J Psychiatry 154:911-917, 1997.

53. Brodkin, E.S., **McDougle, C.J.**, Naylor, S.T., Cohen, D.J., Price, L.H.: Clomipramine in adults with pervasive developmental disorders: A prospective open-label investigation. J Child Adolesc Psychopharmacol 7(2):109-121, 1997.

54. Barr, L.C., Goodman, W.K., Anand, A., **McDougle, C.J.**, Price, L.H.: Addition of

desipramine to serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder. Am J Psychiatry 154:1293-1295, 1997.

55. Price, L.H., Cappiello, A., Malison, R.T., **McDougle, C.J.**, Pelton, G.H., Schöllnhammer, G., Heninger, G.R.: Effects of antiglucocorticoid treatment on 5-HT_{1A} function in depressed patients and healthy subjects. Neuropsychopharmacology 17:246-257, 1997.

56. Price, L.H., Malison, R.T., **McDougle, C.J.**, McCance-Katz, E.F., Owen, K.R., Heninger, G.R.: Neurobiology of tryptophan depletion in depression: Effects of m-Chlorophenylpiperazine (mCPP). Neuropsychopharmacology 17:342-350, 1997.

57. Cappiello, A., Sernyak, M.J., Malison, R.T., **McDougle, C.J.**, Heninger, G.R., Price, L.H. Effects of acute tryptophan depletion in lithium remitted manic patients: A pilot study. Biol Psychiatry 42:1076-1078, 1997.

58. **McDougle, C.J.**, Brodkin, E.S., Naylor, S.T., Carlson, D.C., Cohen, D.J., Price, L.H.: Sertraline in adults with pervasive developmental disorders: A prospective open-label investigation. J Clin Psychopharmacol 18:62-66, 1998.

59. Price, L.H., Malison, R.T., **McDougle, C.J.**, Pelton, G.H., Heninger, G.R.: The neurobiology of tryptophan depletion in depression: Effects of intravenous tryptophan infusion. Biol Psychiatry, 43:339-347, 1998.

60. Calvocoressi, L., Libman, D., Vegso, S.J., **McDougle, C.J.**, Price, L.H.: Global functioning of inpatients with obsessive-compulsive disorder: A preliminary comparison with schizophrenia, and major depression. Psychiatr Serv 49(3):379-381, 1998.

61. Carpenter, L.L., Anderson, G.M., Pelton, G.H., Gudin, J.A., Kirwin, P.D.S., Price, L.H., Heninger, G.R., **McDougle, C.J.**: Tryptophan depletion during continuous CSF sampling in healthy human subjects. Neuropsychopharmacology 19:26-35, 1998.

62. **McDougle, C.J.**, Epperson, C.N., Price, L.H., Gelernter, J.: Evidence for linkage disequilibrium between serotonin transporter protein gene (SLC6A4) and obsessive compulsive disorder. Mol Psychiatry 3:270-273, 1998.

63. **McDougle, C.J.**, Holmes, J.P., Carlson, D.C., Pelton, G.H., Cohen, D.J., Price, L.H.: A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders. Arch Gen Psychiatry 55:633-641, 1998.

64. Epperson, C.N., Carpenter, L., North, W.G., **McDougle, C.J.**: Cerebrospinal fluid oxytocin levels in trichotillomania. CNS Spectrums 3(9):52-55, 1998.

65. Cappiello, A., **McDougle, C.J.**, Delgado, P.L., Malison, R.T., Jatlow, P., Charney, D.S., Heninger, G.R., Price, L.H.: Lithium and desipramine versus desipramine alone in the treatment of major depression: A preliminary study. International Clinical

Psychopharmacology 13:191-198, 1998.

66. Potenza, M.N., **McDougle, C.J.**: Potential of atypical antipsychotics in the treatment of nonpsychotic disorders. CNS Drugs 9 (3):213-232, 1998.

67. Potenza, M.N., Holmes, J.P., Kanes, S.J., **McDougle, C.J.**: Olanzapine treatment of children, adolescents and adults with pervasive developmental disorders: An open-label pilot study. J Clin Psychopharmacol 19:37-44, 1999.

68. Epperson, C.N., Fasula, D., Wasylink, S., Price, L.H., **McDougle, C.J.**: Risperidone addition in serotonin reuptake inhibitor-resistant trichotillomania: Three cases. J Child Adolesc Psychopharmacol 9:43-49, 1999.

69. Dartnall, N.A., Holmes, J.P., Morgan, S.N., **McDougle, C.J.**: Brief report: Two-year control of behavioral symptoms with risperidone in two profoundly retarded adults with autism. J Autism Dev Disord 29:(1):87-91, 1999.

70. Weiss, E.L., Potenza, M.N., **McDougle, C.J.**, Epperson, C.N.: Olanzapine addition in obsessive-compulsive disorder refractory to selective serotonin reuptake inhibitors: An open-label case series. J Clin Psychiatry 60:524-527, 1999.

71. Longhurst, J.G., Carpenter, L.L., Epperson, C.N., Price, L.H., **McDougle, C.J.**: Effects of catecholamine depletion with AMPT (alpha-methyl-para-tyrosine) in obsessive-compulsive disorder. Biol Psychiatry 46:573-576, 1999.

72. Malison, R.T., Anand, A., Pelton, G.H., Kirwin, P., Carpenter, L., **McDougle, C.J.**, Heninger, G.R., Price, L.H.: Limited efficacy of ketoconazole in treatment-refractory major depression. J Clin Psychopharmacol 19:466-469, 1999.

73. Posey, D.J., Walsh, K.H., Wilson, G.A., **McDougle, C.J.**: Risperidone in the treatment of two very young children with autism. J Child Adolesc Psychopharmacol 9(4):273-276, 1999.

74. **McDougle**, **C.J.**, Barr, L.C., Goodman, W.K., Price, L.H.: Possible role of neuropeptides in obsessive compulsive disorder. Psychoneuroendocrinology 24:1-24, 1999.

75. Arnold, L.E., Aman, M.G., Martin, A., Collier-Crespin, A., Vitiello, B., Tierney, E., Asarnow, R., Bell-Bradshaw, F., Freeman, B.J., Gates-Ulanet, P., Klin, A., McCracken, J.T., **McDougle, C.J.**, McGough, J.J., Posey, D.J., Scahill, L., Swiezy, N.B., Ritz, L., Volkmar, F.: Assessment in multisite randomized clinical trials of patients with autistic disorder: The autism RUPP network, J Autism Dev Disord 30(2):99-111, 2000.

76. **McDougle, C.J.**, Epperson, C.N., Pelton, G.H., Wasylink, S., Price, L.H.: A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder. Arch Gen Psychiatry 57:794-801, 2000.

77. **McDougle, C.J.**, Kresch, L.E., Posey, D.J.: Repetitive thoughts and behavior in pervasive developmental disorders: Treatment with serotonin reuptake inhibitors. J Autism Dev Disord 30(5):427-435, 2000.

78. Posey, D.J., Guenin, K.D., Kohburn, A.E., Swiezy, N.B., **McDougle, C.J.**: A naturalistic open-label study of mirtazapine in autistic and other pervasive developmental disorders. J Child Adolesc Psychopharmacol 11(3):267-277, 2001.

79. Sweeten, T.L., Ferris, M., **McDougle, C.J.**, Kwo, P., Taylor, M.W.: Induction of indoleamine 2,3-dioxygenase in vivo by IFN-con1. J Interferon Cytokine Res 21:631-633, 2001.

80. Scahill, L., McCracken, J., **McDougle, C.J.**, Aman, M., Arnold, L.E., Tierney, E., Cronin, P., Davies, M., Ghuman, J., Gonzalez, N., Koenig, K., Lindsay, R., Martin, A., McGough, J., Posey, D.J., Swiezy, N., Volkmar, F., Ritz, L., Vitiello, B.: Methodological Issues in Designing a Multisite Trial of Risperidone in Children and Adolescents with Autism. J Child Adolesc Psychopharmacol 11(4):377-388, 2001.

.

81. Sweeten, T.L., Posey, D.J., Shekhar, A., **McDougle, C.J.**: The amygdala and related structures in the pathophysiology of autism. Pharmacology, Biochemistry and Behavior 71:449-455, 2002.

82. George, T.P., Potenza, M.N., Degen, K., Sernyak, M.J., **McDougle, C.J.,** Woods, S.: Acute tryptophan depletion in schizophrenic patients treated with clozapine. Arch Gen Psychiatry 59:291-292, 2002.

83. **McDougle, C.J.**, Kem, D.L., Posey, D.J.: Case Series: Use of ziprasidone for maladaptive symptoms in youths with autism. J Am Acad Child Adolesc Psychiatry 41(8):921-927, 2002.

84. Research Units on Pediatric Psychopharmacology Autism Network: Risperidone in children with autism and serious behavioral problems. N Engl J Med 347(5):314-321, 2002.

85. **McDougle, C.J.**, Posey, D.: Genetics of childhood disorders: XLIV. Autism, Part 3: Psychopharmacology of autism. J Am Acad Child Adolesc Psychiatry 41(11):1380-1383, 2002.

86. Carpenter, L.L., Heninger, G.R., **McDougle, C.J.**, Tyrka, A.R., Epperson, C.N., Price, L.H.: Cerebrospinal fluid interleukin-6 in obsessive-compulsive disorder and trichotillomania. Psychiatry Research 112(3):257-262, 2002.

87. Biederman, J., Heiligenstein, J.H., Faries, D.E., Galil, N., Dittmann, R., Emslie, G.J., Kratochvil, C.J., Laws, H.F., Schuh, K.J., Ambrosini, P., Block, S.L., Busner, J., Casat, C.D., Conners, C.K., Connor, D.F., Dunn, D., Kaplan, S., **McDougle, C.**, Newcorn, J.H.,

Sallee, F.R., Saylor, K., Spencer, T., Stein, M., Wagner, K.D., West, S.: Efficacy of Atomoxetine versus Placebo in School-Age Girls with Attention-Deficit/Hyperactivity Disorder. Pediatrics 110(6):1-7, 2002.

88. Marek, G.J., Carpenter, L.L., **McDougle, C.J.**, Price, L.H.: Synergistic action of 5-HT_{2A} antagonists and selective serotonin reuptake inhibitors in neuropsychiatric disorders. Neuropsychopharmacology 28:402-412, 2003.

89. Sweeten, T.L., Posey, D.J., **McDougle, C.J.**: High blood monocyte counts and neopterin levels in children with autistic disorder. Am J Psychiatry 160(9):1691-1693, 2003.

90. Sweeten, T.L., Bowyer, S.L., Posey, D.J., Halberstadt, G.M., **McDougle, C.J.**: Increased prevalence of familial autoimmunity in probands with pervasive developmental disorders. Pediatrics 112(5):e420-e424, November, 2003.

91. Arnold, L.E., Vitello, B., **McDougle, C.**, Scahill, L., Shah, B., Gonzalez, N.M., Chuang, S., Davies, M., Holloway, J., Aman, M.G., Cronin, P., Koenig, K., Kohn, A.E., McMahon, D.J., Tierney, E.: Parent-defined target symptoms respond to risperidone in RUPP Autism Study: Customer approach to clinical trials. J Am Acad Child Adolesc Psychiatry 42(12):1443-1450, 2003.

92. Stigler, K.A., Desmond, L.A., Posey, D.J., Wiegand, R.E., **McDougle, C.J.**: A naturalistic retrospective analysis of psychostimulants in pervasive developmental disorders. J Child Adolesc Psychopharmacol 14(1):49-56, 2004.

93. Meighen, K.G., Shelton, H.M., **McDougle, C.J.**: Ziprasidone treatment of two adolescents with psychosis. J Child Adolesc Psychopharmacol 14(1):137-142, 2004.

94. Sweeten, T.L., Posey, D.J., Shankar, S., **McDougle, C.J.**: High nitric oxide production in autistic disorder: A possible role for interferon-□. Biol Psychiatry 55:434-437, 2004.

95. Carpenter, L.L., Tyrka, A.R., **McDougle, C.J.,** Malison, R.T., Owens, M.J., Nemeroff, C.B., Price, L.H.: Cerebrospinal fluid corticotropin-releasing factor and perceived early-life stress in depressed patients and healthy control subjects. Neuropsychopharmacology 29:777-784, 2004.

96. Martin, A., Scahill, L., Anderson, G.M., Aman, M., Arnold, L.E., McCracken, J., **McDougle, C.J.**, Tierney, E., Chuang, S., Vitiello, B., and the RUPP Autism Network: Weight and leptin changes among risperidone-treated youths with autism: 6-month prospective data. Am J Psychiatry 161:1125-1127, 2004.

97. Posey, D.J., Puntney, J.I., Sasher, T.M., Kem, D.L., **McDougle, C.J.**: Guanfacine treatment of hyperactivity and inattention in pervasive developmental disorders: A retrospective analysis of 80 cases. J Child Adolesc Psychopharmacol 14(2):233-241, 2004.

98. Sweeten, T.L., Posey, D.J., **McDougle, C.J.**: Autistic disorder in three children with cytomegalovirus infection. J Autism Dev Disord 34(5):583-586, 2004.

99. Hazaray, E., Ehret, J., Posey, D.J., Petti, T.A., **McDougle, C.J.**: Intramuscular ziprasidone for acute agitation in adolescents. J Child Adolesc Psychopharmacol 14(3):396-402, 2004.

100. Stigler, K.A., Posey, D.J., **McDougle, C.J.**: Case series: Aripiprazole for maladaptive behavior in pervasive developmental disorders. J Child Adolesc Psychopharmacol 14(3):463-471, 2004.

101. Tyrka, A.R., Carpenter, L.L., **McDougle, C.J.**, Kirwin, P.D., Owens, M.J., Nemeroff, C.B., Strong, D.R., Price, L.H.: Increased cerebrospinal fluid corticotropin-releasing factor concentrations during tryptophan depletion in healthy adults. Biol Psychiatry 56:531-534, 2004.

102. Posey, D.J., Kem, D.L., Swiezy, N.B., Sweeten, T.L., Wiegand, R.E., **McDougle, C.J.**: A pilot study of D-cycloserine in autistic disorder. Am J Psychiatry 161:2115-2117, 2004.

103. Corson, A.H., Barkenbus, J.E., Posey, D.J., Stigler, K.A., **McDougle, C.J.**: A retrospective analysis of quetiapine in the treatment of pervasive developmental disorders. J Clin Psychiatry 65:1531-1536, 2004.

104. Vitiello, B., Aman, M.G., Scahill, L., McCracken, J.T., **McDougle, C.J.**, Tierney, E., Davies, M., Arnold, L.E.: Research knowledge among parents of autistic children participating in a randomized clinical trial. J Am Acad Child Adolesc Psychiatry 44(2):145-149, 2005.

105. **McDougle, C.J.**, Scahill, L., Aman, M.G., McCracken, J.T., Tierney, E., Davies, M., Arnold, L.E., Posey, D.J., Martin, A., Ghuman, J.K., Shah, B., Chuang, S.Z., Swiezy, N.B., Gonzalez, N.M., Hollway, J., Koenig, K., McGough, J.J., Ritz, L., Vitiello, B.: Risperidone for the core symptom domains of autism: Results from the study by the Autism Network of the Research Units on Pediatric Psychopharmacology. Am J Psychiatry 162:1142-1148, 2005.

106. Research Units on Pediatric Psychopharmacology Autism Network: Risperidone treatment of autistic disorder: Longer-term benefits and blinded discontinuation after six months. Am J Psychiatry 162:1361-1369, 2005.

107. Research Units on Pediatric Psychopharmacology Autism Network: Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity. Arch Gen Psychiatry 62:1266-1274, 2005.

108. Vitiello, B., Davies, M., Arnold, L.E., **McDougle, C.J.**, Aman, M., McCracken, J.T., Scahill, L., Tierney, E., Posey, D.J., Swiezy, N.B., Koenig, K.: Assessment of the integrity of study blindness in a pediatric clinical trial of risperidone. J Clin Psychopharmcol 25:565-

569, 2005.

109. Aman, M.G., Arnold, L.E., **McDougle, C.J.**, Vitiello, B., Scahill, L., Davies, M., McCracken, J.T., Tierney, E., Nash, P.L., Posey, D.J., Chuang, S., Martin, A., Shah, B., Gonzalez, N.M., Swiezy, N.B., Ritz, L., Koenig, K., McGough, J., Ghuman, J.K., Lindsay, R.L.: Acute and long-term safety and tolerability of risperidone in children with autism. J Child Adolesc Psychopharmacol 15(6):869-884, 2005.

110. Lecavalier, L., Aman, M.G., Scahill, L., **McDougle, C.J.**, McCracken, J.T., Vitiello, B., Tierney, E., Arnold, L.E., Ghuman, J.K., Loftin, R.L., Cronin, P., Koenig, K., Posey, D.J., Martin, A., Hollway, J., Lee, L.S., Kau, A.S.M.: Validity of the Autism Diagnostic Interview-Revised. Am J Ment Retard 111(3):199-215, 2006.

111. Williams, S.K., Scahill, L., Vitiello, B., Aman, M.G., Arnold, L.E., **McDougle, C.J.**, McCracken, J.T., Tierney, E., Ritz, L., Posey, D.J., Swiezy, N.B., Hollway, J., Cronin, P., Ghuman, J., Wheeler, C., Cicchetti, D., C., Sparrow, S.: Risperidone and adaptive behavior in children with autism. J Am Acad Child Adolesc Psychiatry 45(4):431-439, 2006.

112. Scahill, L., **McDougle, C.J.**, Williams, S.K., Dimitropoulos, A., Aman, M.G., McCracken, J.T, Tierney, E., Arnold, L.E., Cronin, P., Grados, M., Ghuman, J., Koenig, K., Lam, K.S.L., McGough, J., Posey, D.J., Ritz, L., Swiezy, N.B., Vitiello, B.: Children's Yale-Brown Obsessive Compulsive Scale modified for pervasive developmental disorders. J Am Acad Child Adolesc Psychiatry 45(9):1114-1123, 2006.

113. Lindsay, R.L., Arnold, L.E., Aman, M.G., Vitiello, B., Posey, D.J., **McDougle, C.J.**, Scahill, L., Pachler, M., McCracken, J.T., Tierney, E., Bozzolo, D.: Dietary status and impact of risperidone on nutritional balance in children with autism: A pilot study. J Intellect Dev Disabil 31(4):204-209, 2006.

114. Posey, D.J., Wiegand, R.E., Wilkerson, J., Maynard, M., Stigler, K.A., **McDougle, C.J.**: Open-label atomoxetine for attention-deficit/hyperactivity disorder symptoms associated with higher-functioning pervasive developmental disorders. J Child Adolesc Psychopharmacol 16(5):599-610, 2006.

115. Scahill, L., Aman, M.G., **McDougle, C.J.**, McCracken, J.T., Tierney, E., Dziura, J., Arnold, L.E., Posey, D., Young, C., Shah, B., Ghuman, J., Ritz, L., Vitiello, B.: A prospective open trial of guanfacine in children with pervasive developmental disorders. J Child Adolesc Psychopharmacol 16(5):589-598, 2006.

116. Sweeten, T.L., Taylor, M.W., Posey, D.J., **McDougle, C.J.**: Plasma kynurenine levels in autistic disorder. J Dev Phys Disabil 18(4):419-426, 2006.

117. Wagner, A., Lecavalier, L., Arnold, L.E., Aman, M.G., Scahill, L., Stigler, K.A., Johnson, C.R., **McDougle, C.J.**, Vitiello, B.: Developmental disabilities modification of the children's global assessment scale. Biol Psychiatry 61(4):504-511, 2007.

118. Posey, D.J., Aman, M.G., McCracken, J.T., Scahill, L., Tierney, E., Arnold, L.E., Vitiello, B., Chuang, S.Z., Davies, M., Ramadan, Y., Witwer, A.N., Swiezy, N.B., Cronin, P., Shah, B., Carroll, D.H., Young, C., Wheeler, C., **McDougle, C.J.**: Positive effects of methylphenidate on inattention and hyperactivity in pervasive developmental disorders: An analysis of secondary measures. Biol Psychiatry 61(4):538-544, 2007.

119. Anderson, G.M., Scahill, L., McCracken, J.T., **McDougle, C.J.**, Aman, M.G., Tierney, E., Arnold, L.E., Martin, A., Katsovich, L., Posey, D.J., Shah, B., Vitiello, B: Effects of short- and long-term risperidone treatment on prolactin levels in children with autism. Biol Psychiatry 61(4):545-550, 2007.

120. Truitt, W.A., Sajdyk, T.J., Dietrich, A.D., Oberlin, B., **McDougle, C.J.**, Shekhar, A.: From anxiety to autism: Spectrum of abnormal social behaviors modeled by progressive disruption of inhibitory neuronal function in the basolateral amygdala in Wistar rats. Psychopharmacology 191:107-118, 2007.

121. Erickson, C.A., Posey, D.J., Stigler, K.A., Mullet, J., Katshke, A.R., **McDougle, C.J.**: A retrospective study of memantine in children and adolescents with pervasive developmental disorders. Psychopharmacology 191:141-147, 2007.

122. Tierney, E., Aman, M., Stout, D., Pappas, K., Arnold, L.E., Vitiello, B., Scahill, L., **McDougle, C.**, McCracken, J., Wheeler, C., Martin, A., Posey, D., Shah, B.: Parent satisfaction in a multi-site acute trial of risperidone in children with autism: A social validity study. Psychopharmacology 191:149-157, 2007.

123. Research Units on Pediatric Psychopharmacology [RUPP] Autism Network: Parent training for children with pervasive developmental disorders: A multi-site feasibility trial. Behav Intervent 22:179-199, 2007.

124. Johnson, C.R., Handen, B.L., Butter, E., Wagner, A., Mulick, J., Sukholdsky, D.G., Williams, S., Swiezy, N.B., Arnold, L.E., Aman, M.G., Scahill, L., Stigler, K.A., **McDougle, C.J**., Vitiello, B., Smith, T.: Development of a parent training program for children with pervasive developmental disorders. Behav Intervent 22:201-221, 2007.

125. Sukhodolsky, D.G., Scahill, L., Gadow, K.D., Arnold, L.E., Aman, M.G., **McDougle, C.J.**, McCracken, J.T., Tierney, E., Williams-White, S., Lecavalier, L., Vitiello, B.: Parent-rated anxiety symptoms in children with pervasive developmental disorders: Frequency and association with core autism symptoms and cognitive functioning. J Abnorm Child Psychol 36:117-128, 2008.

126. Aman, M.G., Hollway, J.A., **McDougle, C.J.**, Scahill, L., Tierney, E., McCracken, J.T., Arnold, L.E., Vitiello, B., Ritz, L., Gavaletz, A., Cronin, P., Swiezy, N., Wheeler, C., Koenig, K., Ghuman, J.K., Posey, D.J.: Cognitive effects of risperidone in children with autism and irritable behavior. J Child Adolesc Psychopharmacol 18(3):227-236, 2008.

127. Liu, X.Q., Paterson, A.D., Szatmari, P., and the AGP Consortium: Genome-wide linkage

analysis of quantitative and categorical autism sub-phenotypes. Biol Psychiatry, 64(7):561-570, 2008.

128. Kryzhanovskaya, L., Schulz, S.C., **McDougle, C.**, Frazier, J., Dittmann, R., Robertson-Plouch, C., Bauer, T., Xu, W., Wang, W., Carlson, J., Tohen, M.: Olanzapine versus placebo in adolescents with schizophrenia: A 6-week, randomized, double-blind, placebo-controlled trial. J Am Acad Child Adolesc Psychiatry 48(1):60-70, 2009.

129. Jahromi, L.B., Kasari, C.L., McCracken, J.T., Lee, L.S-Y, Aman, M.G., **McDougle, C.J.**, Scahill, L., Tierney, E., Arnold, L.E., Vitiello, B., Ritz, L., Witmer, A., Kustan, E., Ghuman, J., Posey, D.J.: Positive effects of methylphenidate on social communication and self-regulation in children with pervasive developmental disorders and hyperactivity. J Autism Dev Disord 39:395-404, 2009.

130. Nikolov, R.N., Bearss, K.E., Lettinga, J., Erickson, C., Rodowski, M., Aman, M.G., McCracken, J.T., **McDougle, C.J.**, Tierney, E., Vitiello, B., Arnold, L.E., Shah, B., Posey, D.J., Ritz, L., Scahill, L.: Gastrointestinal symptoms in a sample of children with pervasive developmental disorders. J Autism Dev Disord 39:405-413, 2009.

131. Handen, B.L., Melmed, R.D., Hansen, R.L., Aman, M.G., Burnham, D.L., Bruss, J.B., **McDougle, C.J.:** A double-blind, placebo-controlled trial of oral human immunoglobulin for gastrointestinal dysfunction in children with autistic disorder. J Autism Dev Disord 39(5):796-805, 2009.

132. Scahill, L., Aman, M.G., **McDougle, C.J.**, Arnold, L.E., McCracken, J.T., Handen, B., Johnson, C., Dziura, J., Butter, E., Sukhodolsky, D., Swiezy, N., Mulick, J., Stigler, K., Bearss, K., Ritz, L., Wagner, A., Vitiello, B.: Trial design challenges when combining medication and parent training in children with pervasive developmental disorders. J Autism Dev Disord 39:720-729, 2009.

133. Stigler, K.A., Diener, J.T., Kohn, A.E., Li, L., Erickson, C.A., Posey, D.J., **McDougle, C.J.**: Aripiprazole in pervasive developmental disorder not otherwise specified and Asperger's disorder: A 14-week, prospective, open-label study. J Child Adolesc Psychopharmacol 19(3):265-274, 2009.

134. Johnson, C.R., Butter, E.M., Handen, B.L., Sukhodolsky, D.G., Mulick, J., Lecavalier, L., Aman, M.G., Arnold, L.E., Scahill, L., Swiezy, N., Sacco, K., Stigler, K.A., **McDougle, C.J.**: Standardized Observation Analogue Procedure (SOAP) for assessing parent and child behaviors in clinical trials. J Intellect Dev Disabil 34(3):1-9, 2009.

135. Glessner, J.T., Wang, K., Cai, G., Korvatska, O., Kim, C.E., Wood, S., Zhang, H., Estes, A., Brune, C., Bradfield, J.P., Imielinski, M., Frackelton, E.C., Reichert, J., Crawford, E.L., Munson, J., Sleiman, P., Chiavacci, R., Annaiah, K., Thomas, K., Hou, C., Glaberson, W., Flory, J., Otieno, F., Garris, M., Soorya, L., Klei, L., Piven, J., Meyer, K.J., Anagnostou, E., Sakurai, T., Game, R.M., Rudd, D.S., Zurawiecki, D., **McDougle, C.**, Davis, L.K., Miller,

J., Posey, D., Michaels, S., Kolevzon, A., Silverman, J.M., Bernier, R., Levy, S.E., Dawson, G., Owley, T., McMahon, W.M., Wassink, T.H., Sweeney, J.A., Nurnberger, Jr., J.I., Coon, H., Sutcliffe, J.S., Minshew, N.J., Grant, S.F.A., Bucan, M., Cook, Jr., E.H., Buxbaum, J.D., Devlin, B., Schellenberg, G.D., Hakonarson, H.: Autism genome wide copy number variation reveals ubiquitin and neuronal genes. Nature 459(7246):569-573, 2009.

136. Weiss, L.A., Arking, D.E., The Gene Discovery Project of Johns Hopkins and the Autism Consortium: A genome-wide linkage and association scan reveals novel loci for autism. Nature 461(7265):802-808, 2009.

137. Erickson, C.A., Mullett, J.E., **McDougle, C.J.**: Open-label memantine in fragile X syndrome. J Autism Dev Disord 39:1629-1635, 2009.

138. Research Units on Pediatrics Psychopharmacology (RUPP) Autism Network: Medication and parent training in children with pervasive developmental disorders and serious behavior problems: Results from a randomized clinical trial. J Am Acad Child Adolesc Psychiatry 48(12):1143-1154, 2009.

139. McCracken, J.T., Aman, M.G., **McDougle, C.J.**, Tierney, E., Shiraga, S., Whelan, F., Arnold, L.E., Posey, D., Ritz, L., Vitiello, B., Scahill, L.: Possible influence of variant of the P-glycoprotein gene (MDR1/ABCBI) on clinical response to guanfacine in children with pervasive developmental disorders and hyperactivity. J Child Adolesc Psychopharmacol 20(1):1-5, 2010.

140. Chowdhury, M., Aman, M.G., Scahill, L., Swiezy, N.B., Arnold, L.E., Lecavalier, L., Johnson, C.R., Handen, B.L., Stigler, K.A., Bearss, K., Sukhodolsky, D.G., **McDougle, C.J.**: The Home Situations Questionnaire – PDD Version: Factor structure and psychometric properties. JIDR 54:281-291, 2010.

141. Arnold, L.E., Farmer, C., Kraemer, H.C., Davies, M., Witwer, A., Chuang, S., Di Silvestro, R., **McDougle, C.J.**, McCracken, J., Vitiello, B., Aman, M.G., Scahill, L., Posey, D.J., Swiezy, N.B: Moderators, mediators, and other predictors of risperidone response in children with autistic disorder and irritability. J Child Adolesc Psychopharmacol 20(2):83-93, 2010.

142. Pinto, D., Pagnamenta, A.T., Klei, L., Anney, R., Merico, D., Regan, R., Conroy, J., Magalhaes, T.R., Correia, C., Abrahams, B.S., Almeida, J., Bacchelli, E., Bader, G.D., Bailey, A.J., Baird, G., Battaglia, A., Berney, T., Bolshakova, N., Bölte, S., Bolton, P.F., Bourgeron, T., Brennan, S., Brian, J., Bryson, S.E., Carson, A.R., Casallo, G., Casey, J., Chung, B.H., Cochrane, L., Corsello, C., Crawford, E.L., Crossett, A., Cytrynbaum, C., Dawson, G., de Jonge, M., Delorme, R., Drmic, I., Duketis, E., Duque, F., Estes, A., Farrar, P., Fernandez, B.A., Folstein, S.E., Fombonne, E., Freitag, C.M., Gilbert, J., Gillberg, C., Glessner, J.T., Goldberg, J., Green, A., Green, J., Guter, S.J., Hakonarson, H., Heron, E.A., Hill, M., Holt, R., Howe, J.L., Hughes, G., Hus, V., Igliozzi, R., Kim, C., Klauck, S.M., Kolevzon, A., Korvatska, O., Kustanovich, V., Lajonchere, C.M., Lamb, J.A., Laskawiec, M., Leboyer, M., Le Couteur, A., Leventhal, B.L., Lionel, A.C., Liu,

X.Q., Lord, C., Lotspeich, L., Lund, S.C., Maestrini, E., Mahoney, W., Mantoulan, C., Marshall, C.R., McConachie, H., **McDougle, C.J.**, McGrath, J., McMahon, W.M., Merikangas, A., Migita, O., Minshew, N.J., Mirza, G.K., Munson, J., Nelson, S.F., Noakes, C., Noor, A., Nygren, G., Oliveira, G., Papanikolaou, K., Parr, J.R., Parrini, B., Paton, T., Pickles, A., Pilorge, M., Piven, J., Ponting, C.P., Posey, D.J., Poustka, A., Poustka, F., Prasad, A., Ragoussis, J., Renshaw K., Rickaby J., Roberts, W., Roeder, K., Roge, B., Rutter, M.L., Bierut, L.J., Rice, J.P., Salt, J., Sansom, K., Sato, D., Segurado, R., Sequeira, A.F., Senman, L., Shah, N., Sheffield, V.C., Soorya, L., Sousa, I., Stein, O., Sykes, N., Stoppioni, V., Strawbridge, C., Tancredi, R., Tansey, K., Thiruvahindrapduram, B., Thompson, A.P., Thomson, S., Tryfon, A., Tsiantis, J., Van Engeland, H., Vincent, J.B., Volkmar, F., Wallace, S., Wang, K., Wang, Z., Wassink, T.H., Webber, C., Weksberg, R., Wing, K., Wittemeyer, K., Wood, S., Wu, J., Yaspan, B.L., Zurawiecki, D., Zwaigenbaum, L., Buxbaum, J.D., Cantor, R.M., Cook, E.H., Coon, H., Cuccaro, M.L., Devlin, B., Ennis, S., Gallagher, L., Geschwind, D.H., Gill, M., Haines, J.L., Hallmayer, J., Miller, J., Monaco, A.P., Nurnberger, J.I. Jr., Paterson, A.D., Pericak-Vance, M.A., Schellenberg, G.D., Szatmari, P., Vicente, A.M., Vieland, V.J., Wijsman, E.M., Scherer, S.W., Sutcliffe, J.S., Betancur, C.: Functional impact of global rare copy number variation in autism spectrum disorders. Nature Jul 15;466(7304):368-372, 2010.

143. Erickson, C.A., Mullett, J.E., **McDougle, C.J.**: Brief Report: Acamprosate in fragile X syndrome. J Autism Dev Disord 40(11):1412-1416, 2010.

144. Wink, L.K., Erickson, C.A., Chambers, J.E., **McDougle, C.J.**: Co-morbid intellectual disability and borderline personality disorder: a case series. Psychiatry: Interpersonal and Biological Processes 73(3):277-287, 2010.

145. Anney, R., Klei, L., Pinto, D., Regan, R., Conroy, J., Magalhaes, T.R., Correia, C., Abrahams, B.S., Sykes, N., Pagnamenta, A.T., Almeida, J., Bacchelli, E., Bailey, A.J., Baird, G., Battaglia, A., Berney, T., Bolshakova, N., Bölte, S., Bolton, P.F., Bourgeron, T., Brennan, S., Brian, J., Carson, A.R., Casallo, G., Casey, J., Chu, S.H., Cochrane, L., Corsello, C., Crawford, E.L., Crossett, A., Dawson, G., de Jonge, M., Delorme, R., Drmic, I., Duketis, E., Duque, F., Estes, A., Farrar, P., Fernandez, B.A., Folstein, S.E., Fombonne, E., Freitag, C.M., Gilbert, J., Gillberg, C., Glessner, J.T., Goldberg, J., Green, J., Guter, S.J., Hakonarson, H., Heron, E.A., Hill, M., Holt, R., Howe, J.L., Hughe, G., Hus, V., Igliozzi, R., Kim, C., Klauck, S.M., Kolevzon, A., Korvatska, O., Kustanovich, V., Lajonchere, C.M., Lamb, J.A., Laskawiec, M., Leboyer, M., Le Couteur, A., Leventhal, B.L., Lionel, A.C., Liu, X.Q., Lord, C., Lotspeich, L., Lund, S.C., Maestrini, E., Mahoney, W., Mantoulan, C., Marshall, C.R., McConachie, H., **McDougle, C.J.**, McGrath, J., McMahon, W.M., Melhem, N.M., Merikangas, A., Migita, O., Minshew, N.J., Mirza, G.K., Munson, J., Nelson, S.F., Noakes, C., Noor, A., Nygren, G., Oliveira, G., Papanikolaou, K., Parr, J.R., Parrini, B., Paton, T., Pickles, A., Piven, J., Posey, D.J., Poustka, A., Poustka, F., Prasad, A., Ragoussis, J., Renshaw, K., Rickaby, J., Roberts, W., Roeder, K., Roge, B., Rutter, M.L., Bierut, L.J., Rice, J.P., Salt, J., Sansom, K., Sato, D., Segurado, R., Senman, L., Shah, N., Sheffield, V.C., Soorya, L., Sousa, I., Stoppioni, V., Strawbridge, C., Tancredi, R., Tansey, K., Thiruvahindrapduram, B., Thompson, A.P., Thomson, S., Tryfon, A., Tsiantis, J., Van Engeland, H., Vincent, J.B., Volkmar, F., Wallace, S., Wang, K., Wang, Z., Wassink, T.H.,

Wing, K., Wittemeyer, K., Wood, S., Yaspan, B.L., Zurawiecki, D., Zwaigenbaum, L., Betancur, C., Buxbaum, J.D., Cantor, R.M., Cook, E.H., Coon, H., Cuccaro, M.L., Gallagher, L., Geschwind, D.H., Gill, M., Haines, J.L., Miller, J., Monaco, A.P., Nurnberger, J.I., Jr., Paterson, A.D., Pericak-Vance, M.A., Schellenberg, G.D., Scherer, S.W., Sutcliffe, J.S., Szatmari, P., Vicente, A.M., Vieland, V.J., Wijsman, E.M., Devlin, B., Ennis, S., Hallmayer, J.: A genomewide scan for common alleles affecting risk for autism. Hum Mol Genet Oct 15;19(20):4072-4082, 2010.

146. Forray, A., Focseneanu, M., Pittman, B., **McDougle, C.J.**, Epperson, C.N.: Onset and exacerbation of obsessive-compulsive disorder in pregnancy and the postpartum period. J Clin Psychiatry 71 (8):1061-1068, 2010.

147. Erickson, C.A., Weng, N., Weiler, I.J., Greenough, W.T., Stigler, K.A., Wink, L.K., **McDougle, C.J.**: Open-label riluzole in fragile-X syndrome. Brain Research, in press.

148. Tobiasova, Z., Van der Lingen, K.H.B., Scahill, L., Leckman, J.F., Zhang, Y., Chae, W., McCracken, J.T., **McDougle, C.J.,** Vitiello, B., Tierney, E., Aman, M.G., Arnold, L.E., Katsovich, L., Hoekstra, P.J., Bothwell, A.L.M., Kawikova, I.: Risperidone-related improvement of irritability in children with autism is not associated with changes in serum levels of EGF and IL-13. J Child Adolesc Psychopharmacol, submitted.

149. McCracken, J.T., Aman, M., **McDougle, C.J.**, Scahill, L., Tierney, E., Arnold, L.E., Posey, D.J., Whelan, F., Chuang, S., Ritz, L., Vitiello, B., and the RUPP Autism Network: Dopamine genes and weight in children with autism treated with risperidone. J Am Acad Child Adolesc Psychiatry, submitted.

150. Szatmari, P., Liu, X.Q., Goldberg, J., Zwaigenbaum, L., Paterson, A.D., Woodbury-Smith, M., Georgiades, S., and the AGP Consortium: Sex differences in repetitive stereotyped behaviors in autism: Implications for genetic liability. Neuropsychiatric Genetics, submitted.

151. Anney, R., Heron, E.A., Segurado, R., and the AGP Consortium: Gene pathways involved in neuron migration show enriched association signals in autism: Evidence from the Autism Genome Project. Mol Psychiatry, submitted.

152. Aman, M.G., Nagaraja, H.N., Rettiganti, M., and the RUPP Autism Network: Tolerability, safety, and efficacy of risperidone in children and adolescents with autism: Findings 21 months following an acute controlled trial. J Child Adolesc Psychopharmacol, submitted.

153. Erickson, C.A., Stigler, K.A., Wink, L.K., Mullett, J.E., Kohn, A., Posey, D.J., **McDougle, C.J.**: A prospective open-label trial of aripiprazole in Fragile X Syndrome. Psychopharmacology, submitted.

154. Casey, J.P., Magalhaes, T., Conroy, J.M., Regan, R., Shah, N., Anney, R., Shields, D.C., Abrahams, B.S., Almeida, J., Bacchelli, E., Bailey, A.J., Baird, G., Battaglia, A., Berney, T., Bolton, P.F., Bourgeron, T., Brennan, S., Cali, P., Correia, C., Corsello, C., Dawson,

G., de Jonge, M., Delorme, R., Duketis, E., Duque, F., Estes, A., Farrar, P., Fernandez, B.A., Folstein, S.E., Fombonne, E., Freitag, C.M., Gilbert, J., Gillberg, C., Glessner, J.T., Green, J., Guter, S.J., Hakonarson, H., Holt, R., Hughes, G., Hus, V., Igliozzi, R., Kim, C., Klauck, S.M., Kolevzon, A., Lamb, J.A., Leboyer, M., Couteur, A.L., Leventhal, B.L., Lord, C., Lund, S.C., Maestrini, E., Mantoulan, C., Marshall, C.R., McConachie, H., **McDougle, C.J.,** McGrath, J., McMahon, W.M., Merikangas, A., Miller, J., Minopoli, F., Mirza, G.K., Munson, J., Nelson, S.F., Nygren, G., Oliveira, G., Pagnamenta, A., Papanikolaou, K., Parr, J.R., Parrini, B., Pickles, A., Pinto, D., Piven, J., Posey, D.J., Poustka, A., Poustka, F., Ragoussis, J., Roge, B., Rutter, M.L., Sequeira, A.F., Soorya, L., Sousa, I., Sykes, N., Stoppioni, V., Tancredi, R., Tauber, M., Thompson, A.P., Thomson, S., Tsiantis, J., Van Engeland, H., Vincent, J.B., Volkmar, F., Vorstman, J.A.S., Yaspan, S., Wang, K., Wassink, T.H., Wing, K., Wittemeyer, K., Yaspan, B.L., Zwaigenbaum, L., Betancur, C., Buxbaum, J.D., Cantor, R.M., Cook, E.H., Coon, H., Cuccaro, M.L., Geschwind, D.H., Haines, J.L., Hallmayer, J., Monaco, A.P., Nurnberger Jr., J.I., Pericak-Vance, M.A., Schellenberg, G.D., Scherer, S.W., Sutcliffe, J.S., Szatmari, P., Vieland, V.J., Wijsman, E.M., Green, A., Gill, M., Gallagher, L., Vicente, A., Ennis, S.: Homozygous haplotype sharing reveals candidate genes in autism spectrum disorder. Nature Genetics, submitted.

155. Farmer, C., Lecavalier, L., Yu, S., Arnold, L.E., **McDougle, C.J.**, Scahill, L., Handen, B., Johnson, C., Stigler, K.A., Bearrs, K., Swiezy, N.B., Aman, M.: Predictors and moderators of parent training efficacy in a sample of children with autism spectrum disorders and serious behavioral problems. J Autism Dev Disord, submitted.

156. Anney, R.J.L., Heron, E.A., Segurado, R., Kenny, E.M., O'Dushlaine, C., Yaspan, B.L., Parkhomenka, E., The Autism Genome Project, Buxbaum, J.D., Sutcliffe, J., Gill, M., Gallagher, L.: Gene ontology enrichment analysis in two independent family-based samples highlights biologically plausible processes for autism spectrum disorders. Mol Psychiatry, submitted

Case Reports:

1. **McDougle, C.J.**, Goodman, W.K., Delgado, P.L., Price, L.H.: Pathophysiology of obsessive compulsive disorder. Am J Psychiatry 146:1350-1351, 1989.

2. **McDougle, C.J.**, Southwick, S.M.: Emergence of an alternate personality in combat-related posttraumatic stress disorder. Hospital and Community Psychiatry 41:554-556, 1990.

3. **McDougle, C.J.**, Southwick, S.M., Rohrbaugh, R.M.: Tourette's disorder and associated complex behaviors: A case report. Yale Journal of Biology and Medicine 63:209-214, 1990.

4. **McDougle, C.J.**, Price, L.H., Goodman, W.K.: Fluvoxamine treatment of coincident autistic disorder and obsessive compulsive disorder: A case report. J Autism Dev Disord 20(4):537-543, 1990.

5. Satel, S.L., **McDougle, C.J.**: Obsessions and compulsions associated with cocaine abuse. Am J Psychiatry 148:947, 1991.

6. **McDougle, C.J.**, Naylor, S.T., Goodman, W.K., Volkmar, F.R., Cohen, D.J., Price, L.H.: Acute tryptophan depletion in autistic disorder: A controlled case study. Biol Psychiatry 33:547-550, 1993.

7. Epperson, C.N., **McDougle, C.J.**, Anand, A., Marek, G.J., Naylor, S.T., Volkmar, F.R., Cohen, D.J., Price, L.H.: Lithium augmentation of fluvoxamine in autistic disorder: A case report. J Child Adolesc Psychopharmacol 4:201-207, 1994.

8. Anand, A., Malison, R., **McDougle, C.J.**, Price, L.H.: Antiglucocorticoid treatment of refractory depression with ketoconazole: A case report. Biol Psychiatry 37:338-340, 1995.

9. Potenza, M.N., Wasylink, S., Epperson, C.N., **McDougle, C.J.**: Olanzapine augmentation of fluoxetine in the treatment of trichotillomania. Am J Psychiatry, 155:1299-1300, 1998.

10. Potenza, M.N., Wasylink, S., Longhurst, J.G., Epperson, C.N., **McDougle, C.J.**: Olanzapine augmentation of fluoxetine in the treatment of refractory obsessive-compulsive disorder. J Clin Psychopharmacol 18(5):423-424, 1998.

11. Posey, D.J., Litwiller, M., Kohburn, A., **McDougle, C.J.**: Paroxetine in autism. J Am Acad Child Adolesc Psychiatry 38:111-112, 1999.

12. Gensheimer, P.M., Meighen, K.G., **McDougle, C.J.**: ECT in an adolescent with Down syndrome and treatment-refractory major depressive disorder. J Dev Phys Disabil 14(3): 291-295, 2002.

13. Kem, D.L., Posey, D.J., **McDougle, C.J.**: Priapism associated with trazodone in an adolescent with autism. J Am Acad Child Adolesc Psychiatry 41(7):758, 2002.

14. Morris, D.R., Meighen, K.G., **McDougle, C.J**.: Acute onset of obsessive-compulsive disorder in an adolescent with acute lymphoblastic leukemia. Psychosomatics 46(5):458-460, 2005.

15. Stigler, K.A., Posey, D.J., **McDougle, C.J.**: Ramelteon for insomnia in two youth with autistic disorder. J Child Adolesc Psychopharmacol 16(5):631-636, 2006.

16. Stigler, K.A., Erickson, C.A., Mullett, J.E., Posey, D.J., **McDougle, C.J.**: Paliperidone for irritability in autistic disorder. J Child Adolesc Psychopharmacol 20(1):75-78, 2010.

17. Blankenship, K., Erickson, C.A., Stigler, K.A., Posey, D.J., **McDougle, C.J.**: Guanfacine XR in pervasive developmental disorders. J Child Adolesc Psychopharmacol, in press.

18. Orsagh-Yentis, D.K., Wink, L.K., Erickson, C.A., **McDougle, C.J.**: Buspirone for bruxism in a child with pervasive developmental disorder not otherwise specified. J Child Adolesc

Psychopharmacol, submitted.

Reviews/Chapters:

1. **McDougle, C.J.**, Goodman, W.K.: Obsessive compulsive disorder: Recent neurobiological developments. Current Opinion in Psychiatry 3:239-244, 1990.

2. Goodman, W.K., **McDougle, C.J.**: Serotonin reuptake inhibitors in obsessive compulsive disorder. Ann Clin Psychiatry 2(3):173-181, 1990.

3. **McDougle, C.J.**, Goodman, W.K.: Obsessive compulsive disorders: Pharmacotherapy and pathophysiology. Current Opinion in Psychiatry 4:267-272, 1991.

4. Woods, S.W., O'Malley, S., Martini, B.L., **McDougle, C.J.**, Price, L.H., Krystal, J.H., Hoffer, P.B., Kosten, T.R.: SPECT regional cerebral blood flow in HIV infected drug abusers. NIDA Research Monograph, Problems of Drug Dependence, Proceedings of the 53rd Annual Scientific Meeting, Committee on Problems of Drug Dependence, 1991.

5. **McDougle, C.J.**, Goodman, W.K.: Studies of fluvoxamine in OCD, In Symposium: Rational Pharmacotherapy in Obsessive Compulsive Disorders - From Animal Models to Studies in Man, 5th World Congress of Biological Psychiatry, Florence, Italy, June 9-14, 1991, Biological Psychiatry, Volume 1, pp. 671-674, Elsevier Science Publisher, 1991.

6. **McDougle, C.J.**: Aggression and serotonin in autistic patients. In Conference Proceedings, Destructive Drives and Impulse Control, Fourth International Symposium, Amsterdam, The Netherlands, 1991.

7. Goodman, W.K., **McDougle, C.J.**, Price, L.H.: Pharmacotherapy of obsessive compulsive disorder. J Clin Psychiatry 53[4,suppl]:29-37, 1992.

8. **McDougle, C.J.**, Goodman, W.K., Price, L.H.: New research on the neurobiology of obsessive compulsive disorder. Current Opinion in Psychiatry 5:249-254, 1992.

9. **McDougle, C.J.**: The pharmacotherapy of treatment-resistant OCD. In Conference Proceedings, Obsessive-Compulsive Disorders: New Research Results, Hamburg, Germany, pp. 152-156, Springer-Verlag, 1992.

10. Black, J., **McDougle, C.J.**, Price, L.H.: Clinical neurobiology of cocaine administration and abstinence. In, Clinician's Guide to Cocaine Addiction: Theory, Research, and Treatment, Kosten TR, Kleber HD (eds), Guilford Publications, New York, pp 151-171, 1992.

11. Goodman, W.K., **McDougle, C.J.**, Price, L.H.: The role of serotonin and dopamine in the pathophysiology of obsessive compulsive disorder. International Clinical Psychopharmacology 7:35-38, 1992.

12. **McDougle, C.J.**, Goodman, W.K., Price, L.H.: The pharmacotherapy of obsessive

compulsive disorder. Pharmacopsychiatry 26(Supplement):24-29, 1993.

13. Sherman, T.S., **McDougle, C.J.**, Price, L.H.: Paroxetine: A new serotonin uptake inhibitor for the treatment of depression. Conn Med 57(9):587-592, 1993.

14. **McDougle, C.J.**, Goodman, W.K., Leckman, J.F., Price, L.H.: The Psychopharmacology of Obsessive Compulsive Disorder: Implications for Treatment and Pathogenesis. In Psychiatric Clinics of North America, Vol 16(4), Dunner DL (ed), W. B. Saunders Co., Philadelphia, pp 749-766, 1993.

15. **McDougle, C.J.**: Treatment of nonresponders to serotonin reuptake inhibitors. In Conference Proceedings, Obsessive Compulsive Disorder: Clinical Frontiers, University of Chicago, Chicago, IL, 1993.

16. Goodman, W.K., **McDougle, C.J.**, Barr, L.C., Aronson, S., Price, L.H.: Biological approaches to treatment-resistant obsessive compulsive disorder. J Clin Psychiatry 54(6, suppl):16-26, 1993.

17. **McDougle, C.J.**, Price, L.H., Volkmar, F.R.: Recent advances in the pharmacotherapy of autism and related conditions. In Child and Adolescent Psychiatric Clinics of North America, Vol 3(1), Volkmar, F.R. (ed), WB Saunders Co., Philadelphia, pp 71-89, 1994.

18. **McDougle, C.J.**, Goodman, W.K., Price, L.H.: Dopamine antagonists in tic-related and psychotic spectrum OCD. J Clin Psychiatry 55[3,suppl]:24-31, 1994.

19. Volkmar, F.R., Klin, A., Marans, W.D., **McDougle, C.J.**: Autistic disorder. In Psychoses and Pervasive Developmental Disorders in Childhood and Adolescence, Volkmar, F. (ed), American Psychiatric Press, Inc., Washington, DC, pp 129-190, 1996.

20. Brodkin, E.S., **McDougle, C.J.**, Leckman, J.F. Antipsychotic drugs in children and adolescents. In Handbook of Experimental Pharmacology: Antipsychotics, Csernansky, J.G. (ed), Springer-Verlag, Berlin, Volume 120, pp. 479-504, 1996.

21. Carpenter, L., **McDougle, C.J.**, Epperson, C.N., Price, L.H.: A risk-benefit assessment of drugs used in the management of obsessive-compulsive disorder. Drug Safety 15(2):116-134, August, 1996.

22. **McDougle, C.J.**, Goodman, W.K.: Combination pharmacological treatment strategies. In Obsessive-Compulsive Disorders: Diagnosis, Etiology, and Treatment, Hollander, E., Stein, D. (eds), Marcel Dekker, Inc., New York, pp. 203-223, 1997.

23. **McDougle, C.J.**: Risperidone in treatment-refractory obsessive-compulsive disorder and autism-spectrum disorders. In, The Art of Rational Risperidone Therapy, Ayd, Jr., F. (ed), Ayd Medical Communications, Baltimore, MD, pp 59-72, 1997.

24. Potenza, M.N., **McDougle, C.J.**: The role of serotonin in autism-spectrum disorders. CNS

Spectrums 2(5):25-42, 1997.

25. **McDougle, C.J.**: Psychopharmacology (Chapter 32). In Handbook of Autism and Pervasive Developmental Disorders, Second Edition. Cohen, D.J., Volkmar, F.R. (eds), John Wiley & Sons, New York, pp. 707-729, 1997.

26. Potenza, M.N., **McDougle, C.J.**: New findings on the causes and treatment of autism. Medscape Mental Health 2(8), 1997 (electronic journal).

27. **McDougle, C.J.**: Update on pharmacologic management of OCD: Agents and augmentation. J Clin Psychiatry 58(suppl 12):11-17, 1997.

28. **McDougle**, C.J.: Psychopharmacology (Chapter 6). In Autism and Pervasive Developmental Disorders, Volkmar, F.R. (ed), Cambridge University Press, New York, pp. 169-194, 1998.

29. **McDougle, C.J.**: Repetitive thoughts and behavior in pervasive developmental disorders: Phenomenology and pharmacotherapy (Chapter 13). In Asperger Syndrome or High Functioning Autism?, Schopler, E., Mesibov, G.B., Kunce, L.J. (eds), Current Issues in Autism Series, Plenum Publishing Corporation, New York, pp. 293-316, 1998.

30. Carpenter, L.L., Leckman, J.F., Scahill, L., **McDougle, C.J.**: Pharmacological and other somatic approaches to treatment (Chapter 19). In Tourette's Syndrome and Tic-Related Obsessive Compulsive Disorder: Natural History, Genetics, Neurobiology and Treatment, Leckman, J.F., Cohen, D.J. (eds), New York: Wiley-Liss, Inc. pp. 340-367, 1998.

31. **McDougle, C.J.**, Potenza, M.N.: Atypical neuroleptics in obsessive-compulsive disorder. Int Drug Ther Newsl 33(6):21-24, 1998.

32. **McDougle, C.J.**, Potenza, M.N.: Use of typical neuroleptics in OCD and Psychotic Disorders. Int Drug Ther Newsl 33(7): 25-28, 1998.

33. Price, L.H., Malison, R.T., **McDougle, C.J.**, Pelton, G.H.: Antiglucocorticoids as treatments for depression: Rationale for use and therapeutic potential. In Disease Management Review - Depression, Adis International, Auckland, I:99-108, 1998.

34. **McDougle, C.J.**: The Neurobiology and Treatment of Obsessive-Compulsive Disorder (Chapter 37). In The Neurobiology of Mental Illness, Charney, D.S., Nestler, E.J., Bunney, B.S. (eds), Oxford University Press, New York, pp. 518-533, 1999.

35. Walsh, K.H., **McDougle, C.J.**: SSRIs in children and adolescents: Research in autism, selective mutism, and Prader-Willi syndrome. Int Drug Ther Newsl 34(12): 89-94, 1999.

36. Leckman, J.F., **McDougle, C.J.**, Pauls, D.L., Peterson, B.S., Grice, D.E., King, R.A., Scahill, L., Price, L.H., Rasmussen, S.A.: Tic-related versus non-tic-related obsessive-compulsive disorder (Chapter 3). In Obsessive-Compulsive Disorder:

Contemporary Issues in Treatment, Goodman, W.K., Rudorfer, M.V., Maser, J.D. (eds), Lawrence Erlbaum Associates, Inc., Publishers, Mahwah, NJ, pp. 43-68, 2000.

37. **McDougle, C.J.**, Epperson, C.N., Price, L.H.: The role of neuroleptics in treatment-refractory obsessive-compulsive disorder (Chapter 19). In Obsessive-Compulsive Disorder: Contemporary Issues in Treatment, Goodman, W.K., Rudorfer, M.V.., Maser, J.D. (eds), Lawrence Erlbaum Associates, Inc., Publishers, Mahwah, NJ, pp. 371-391, 2000.

38. Walsh, K.H., **McDougle, C.J.**: When SSRIs make sense. Contemporary Pediatrics, 1:83-105, 2000.

39. **McDougle, C.J.**, Scahill, L., McCracken, J.T., Aman, M.G., Tierney, E., Arnold, L.E., Freeman, B.J., Martin, A., McGough, J.J., Posey, D.J., Riddle, M.A., Ritz, L., Swiezy, N.B., Vitiello, B., Volkmar, F.R., Votolato, N., Walson, P.: Research Units on Pediatric Psychopharmacology (RUPP) - Autism Network: Background and rationale for an initial controlled study of risperidone, In Child and Adolescent Psychiatric Clinics of North America, Vol 9 (1), Martin, A., Scahill, L. (eds), WB Saunders Co., Philadelphia, pp. 201-224, 2000.

40. Goodman, W.K., **McDougle, C.J.**, Byerly, M., Murphy, T., Ward, H.E.: Chapter 31. New approaches to treatment-refractory obsessive-compulsive disorder. In Pharmacotherapy for Mood, Anxiety, and Cognitive Disorders, Halbreich, U. Montgomery, S.A. (eds), American Psychiatric Press, Washington DC, pp. 479-498, 2000.

41. Posey, D.J., **McDougle, C.J.**: The pharmacotherapy of target symptoms associated with autistic disorder and other pervasive developmental disorders. Harvard Review of Psychiatry 8:45-63, 2000.

42. Bangs, M.E., **McDougle, C.J.**: Bipolar disorder in children and adolescents. Part I: Diagnostic issues and treatment with lithium and carbamazepine. Int Drug Ther Newsl 35(12):89-95, 2000.

43. Bangs, M.E., **McDougle, C.J.**: Bipolar disorder in children and adolescents. Part II: Valproate and other newer treatments. Int Drug Ther Newsl 36(1):1-6, 2001.

44. Posey, D.J., **McDougle, C.J.**: Pharmacotherapeutic management of autism. Expert Opinion in Pharmacotherapy, 2(4):587-600, 2001.

45. Posey, D.J., **McDougle, C.J.**: The pathophysiology and treatment of autism. Current Psychiatry Reports 3:101-108, 2001.

46. Dunn, D.W., **McDougle, C.J.**: Childhood-onset schizophrenia (Chapter 21). In Current Issues in the Psychopharmacology of Schizophrenia, Breier, A., Tran, P.V., Herrera, J.M., Bymaster, F., Tollefson, G.D., (eds), Lippincott-Williams & Wilkens, Philadelphia, PA, pp. 375-388, 2001.

47. **McDougle, C.J.**, Walsh, K.H.: Treatment of Refractory OCD. In Obsessive Compulsive Disorder: A Practical Guide, Feinberg, N., Marazzitti, D., Stein, D.J. (eds), Martin Dunitz Ltd, London, pp. 135-152, 2001.

48. Walsh, K.H., **McDougle, C.J.**: Trichotillomania: Presentation, etiology, diagnosis and therapy. American Journal of Clinical Dermatology, 2(5):327-333, 2001.

49. Stigler, K.A., Potenza, M.N., **McDougle, C.J.**: Tolerability profile of atypical antipsychotics in children and adolescents. Paediatric Drugs, 3(12):927-942, 2001.

50. Posey, D.J., **McDougle, C.J.**: Practical pharmacotherapeutic management of autism: A review and update of commonly prescribed drugs. Int Drug Ther Newsl 37(1):1-8, 2002.

51. **McDougle, C.J.**: Current and emerging therapeutics of autistic disorder and related pervasive developmental disorders (Chapter 42). In Neuropsychopharmacology - The Fifth Generation of Progress, Davis, K.L., Charney, D., Coyle, J.T., Nemeroff, C. (eds), Lippincott - Williams & Wilkens, Philadelphia, PA, pp. 565-576, 2002.

52. Walsh, K.H., **McDougle, C.J.**: When SSRIs make sense for pediatric use. Patient Care 2: 25-33, 2002.

53. Dunn, D.W., **McDougle, C.J.**: Childhood-onset schizophrenia. Child and Adolescent Psychopharmacology News 7(2):1-4, 2002.

54. Walsh, K.H., **McDougle, C.J.**: A rational approach to Tourette's disorder, Patient Care 7:59-75, 2002.

55. Stigler, K.A., Posey, D.J., **McDougle, C.J.**: Recent advances in the pharmacotherapy of autism. Expert Review of Neurotherapeutics 2(4):499-510, 2002.

56. Posey, D.J., **McDougle, C.J.**: Autism: A three-step practical approach to making the diagnosis. Current Psychiatry 1(7):21-28, 2002.

57. Posey, D.J., **McDougle, C.J.**: Risperidone: A potential treatment for autism. Curr Opin Investig Drugs 3(8):1212-1216, 2002.

58. Goddard, A.W., Shekhar, A., Anand, A., Walsh, K., **McDougle, C.J.**: Psychopharmacology of pediatric anxiety disorders. Int Drug Ther Newsl 37(12): 89-96, 2002.

59. **McDougle, C.J.**, Posey, D.J.: Autistic and other pervasive developmental disorders (Chapter 42). In Pediatric Psychopharmacology: Principles and Practice, Martin, A., Scahill, L., Charney, D.S., Leckman, J.F. (eds), Oxford University Press, New York, NY, pp. 563-579, 2003.

60. **McDougle, C.J.**, Posey, D.J., Potenza, M.N.: Neurobiology of serotonin function in

autism (Chapter 10). In Autism Spectrum Disorders, Hollander, E. (ed), Marcel Dekker, Inc., New York, NY, pp. 199-220, 2003.

61. Posey, D.J., **McDougle, C.J.**: Use of atypical antipsychotics in autism (Chapter 13). In Autism Spectrum Disorders, Hollander, E. (ed), Marcel Dekker, Inc., New York, NY, pp. 247-264, 2003.

62. **McDougle, C.J.**, Stigler, K.A., Posey, D.J.: Treatment of aggression in children and adolescents with autism and conduct disorder. J Clin Psychiatry, 64[suppl 4]:16-25, 2003.

63. Stigler, K.A., Posey, D.J., **McDougle, C.J.**: Atypical antipsychotics in pediatric psychiatry: Efficacy and tolerability in well-designed trials. Child and Adolescent Psychopharmacology News, 8(1):8-11, 2003.

64. Stigler, K.A., Posey, D.J., **McDougle, C.J.**: Drug therapy algorithms target autism's problem behaviors. Current Psychiatry, 2(4):33-48, 2003.

65. Bukhari, L., Anand, A., **McDougle, C.J.**: Psychopharmacology of pediatric depression. Int Drug Ther Newsl 38(10):73-80, 2003.

66. Stigler, K.A., Posey, D.J., **McDougle, C.J.**: Advances in the pharmacotherapy of pervasive developmental disorders. Child and Adolescent Psychopharmacology News 8(7):6-11, 2003.

67. Stigler, K.A., Potenza, M.N., Posey, D.J., **McDougle, C.J.**: Weight gain associated with atypical antipsychotic use in children and adolescents: Prevalence, clinical relevance, and management. Pediatric Drugs 6(1):33-44, 2004.

68. Stigler, K.A., Posey, D.J., **McDougle, C.J.**: Are psychostimulants useful in pervasive developmental disorders? Current Psychiatry 3(7):55-65, 2004.

69. Stigler, K.A., Posey, D.J., **McDougle, C.J.**: Pharmacotherapy of hyperactivity and inattention in pervasive developmental disorders. Int Drug Ther News 39(8):57-64, 2004.

70. Walsh, K.H., **McDougle, C.J.**: Pharmacological augmentation strategies for treatment-resistant obsessive-compulsive disorder. Expert Opinion on Pharmacotherapy 5(10):2059-2067, 2004.

71. Stigler, K.A., Posey, D.J., **McDougle, C.J.**: Psychotropic medications for mood disorders in persons with mental retardation (Chapter 10). In Mood Disorders in People with Mental Retardation, Sturmey, P. (ed), NADD Press, Kingston, NY, pp. 211-228, 2005.

72. Walsh, K.H., **McDougle, C.J.**: Pharmacological strategies for trichotillomania. Expert Opin Pharmacother 6(6):975-984, 2005.

73. Erickson, C.A., Stigler, K.A., Posey, D.J., **McDougle, C.J.**: Risperidone in pervasive

developmental disorders. Expert Rev Neurothe 5(6):713-719, 2005.

74. **McDougle, C.J.**, Erickson, C.A., Stigler, K.A., Posey, D.J.: Neurochemistry in the pathophysiology of autism. J Clin Psychiatry 66[suppl 10]:9-18, 2005.

75. Erickson, C.A., Stigler, K.A., Corkins, M.R., Posey, D.J., Fitzgerald, J.F., **McDougle, C.J.**: Gastrointestinal factors in autistic disorder: A critical review. J Autism Dev Disord 35(6): 713-727, 2005.

76. **McDougle, C.J.**, Posey, D.J., Stigler, K.A.: Pharmacological treatments (Chapter 18). In Understanding Autism: From Basic Neuroscience to Treatment, Moldin, S.O., Rubenstein, J.L.R. (eds), CRC Press, Boca Raton, pp. 417-442, 2006.

77. Posey, D.J., Erickson, C.A., Stigler, K.A., **McDougle, C.J.**: The use of selective serotonin reuptake inhibitors in autism and related disorders. J Child Adolesc Psychopharmacol 16(1/2):181-186, 2006.

78. Erickson, C.A., Stigler, K.A., Posey, D.J., **McDougle, C.J.**: Managing maladaptive behaviors in Fragile X patients. Current Psychiatry 5(10):80-92, 2006.

79. **McDougle, C.J.**, Stigler, K.A., Erickson, C.A., Posey, D.J.: Pharmacology of autism. Clinical Neuroscience Research 6:179-188, 2006.

80. Erickson, C.A., Stigler, K.A., Posey, D.J., **McDougle, C.J.**: Psychopharmacology (Chapter 7). In Autism and Pervasive Developmental Disorders, 2nd Edition, Volkmar, F.R. (ed), Cambridge University Press, Cambridge, pp. 221-253, 2007.

81. Erickson, C.A., Stigler, K.A., Posey, D.J., **McDougle, C.J.**: The psychopharmacology of Fragile X Syndrome. Int Drug Ther Newsl 42(5):35-42, 2007.

82. Stigler, K.A., Erickson, C.A., Posey, D.J., **McDougle, C.J.**: Autism and other pervasive developmental disorders (Chapter 7). In Clinical Manual of Child and Adolescent Psychopharmacology, Findling, R.L., (ed.), American Psychiatric Publishing, Inc., Arlington, VA, pp. 265-300, 2007.

83. Odom, S.L., Rogers, S., **McDougle, C.J.**, Hume, K., McGee, G.: Early Intervention for Children with Autism Spectrum Disorder (Chapter 10). In Handbook of Developmental Disabilities, Odom, S.L., Horner, R.H., Snell, M.E., Blacher, J. (eds.), Guilford Press, New York, NY, pp. 199-223, 2007.

84. Erickson, C.A., Posey, D.J., Stigler, K.A., **McDougle, C.J.**: Pharmacotherapy of autism and related disorders. Psychiatr Ann 37(7):490-500, 2007.

85. Posey, D.J., Stigler, K.A., Erickson, C.A., **McDougle, C.J.**: Treatment of autism with antipsychotics (Chapter 5). In Clinical Manual for the Treatment of Autism, Hollander, E., Anagnostou, E. (eds.), American Psychiatric Publishing, Inc., Arlington, VA, pp. 99-120,

2007.

86. Erickson, C.A., Posey, D.J., Stigler, K.A., **McDougle, C.J.**: Pharmacologic treatment of autism and related disorders. Pediatric Ann 36(9):575-585, 2007.

87. Posey, D.J., **McDougle, C.J.**: Guanfacine and guanfacine extended release: Treatment for ADHD and related disorders. CNS Drug Rev 13(4):465-474, 2007.

88. Posey, D.J., Stigler, K.A., Erickson, C.A., **McDougle, C.J.**: Antipsychotics in the treatment of autism. J Clin Invest 118(1):6-14, 2008.

89. **McDougle, C.J.**, Hulvershorn, L.A., Erickson, C.A., Stigler, K.A., Posey, D.J.: Autistic syndromes (Chapter 16). In Clinical Handbook of Obsessive-Compulsive Disorder and Related Problems, Abramowitz, J.S., McKay, D., Taylor, S. (eds), The Johns Hopkins University Press, Baltimore, pp.238-256, 2008.

90. Goddard, A.W., Shekhar, A., Whiteman, A.F., **McDougle, C.J.**: Serotoninergic mechanisms in the treatment of obsessive-compulsive disorder. Drug Discovery Today 13(7/8):325-332, 2008.

91. Walsh, K.H., Scott, E.L., **McDougle, C.J.**: The use of antipsychotics in the treatment of obsessive-compulsive disorder. Psychopharm Review 43(4):27-34, 2008.

92. Scott, E.L., Walsh, K.H., **McDougle, C.J.**: Treatment of Tourette's Syndrome. Psychopharm Review 43(6):43-50, 2008.

93. **McDougle, C.J.**, Stigler, K.A., Erickson, C.A., Posey, D.J.: Atypical antipsychotics in autistic and other pervasive developmental disorders. J Clin Psychiatry 69[suppl 4]:15-20, 2008.

94. Stigler KA, **McDougle CJ**: Pharmacotherapy of irritability in pervasive developmental disorders. Child Adolesc Psychiatr Clin N Am 17:739-752, 2008.

95. Posey, D.J., Erickson, C.A., **McDougle, C.J.**: Developing drugs for core social and communication impairment in autism. Child Adolesc Psychiatr Clin N Am 17:787-801, 2008.

96. Erickson, C.A., **McDougle, C.J.**, Stigler, K.A., Posey, D.J.: Glutamatergic function in autism. In Glutamate in Neuropsychiatric Disorders, Heresco-Levy U, Javitt DC (eds.), Research Signpost, Trivandrum, Kerala, India, pp. 197-212, 2008.

97. Stigler, K.A., Sweeten, T.L., Posey, D.J., **McDougle, C.J.**: Autism and immune factors: A comprehensive review. Res Autism Spectr Disord 3:840-860, 2009.

98. Minshawi, N.F., Swiezy, N.B., Pozdol, S., Stuart, M., **McDougle, C.J.**: Pervasive developmental disorders. In Young Adult Mental Health, Grant, J.E., Potenza, M.N. (eds),

Oxford University Press, New York, pp. 406-423, 2010.

99. Blankenship, K., Erickson, C.A., **McDougle, C.J.**: Pharmacotherapy of autism and related disorders. Psychiatr Ann 40(4):203-209, 2010.

100. **McDougle, C.J.**: Psychopharmacology of Autism. In Model Psychopharmacology Curriculum, Sixth Edition, Glick, I., Balon, R., Zisook, S. (eds), American Society of Clinical Psychopharmacology, Glen Oaks, NY, Volume III, Lecture Modules, Child and Adolescent Psychopharmacology, 505.1-505.17, 2010.

101. Erickson, C.A., Stigler, K.A., Posey, D.J., **McDougle, C.J.**: Aripiprazole in autism spectrum disorders and fragile X syndrome. Neurotherapeutics 7(3):258-263, 2010.

102. Wink, L.K., Plawecki, M.H., Erickson, C.A., Stigler, K.A., **McDougle, C.J.**: Emerging drugs for the treatment of symptoms associated with autism spectrum disorders. Expert Opin Emerg Drugs, 15(3):481-494, 2010.

103. Blankenship, K., Erickson, C.A., Stigler, K.A., Posey, D.J., **McDougle, C.J.**: Aripiprazole for irritability associated with autistic disorder in children and adolescents ages 6 to 17 years. Pediatric Health 4(4):375-381, 2010.

104. **McDougle, C.J.**, Posey, D.J.: Assessment and Treatment of Autistic and Other Pervasive Developmental Disorders (Chapter 38). In Pediatric Psychopharmacology: Principles and Practice, Second Edition, Martin, A., Scahill, L., Kratochvil, C. (eds), Oxford University Press, New York, NY, pp. 547-560, 2010.

105. Wink, L.K., Erickson, C.A., **McDougle, C.J.**: Pharmacologic treatment of behavioral symptoms associated with autism and other pervasive developmental disorders. Curr Treat Options Neurol, 12(6):529-538, 2010.

106. Erickson, C.A., Stigler, K.A., Posey, D.J., **McDougle, C.J**.: Antipsychotics (Chapter 40). In Textbook of Autism Spectrum Disorders, Hollander, E., Kolevzon, A., Coyle, J.T. (eds), American Psychiatric Publishing, Inc., Arlington, VA, pp. 467-477, 2011.

107. Posey, D.J., Lodin, Z., Erickson, C.A., Stigler, K.A., **McDougle, C.J.:** The neurochemistry of ASD (Chapter 4). In The Neuropsychology of Autism, Fein DA (ed), Oxford University Press, New York, pp. 77-96, 2011.

108. Blankenship, K., Stigler, K.A., Erickson, C.A., Posey, C.J., **McDougle, C.J.**: Psychopharmacological treatment of autism. In Autism Spectrum Disorders, Amaral, D., Dawson, G., Geschwind, D. (eds), Oxford University Press, New York, in press.

109. Erickson, C.A., **McDougle, C.J.**: Developmental disabilities. In Principles of Psychiatric Genetics, Nurnberger, J., Berrettini, W. (eds), Cambridge University Press, New York, in press.

110. Blankenship, K., Erickson, C.A., Stigler, K.A., Posey, D.J., **McDougle, C.J**.: Autism spectrum disorders and mental retardation. In Encyclopedia of Psychopharmacology, Stolerman, I.P. (ed), Springer-Verlag, Berlin/Heidelberg, Germany, in press.

111. Walsh, K.H., **McDougle, C.J.**: Impulsivity in childhood. In Oxford Handbook of Impulse Control Disorders, Grant, J.E., Potenza, M.N. (eds), Oxford University Press, New York, NY, in press.

112. Stigler, K.A., Erickson, C.A., Posey, D.J., **McDougle, C.J.**: Historical perspectives on the use of therapeutic agents to treat neurodevelopmental disorders. In Translational Neuroscience: Applications in Neurology, Psychiatry, and Neurodevelopmental Disorders, Barrett, J.E., Coyle, J.T., Williams, M. (eds), Cambridge University Press, New York, in press.

113. Stigler, K.A., McDonald, B.C., Anand, A., Saykin, A.J., **McDougle, C.J.**: Structured and functional magnetic resonance imaging of autism spectrum disorders. Brain Research, in press.

Miscellaneous:

1. **McDougle, C.J.**, Milstein, V.: MHPG, ECT and depression (Letter to the Editor). Biol Psychiatry 20:927, 1985.

2. **McDougle, C.J.**: Obsessive-compulsive disorder reconsidered. Book review of Obsessive-Compulsive Disorders: Theory and Management by Jenike, M.A., et. al. (eds.). Jefferson Journal of Psychiatry 6:72-75, 1988.

3. **McDougle, C.J.**, Seibyl, J.P.: Research training in the residency years: A question of balance. Psychiatric Research Report 3(3):7,10, 1988.

4. Seibyl, J.P., **McDougle, C.J.**: Research training in the residency years. A survey of training program experiences. Psychiatric Research Report 3(4):6-7, 1988.

5. **McDougle, C.J.**, Seibyl, J.P.: Research training in the residency years: The state hospital experience. Psychiatric Research Report 4(1):8-9, 1989.

6. **McDougle, C.J.**, Seibyl, J.P.: APA young investigators poster session provides new forum for discussion of research projects. Psychiatric Research Report 4(2):6-7, 1989.

7. **McDougle, C.J.**, Goodman, W.K., Price, L.H., Delgado, P.L., Krystal, J.H., Charney, D.S., Heninger, G.R.: Neuroleptic addition in fluvoxamine-refractory obsessive compulsive disorder. Yale Psychiatr Quart 12(1):9-10, 1989.

8. **McDougle, C.J.**, Seibyl, J.P.: Choosing a research career: Two vignettes. Psychiatric Research Report 4(3):6, 1989.

9. **McDougle, C.J.**, Seibyl, J.P.: Psychiatric research and women: Will ever the twain meet? Psychiatric Research Report 4(4):6-7,1990.

10. **McDougle, C.J.**, Seibyl, J.P.: Psychiatric research and women II: Will ever the twain meet? Psychiatric Research Report 5(1):11-12, 1990.

11. **McDougle, C.J.**, Seibyl, J.P.: Expanded young investigators poster session provides increased opportunities for new researchers. Psychiatric Research Report 5(2)5-6, 1990.

12. **McDougle, C.J.**, Price, L.H., Goodman, W.K., Charney, D.S., Heninger, G.R.: Lithium augmentation in fluvoxamine-refractory obsessive compulsive disorder. Yale Psychiatr Quart 13(3+4):15-16, 1990.

13. **McDougle, C.J.**: Serotonin uptake inhibitors in obsessive-compulsive disorder. Neuroscience Forum 4(2):9-11,15, 1994.

14. Price, L.H., Anand, A., Charney, D.S., Delgado, P.L., **McDougle, C.J.**, Heninger, G.R.: In reply to "Responses to mCPP in depression" (Ltr to the Ed). Am J Psychiatry 152:1834-1835, 1995.

15. **McDougle, C.J.**, Epperson, C.N., Price, L.H.: Obsessive-compulsive symptoms with neuroleptics (Ltr to the Ed). J Am Acad Child Adolesc Psychiatry 35:837, 1996.

16. **McDougle, C.J.**: Managing obsessive-compulsive patients in conjunction with the nonspecialist. Primary Psychiatry 3:19, 1996.

17. **McDougle, C.J.**: Managing obsessive-compulsive patients in conjunction with the nonspecialist. CNS Spectrums 1(1):56-58,61, 1996.

18. Epperson, C.N., Anderson, G.M., **McDougle, C.J.**: Sertraline and breast-feeding (Ltr to the Ed). N Engl J Med 336:1189-1190, 1997.

19. Longhurst, J.G, Potenza, M.N., **McDougle, C.J.**: Autism (Ltr to the Ed). N Engl J Med 337:1555-1556, 1997.

20. Potenza, M.N., **McDougle, C.J.**: Autism (Ltr to the Ed). CNS Spectrums 3(9):22, 1998.

21. Klaeger, D., **McDougle, C.J.**: Secretin in autism - a parent's perspective (Ltr to the Ed). J Autism Dev Disord 30(1):72-73, 2000.

22. **McDougle, C.J.**: Beyond serotonin reuptake inhibitors: Do we have our second wind? In Obsessive-Compulsive Disorder, M. Maj, N. Sartorius, A. Okasha, J. Zohar (eds), Evidence and Experience in Psychiatry Series, World Psychiatric Association, John Wiley & Sons, LTD, Chichester, Vol. 4, pp. 65-68, 2000.

23. Potenza, M.N., **McDougle, C.J.**: In reply to comments on "Olanzapine Treatment of Children, Adolescents, and Adults with Pervasive Developmental Disorders: An Open-Label Pilot Study" (Letter to the Editor). J Clin Psychopharmacol 21(2):246-247, 2001.

24. **McDougle, C.J.**, Price, L.H.: In Reply to: "Antiobsessional Effect of Risperidone Add-On Treatment in Serotonin Reuptake Inhibitor - Refractory Obsessive-Compulsive Disorder May Be Dose-Dependent." (Letter to the Editor). Arch Gen Psychiatry 59:472-473, 2002.

25. Posey, D.J., **McDougle, C.J.**: In Reply to: "Communication impairments in Asperger's disorder." (Letter to the Editor). Current Psychiatry 1(6):13, 2002.

26. Scahill, L., Vitiello, B., and the RUPP Autism Network. In reply to Munarriz and colleagues (Letter to the Editor). N Engl J Med, 347(23):1890-1891, 2002.

27. Stigler, K.A., Swiezy, N.B., Posey, D.J., **McDougle, C.J.**: In Reply to: "Treating autism's problem behaviors." (Letter to the Editor). Current Psychiatry 2(7):3-4, 2003.

28. **McDougle, C.J.**: Beyond stimulants: Evidence-based treatment using atypical antipsychotics. Presentations in Focus: Reports and Expert Commentary, pp. 9-11, 2003.

29. **McDougle, C.J.**, King, B.H., Pappadopulos, E.: A case-based approach to learning about the spectrum of psychiatric and behavioral disorders: What do you see in your practice? Presentations in Focus: Reports and Expert Commentary, pp. 12-14, 2003.

30. **McDougle, C.J.**: Editorial Preface. J Autism Dev Disord 34(5):469-471, 2004.

31. **McDougle, C.J.**: Ask the Editor. J Autism Dev Disord 34(5):593-594, 2004.

32. Kratochvil, C.J., Findling, R.L., **McDougle, C.J.**, Scahill, L., Hamarman, S.: Pharmacological management of agitation and aggression in an adolescent with autism. J Am Acad Child Adolesc Psychiatry 44(8):829-832, 2005.

33. Erickson, C.A., Swiezy, N.B., Stigler, K.A., **McDougle, C.J.**, Posey, D.J.: Behavioral and pharmacologic treatment of aggression in children with autism. Psychiatric Times 9:30-33, 2005.

34. **McDougle, C.J.**: Editorial Preface. J Autism Dev Disord 35(5):541-543, 2005.

35. **McDougle, C.J.**: Ask the Editor. J Autism Dev Disord 35(5):685-686, 2005.

36. **McDougle, C.J.**, Scahill, L., Aman, M.G., Arnold, L.E., McCracken, J.T., Tierney, E., Vitiello, B.: In reply to "Risperidone for the Core Symptom Domains of Autism" (Ltr to the Ed). Am J Psychiatry 163:551-552, 2006.

37. **McDougle, C.J.**: Editorial Preface. J Autism Dev Disord 36(5):581-583, 2006.

38. **McDougle, C.J.**, Krystal, J.H. (Co-Editors): Introduction to Special Issue on Pediatric Psychopharmacology: Mood, anxiety and disruptive behavior/pervasive developmental disorders. Psychopharmacology 191:1-3, 2007.

39. Krystal, J.H., Carter, C.S., Geschwind, D., Manji, H.K., March, J.S., Nestler, E.J., Zubieta, J.K., Charney, D.S., Goldman, D., Gur, R.E., Lieberman, J.A., Roy-Byrne, P., Rubinow, D.R., Anderson, S.A., Barondes, S., Berman, K.F., Blair, J., Braff, D.L., Brown, E.S., Calabrese, J.R., Carlezon, W.A., Cook, E.H., Davidson, R.J., Davis, M., Desimone, R., Drevets, W.C., Duman, R.S., Essock, S.M., Faraone, S.V., Freedman, R., Friston, K.J., Gelernter, J., Geller, B., Gill, M., Gould, E., Grace, A.A., Grillon, C., Gueorguieva, R., Hariri, A.R., Innis, R.B., Jones, E.G., Kleinman, J.E., Koob, G.F., Krystal, A.D., Leibenluft, E., Levinson, D.F., Levitt, P.R., Lewis, D.A., Liberzon, I., Lipska, B.K., Marder, S.R., Markou, A., Mason, G.F., **McDougle, C.J.**, McEwen, B.S., McMahon, F.J., Meaney, M.J., Meltzer, H.Y., Merikangas, K.R., Meyer-Lindenberg, A., Mirnics, K., Monteggia, L.M., Neumeister, A., O'Brien, C.P., Owen, M.J., Pine, D.S., Rapoport, J.L., Rauch, S.L., Robbins, T.W., Rosenbaum, J.F., Rosenberg, D.R., Ross, C.A., Rush, A.J., Sackeim, H.A., Sanacora, G., Schatzberg, A.F., Shaham, Y., Siever, L.J., Sunderland, T., Tecott, L.H., Thase, M.E., Todd, R.D., Weissman, M.M., Yehuda, R., Yoshikawa, T., Young, E.A., McCandless, R.: Commentaries: It is time to take a stand for medical research and against terrorism targeting medical scientists. Biol Psychiatry 63:725-727, 2008.

40. Posey, D.J., **McDougle, C.J.**: Preface to Treating Autism Spectrum Disorders. Child Adolesc Psychiatric Clin N Am 17:xv-xviii, 2008.

41. **McDougle, C.J.**: Commentary – Serotonin and dopamine transporter binding in children with autism. Dev Med Child Neurol 50(8):593-597, 2008.

42. Scahill, L., Aman, M.G., McCracken, J.T., **McDougle, C.J.**, Vitiello, B.: Beware of over-interpreting negative trials. (Ltr to the Ed). J Autism Dev Disord 38:1609-1610, 2008.

43. Aman, M.G., **McDougle, C.J.**, Arnold, L.E., Handen, B., Johnson, C., Lecavalier, L., Swiezy, N.B., Bearss, K., Stigler, K.A., Dziura, J., Hollway, J.A., Mulick, J.A., Vitiello, B., Scahill, L.: Risperidone and parent training in pervasive developmental disorders (Ltr to the Ed). J Am Acad Child Adolesc Psychiatry 49(4):407-408, 2010.

Abstracts:

A1. **McDougle, C.J.**, Goodman, W.K., Price, L.H., Delgado, P.L., Krystal, J.H., Charney, D.S., Heninger, G.R.: Neuroleptic addition in fluvoxamine-refractory OCD. Amer. Psychiat. Assoc. New Research Abstracts, p. 189 (#NR350), May, 1989.

A2. **McDougle, C.J.**, Krystal, J.H., Kosten, T.R., Woods, S.W., Seibyl, J., Price, L.H., Zubal, G., Hoffer, P., Kleber, H.D., Charney, D.S.: Opiate Withdrawal Effects on Regional Cerebral Blood Flow. Amer. Psychiat. Assoc. New Research Poster Session, San Francisco, California, May 11, 1989.

A3. **McDougle, C.J.**, Goodman, W.K., Price, L.H., Delgado, P.L., Krystal, J.H., Charney, D.S., Heninger, G.R.: Addition of dopamine antagonists in fluvoxamine-refractory obsessive compulsive disorder. Soc. for Neurosci. Abstr., November, 1989.

A4. Goodman, W.K., Price, L.H., **McDougle, C.J.**, Riddle, M.A., Hoffer, P.B., Woods, S.W.: SPECT regional cerebral blood flow in OCD. Soc. for Neurosci. Abstr., November, 1989.

A5. Krystal, J., Kosten, T., Woods, S., Seibyl, J., **McDougle, C.**, Price, L., Zubal, G., Hoffer, P., Kleber, H., Charney D.: Human regional cerebral blood flow alterations during naloxone-precipitated opiate withdrawal. Soc. for Neurosci. Abstr., November, 1989.

A6. **McDougle, C.J.**, Goodman, W.K., Price, L.H.: Lithium augmentation in fluvoxamine-refractory obsessive compulsive disorder. Abstr. Amer. Coll. Neuropsychopharm., December, 1989.

A7. Woods, S.W., O'Malley, S.S., Price, L.H., Krystal, J.H., Hoffer, P.B., **McDougle, C.J.**, Kosten, T.R.: SPECT regional cerebral blood flow in asymptomatic HIV + drug abusers. Abstr. Amer. Coll. Neuropsychopharm., December, 1989.

A8. Woods, S.W., Kosten, T.R., Price, L.H., **McDougle, C.J.**, Smith, E.O., Hoffer, P.B.: SPECT imaging of asymptomatic HIV+ drug abusers with Tc-99m d,l-HMPAO. The Society of Nuclear Medicine Annual Meeting, Washington, D.C., 1990.

A9. Goodman, W.K., **McDougle, C.J.**, Price, L.M., Riddle, M.A., Smith, E.O., Hoffer, P.B., Woods, S.W.: SPECT imaging of obsessive-compulsive disorder with Tc-99m d,l-HMPAO. The Society of Nuclear Medicine Annual Meeting, Washington, D.C., 1990.

A10. **McDougle, C.J.**, Price, L.H., Goodman, W.K., Charney, D.S., Heninger, G.R.: Lithium augmentation in fluvoxamine-refractory obsessive compulsive disorder. Amer. Psychiat. Assoc. New Research Abstract #302, May, 1990.

A11. **McDougle, C.J.**, Southwick, S.M., St. James, R.L., Charney, D.S.: An open trial of fluoxetine in PTSD. Amer. Psychiat. Assoc. New Research Abstract #301, May, 1990.

A12. **McDougle, C.J.**, Price, L.H., Palumbo, J., Kosten, T.R., Kleber, H.D., Heninger, G.R.: Clinical neurobiology of cocaine withdrawal. Amer. Psychiat. Assoc. New Research Abstract #551, May, 1990.

A13. Woods, S.W., O'Malley, S.S., Price, L.H., **McDougle, C.J.**, Hoffer, P.B., Kosten, T.R.: SPECT brain imaging of HIV patients with HMPAO. Amer. Psychiat. Assoc. New Research Abstract #569, May, 1990.

A14. **McDougle, C.J.**, Price, L.H., Goodman, W.K., Charney, D.S., Heninger, G.R.: Lithium augmentation in fluvoxamine-refractory obsessive compulsive disorder. New Clinical Drug Evaluation Unit Program, Session A., No. 5, May, 1990.

A15. Price, L.H., **McDougle, C.J.**, Palumbo, J., Kosten, T.R., Kleber, H.D., Heninger, G.R.: Clinical neurobiology of cocaine withdrawal. Soc. for Neurosci. Abstr., November, 1990.

A16. Goodman, W.K., **McDougle, C.J.**, Price, L.H., Charney, D.S., Heninger, G.R.: Lithium augmentation in fluvoxamine-refractory obsessive compulsive disorder. Soc. for Neurosci. Abstr., November, 1990.

A17. **McDougle, C.J.**, Krystal, J.H., Woods, S.W., Price, L.H., Herbst, D.A., Heninger, G.R., Charney, D.S.: The effects of idazoxan vs yohimbine in healthy subjects. Soc. for Neurosci. Abstr., November, 1990.

A18. **McDougle, C.J.**, Goodman, W.K., Price, L.H., Delgado, P.L., Krystal, J.H., Charney, D.S., Heninger, G.R.: Neuroleptic addition in fluvoxamine-refractory obsessive compulsive disorder. Clinical Digest Series, 1990.

A19. Holzer, J.C., Boyarsky, B.K., **McDougle, C.J.**, Lee, N., Price, L.H., Goodman, W.K.: Differential symptoms in OCD with and without a tic disorder. Abst. Amer. Coll. Neuropsychopharmacol., p. 195, 1990.

A20 Satel, S., Price, L.H., Palumbo, P., **McDougle, C.**, Charney, D.S.: Subjective and neuroendocrine aspects of cocaine withdrawal. Abst. Amer. Coll. Neuropsychopharmacol., p. 211, 1990.

A21. **McDougle, C.J.**, Price, L.H., Palumbo, J., Kosten, T.R., Kleber, H.D., Heninger, G.R.: Clinical neurobiology of cocaine abstinence. Abst. Amer. Coll. Neuropsychopharmacol., p 211, 1990.

A22. Fayad, P.B., Price, L.H., **McDougle, C.J.**, Brass, L.M.: Effects of intranasal cocaine on cerebral blood velocities in humans. 5th International Symposium on Intracranial Hemodynamics: Transcranial Doppler, Cerebral Blood Flow and Other Modalities. San Francisco, CA, February 18-20, 1991.

A23. **McDougle, C.J.**, Krystal, J.H., Woods, S.W., Price, L.H., Herbst, D.A., Heninger, G.R., Charney, D.S.: Oral idazoxan vs yohimbine in healthy subjects. Amer. Psychiat. Assoc. New Research Abstract #329, p. 127, May, 1991.

A24. **McDougle, C.J.**, Goodman, W.K., Price, L.H., Holzer, J.C., McCance-Katz, E.F., Heninger, G.R.: Buspirone addition in fluvoxamine-refractory OCD. Amer. Psychiat. Assoc. New Research Abstract #328, p. 126, May, 1991.

A25. **McDougle, C.J.**, Krystal, J.H. Price, L.H., Heninger, G.R., Charney, D.S.: Noradrenergic function and ethanol intoxication. Amer. Psychiatr. Assoc. New Research Abstract #287, p. 117, May, 1991.

A26. **McDougle, C.J.**, Calvocoressi, L., Seibyl, J.P., Krystal, J.H., Heninger, G.R., Price, L.H.:

Neurobiology of early-life trauma in depression. Amer. Psychiat. Assoc. New Research Abstract #648, p. 203, May, 1991.

A27. van Dyck, C.H., Woods, S.W., O'Malley, S., Price, L.H., **McDougle, C.J.**, Kosten, T.R.: SPECT regional cerebral blood flow in HIV disease. Amer. Psychiat. Assoc. New Research Abstract #129, p. 79, May, 1991.

A28. Holzer, J.C., Price, L.H., **McDougle, C.J.**, Boyarsky, B.K., Goodman, W.K.: Symptoms of OCD with and without tic disorder. Amer. Psychiat. Assoc. New Research Abstract #358, p. 134, May, 1991.

A29. **McDougle, C.J.**, Goodman, W.K., Price, L.H., Heninger, G.R.: Medication approaches to treatment-resistant OCD. Symposium #20: Serotonin hypothesis of OCD: A critical review. APA Annual Meeting, New Orleans, LA, May 13, 1991.

A30. **McDougle, C.J.**: Contributions of serotonin function to the neurobiology and treatment of autistic disorder. Autism Society of America, Conference Proceedings, pp. 35-37, 1991.

A31. **McDougle, C.J.**, Goodman, W.K., Price, L.H., Lee, N.C., Heninger, G.R.: Efficacy of haloperidol addition in fluvoxamine-refractory obsessive compulsive disorder: A double-blind placebo-controlled study. Destructive Drives and Impulse Control, Fourth International Symposium, Amsterdam, The Netherlands, September 12-13, 1991.

A32. Woods, S.W., Hoffer, P.B., **McDougle, C.J.**, Krystal, J.H., Heninger, G.R., Charney, D.S.: Effects of yohimbine on regional cerebral blood flow in panic disorder. Soc. for Neurosci. Abstr., November, 1991.

A33. McCance-Katz, E.F., Price, L.H., **McDougle, C.J.**, Marek, G.J., Kosten, T.R., Jatlow, P.: Cocaethylene formation following sequential administration of cocaine and ethanol to humans: Pharmacological, physiological and behavioral studies. Soc. for Neurosci. Abstr., November, 1991.

A34. **McDougle, C.J.**, Krystal, J.H., Price, L.H., Heninger, G.R., Charney, D.S.: Noradrenergic function and ethanol intoxication. Soc. for Neurosci. Abstr., November, 1991.

A35. Rosen, M.I., Pearsall, H.R., **McDougle, C.J.**, Woods, S.W., Kosten, T.R.: Acute buprenorphine accentuates intranasal cocaine effects. Abstr. Amer. Coll. Neuropsychopharm., December, 1991.

A36. Price, L.H., Malison, R., McCance-Katz, E.F., **McDougle, C.J.**, Owen, K., Delgado, P.L., Heninger, G.R.: Neuroendocrine and mood responses to I.V. M-CPP during tryptophan depletion in depressed patients. Abstr. Amer. Coll. Neuropsychopharm., December, 1991.

A37. Woods, S.W., **McDougle, C.J.**, Seibyl, J.P., Krystal, J.K., Charney, D.S.: Effects of yohimbine on regional cerebral blood flow in panic disorder patients and healthy subjects. Abstr. Amer. Coll. Neuropsychopharm., December, 1991.

A38. **McDougle, C.J.**, Goodman, W.K., Leckman, J.F., Lee, N.C., Heninger, G.R., Price, L.H.: Efficacy of haloperidol addition in fluvoxamine-refractory obsessive compulsive disorder: A double-blind placebo-controlled study. Abstr. Amer. Coll. Neuropsychopharm., December, 1991.

A39. Fayad, P.B., Price, L.H., **McDougle, C.J.**, Pavalkis, F.J., Brass, L.M.: Acute hemodynamic effects of intranasal cocaine on the cerebral circulation. 6th International Symposium on Cerebral Hemodynamics: Transcranial Doppler, Cerebral Blood Flow, and Other Modalities, Phoenix, AZ, January 26-29, 1992.

A40. Fayad, P.B., Price, L.H., **McDougle, C.J.**, Pavalkis, F.J., Brass, L.M.: Acute hemodynamic effects of intranasal cocaine on the cerebral and cardiovascular systems. 17th International Joint Conference on Stroke and Cerebral Circulation, Phoenix, AZ, January 30 - February 1, 1992.

A41. Zimmermann, R.C., Svoboda, J., **McDougle, C.J.**, Olcese, J., Schumacher, M., Werner, R., Heninger, G.R., Price, L.H.: The effect of acute tryptophan depletion on human melatonin secretion. Deutsche Gesellschaft fur Endokrinologie, Erlanger, March, 1992.

A42. **McDougle, C.J.**, Krystal, J.K., Price, L.H., Heninger, G.R., Charney, D.S.: Noradrenergic modulation of ethanol intoxication. 1992 Research Society on Alcoholism Scientific Conference.

A43. McCance-Katz, E.F., Price, L.H., **McDougle, C.J.**, Black, j.E., Kosten, T.R., Jatlow, P.I.: Cocaine-ethanol and cocaethylene: Clinical effects. Amer. Psychiatr. Assoc. New Research Abstract #100, p. 71, May, 1992.

A44. Barr, L.C., Price, L.H., **McDougle, C.J.**, Delgado, P.L., Goodman, W.K.: Acute tryptophan depletion in drug-remitted OCD. Amer. Psychiatr. Assoc. New Research Abstract #141, p. 81, May, 1992.

A45. Naylor, S.T., **McDougle, C.J.**, Volkmar, F.R., Goodman, W.K., Cohen, D.J., Hawkins, K.A., Price, L.H.: OCD symptoms in adults with autistic disorder. Amer. Psychiatr. Assoc. New Research Abstract #200, p. 96, May, 1992.

A46. Goodman, W.K., **McDougle, C.J.**, Price, L.H., Barr, L.C., Heninger, G.R.: Oral and parenteral M-CPP in 12 patients with OCD. Amer. Psychiatr. Assoc. New Research Abstract #509, p. 171, May, 1992.

A47. **McDougle, C.J.**, Goodman, W.K., Leckman, J.F., Lee, N.C., Heninger, G.R., Price, L.H.: Haloperidol addition in fluvoxamine-refractory OCD. Amer. Psychiatr. Assoc. New Research Abstract #513, p. 172, May, 1992.

A48. Fayad, P.B., Price, L.H., **McDougle, C.J.**, Pavalkis, F.J,. Brass, L.M.: Acute effects of cocaine on cerebral hemodynamics and cardiovascular system: A study in humans.

2ndWorld Congr of Stroke September, 1992 (published in J Stroke Cerebrovasc Dis 2(Suppl 1):S79, 1992).

A49. Barr, L.C., Price, L.H., **McDougle, C.J.**, Delgado, P.L., Goodman, W.K.: Effects of acute tryptophan depletion in drug-remitted obsessive-compulsive disorder patients. Soc Neurosci Abstr 18(1):3(#7.3), November, 1992.

A50. **McDougle, C.J.**, Price, L.H., Kosten, T.R., Black, J., Malison, R.T., Zimmermann, R.C., Kleber, H.D.: Noradrenergic responsivity during cocaine abstinence. Soc Neurosci Abstr 18(2):1239(#516.10), November, 1992.

A51. Barr, L.C., Price, L.H., **McDougle, C.J.**, Delgado, P.L., Goodman, W.K.: Acute tryptophan depletion exacerbates depressive, but not obsessive compulsive, symptoms in drug-remitted obsessive-compulsive disorder patients. Abst. Amer. Coll. Neuropsychopharmacol., p 154, 1992.

A52. **McDougle, C.J.**, Price, L.H., Kosten, T.R., Black, J., Malison, R.T., Zimmermann, R.C., Kleber, H.D.: Noradrenergic responsivity during cocaine abstinence. Abst. Amer. Coll. Neuropsychopharmacol., p 226, 1992.

A53. Goodman, W.K., **McDougle, C.J.**, Barr, L.C., Price, L.H.: Biological approaches to the treatment-refractory patient. First International Obsessive Compulsive Disorder Conference, Capri, Italy, March 12-13, 1993.

A54. Goodman, W.K., **McDougle, C.J.**, Price, L.H.: Pharmacotherapy of obsessive compulsive disorder. First International Obsessive Compulsive Disorder Conference, Capri, Italy, March 12-13, 1993.

A55. Aronson, S.C., Black, J.E., **McDougle, C.J.**, Scanley, B.E., Kosten, T.R., Heninger, G.R., Price, L.H.: Serotonin and cocaine effect in humans. Amer. Psychiatr. Assoc. New Research Abstract #19, p. 64, May 24, 1993.

A56. **McDougle, C.J.**, Aronson, S.C., Black, J.E., Scanley, B.E., Kosten, T.R., Heninger, G.R., Price, L.H.: Serotonin and cocaine effect in humans. Soc Neurosci Abstr 19(3):1864(#762.6), November, 1993.

A57. **McDougle, C.J.**, Aronson, S.C., Black, J.E., Scanley, B.E., Kosten, T.R., Heninger, G.R., Price, L.H.: Serotonin and cocaine effect in humans. Abst. Amer. Coll. Neuropsychopharmacol., p 170, 1993.

A58. Chappell, P.B., Leckman, J.F., Goodman, W.K., Bissette, G., Pauls, D.L., Anderson, G.M., Riddle, M.A., Scahill, L.D., Price, L.H., **McDougle, C.J.**, Barr, L.C., Cohen, D.J.: Elevated levels of CSF CRF in Tourette's syndrome: Comparison to obsessive compulsive disorder and normal controls. Abst. Amer. Coll. Neuropsychopharmacol., p 195, 1993.

A59. Leckman, J.F., Goodman, W.K., North, W.G., Chappell, P.B., Price, L.H., Pauls, D.L., Anderson, G.M., Riddle, M.A., McSwiggan-Hardin, M., **McDougle, C.J.**, Barr, L.C., Cohen, D.J.: Elevated levels of CSF oxytocin in obsessive compulsive disorder: Comparison with Tourette's syndrome and healthy controls. Abst. Amer. Coll. Neuropsychopharmacol., p 195, 1993.

A60. Farren, C.K., **McDougle, C.J.**, Price, L.H., Hameedi, F.A., Ziedonis, D., Kosten, T.R.: Growth hormone response to dopamine agonists in alcoholics and cocaine addicts. College for Prevention of Drug Dependence, June 25, 1993.

A61. Cappiello, A., **McDougle, C.J.**, Delgado, P.L., Malison, R.T., Charney, D.S., Heninger, G.R., Price, L.H.: Lithium and desipramine for the treatment of major depression: Is the combination superior to desipramine alone? Soc Neurosci Abstr 20(1):384(#164.10), November, 1994.

A62. **McDougle, C.J.**, Naylor, S.T., Volkmar, F.R., Cohen, D.J., Heninger, G.R., Price, L.H.: A double-blind, placebo-controlled investigation of fluvoxamine in adults with autism. Soc Neurosci Abstr 20(1):396(#168.12), November, 1994.

A63. Leckman, J.F., Peterson, B.S., **McDougle, C.J.**, Chappell, P.B., Pauls, D.L.: Pathogenesis of Tourette's syndrome: Clues from the clinical phenotype and natural history. Abst. Amer. Coll. Neuropsychopharmacol., p. 21, 1994.

A64. **McDougle, C.J.**, Naylor, S.T., Volkmar, F.R., Cohen, D.J., Heninger, G.R., Price, L.H.: A double-blind, placebo-controlled investigation of fluvoxamine in adults with autism. Abst. Amer. Coll. Neuropsychopharmacol., p. 90, 1994.

A65. Price, L.H., Cappiello, A., **McDougle, C.J.**, Delgado, P.L., Malison, R.T., Charney, D.S., Heninger, G.R.: Lithium+desipramine vs. desipramine alone in the treatment of major depression: A controlled study. Abst. Amer. Coll. Neuropsychopharmacol., p. 103, 1994.

A66. Brodkin, E.S., **McDougle, C.J.**, Naylor, S.T., Cohen, D.J., Price, L.H.: Clomipramine in adults with pervasive developmental disorder. Amer. Psychiatr. Assoc. New Research Abstract #NR76, p. 74, May 22, 1995.

A67. Cappiello, A.C., **McDougle, C.J.**, Malison, R.T., Heninger, G.R., Price, L.H.: Yohimbine augmentation of fluvoxamine in refractory depression: A preliminary, single-blind study. Amer. Psychiatr. Assoc. New Research Abstract #NR95, p. 80, May 22, 1995.

A68. Epperson, C.N., **McDougle, C.J.**, Brown, R.M., Leckman, J.F., Goodman, W.K., Price, L.H.: OCD during pregnancy and the puerperium. Amer. Psychiatr. Assoc. New Research Abstract #NR112, p. 84, May 22, 1995.

A69. Brown, R.M., **McDougle, C.J.**, Epperson, C.N., Wasylink, S., Goodman, W.K., Price, L.H.: OCD and suicide: A systematic investigation. Amer. Psychiatr. Assoc. New

Research Abstract #NR116, p. 85, May 22, 1995.

A70. Pelton, G.H., Cappiello, A.C., **McDougle, C.J.**, Malison, R.T., Kosten, T.R., Price, L.H.: Reserpine/cocaine interactions in cocaine addicts. Amer. Psychiatr. Assoc. New Research Abstract #NR161, p. 97, May 22, 1995.

A71. Price, L.H., Cappiello, A.C., **McDougle, C.J.**, Malison, R.T., Charney, D.S., Heninger, G.R.: Lithium plus desipramine versus desipramine alone in the treatment of major depression: A controlled study. Amer. Psychiatr. Assoc. New Research Abstract #NR284, p. 132, May 23, 1995.

A72. Malison, R.T., **McDougle, C.J.**, Van Dyck, C., Scahill, L., Baldwin, R.M., Seibyl, J.P., Price, L.H., Leckman, J.F., Innis, R.B.: [^{123}I]B-CT SPECT imaging demonstrates increased striatal dopamine transporter binding in Tourette's syndrome. Amer. Psychiatr. Assoc. New Research Abstract #NR527, p. 196, May 24, 1995.

A73. **McDougle, C.J.**, Naylor, S.T., Cohen, D.J., Aghajanian, G.K., Heninger ,G.R,. Price, L.H. Acute tryptophan depletion in adults with autism. Amer. Psychiatr. Assoc. New Research Abstract #NR531, p. 197, May 24, 1995.

A74. **McDougle, C.J.**, Naylor, S.T., Cohen, D.J., Aghajanian, G.K., Heninger, G.R., Price, L.H.: Acute tryptophan depletion in adults with autism. Soc Neurosci Abstr 21(1):735(#293.14), November, 1995.

A75. Cappiello, A., Malison, R.T., **McDougle, C.J.**, Vegso, S., Charney, D.S,. Heninger, G.R., Price, L.H.: Seasonal variation in neuroendocrine and mood response to L-tryptophan infusion in depressed patients and healthy subjects. Soc Neurosci Abstr 21(3):2057(#809.6), November, 1995.

A76. Price, L.H., Pelton, G.H., Cappiello, A., **McDougle, C.J.**, Malison, R.T., Jatlow, P., Kosten, T.R., Heninger, G.R.: Attenuation of cocaine effects by reserpine in cocaine-dependent humans. Abstr Amer Coll Neuropsychopharm, p. 193, 1995.

A77. **McDougle, C.J.**, Naylor, S.T., Cohen, D.J., Aghajanian, G.K., Heninger, G.R., Price, L.H.: Acute tryptophan depletion in adults with autism. Abstr Amer Coll Neuropsychopharm, p. 206, 1995.

A78. Epperson, C.N., **McDougle, C.J.**, Ward-O'Brien, D., Price, L.H.: A controlled study of sertraline versus placebo in the treatment of postpartum depression: Preliminary findings. Soc for Biological Psychiatry Annual Meeting, New York, NY, May 1, 1996.

A79. Epperson, C.N., **McDougle, C.J.**, Ward-O'Brien, D., Price, L.H.: A controlled study of antidepressant treatment of postpartum depression. Amer. Psychiatr. Assoc. New Research Abstract #NR28, p. 74, May 6, 1996.

A80. Kirwin, P.D., **McDougle, C.J.**, Anderson, G.M., Heninger, G.R., Leckman, J.F., Price, L.H.: Diurnal variation in CSF serotonin concentrations in healthy humans. Amer. Psychiatr. Assoc. New Research Abstract #NR34, p. 75, May 6, 1996.

A81. Epperson, C.N., Ward-O'Brien, D., Price, L.H., **McDougle, C.J.**: A double-blind study of sertraline versus placebo in the treatment of postpartum depression: Preliminary findings. Soc Neurosci Abstr 22(1):179(#76.3), November, 1996.

A82. Kirwin, P.D., **McDougle, C.J.**, Anderson, G.M., Heninger, G.R., Geracioti, T.D., Chappell, P.B., Leckman, J.F., Price, L.H.: Diurnal variation in cerebral spinal fluid (CSF) serotonin concentrations in healthy humans. Soc Neurosci Abstr 22(1):604(#242.4), November, 1996.

A83. Price, L.H., Pelton, G.H., **McDougle, C.J.**, Malison, R.T., Jatlow, P., Carpenter, L., Kirwin, P.D.: Effects of acute pretreatment with risperidone on responses to cocaine in cocaine-dependent humans. Soc Neurosci Abstr 22(1):933(#365.7), November, 1996.

A84. Anderson, G.M., Szatmari, P., **McDougle, C.J.**, McBride, P.A., Hall, L.M., Hoult, L.A., Cohen, D.J.: Platelet serotonin in autism, Aspergers syndrome, and PDD-NOS: Group comparisons and the effects of familial loading. Soc Neurosci Abstr 22(1):1168(#460.11), November, 1996.

A85. Hollander, E., Piven, J., McBride, A., Silverman, J., Folstein, S., **McDougle, C.**: Strategies for defining a more homogeneous phenotype of autism for family/genetic studies. Abstr Amer Coll Neuropsychopharm, p. 43, 1996.

A86. Price, L.H., Cappiello, A., Malison, R.T., **McDougle, C.J.**, Pelton, G.H., Heninger, G.R.: Effects of antiglucocorticoid treatment on 5-HT_{1A} function in depressed patients and healthy subjects. Abstr Amer Coll Neuropsychopharm, p. 156, 1996.

A87. Epperson, C.N., Ward-O'Brien, D., Price, L.H., **McDougle, C.J.**: A double-blind study of sertraline versus placebo in the treatment of postpartum depression: Preliminary findings. Abstr Amer Coll Neuropsychopharm, p. 172, 1996.

A88. Leckman, J.F., Grice, D.E., Boardman, J., Zhang, H., Vitale, A., Bondi, C., Alsobrook, J., Peterson, B.S., Cohen, D.J., Rasmussen, S.A., Goodman, W.K., **McDougle, C.J.**, Pauls, D.L.: A factor analysis study of obsessive compulsive disorder. Abstr Amer Coll Neuropsychopharm, p. 216, 1996.

A89. Pelton, G.H., Price, L.H., **McDougle, C.J.**, Malison, R.T.: Neuroendocrine responses to immune stimulants in major depression. Abstr Amer Coll Neuropsychopharm, p. 233, 1996.

A90. Cappiello, A., Serynak, M., Malison, R.T., **McDougle, C.J.**, Heninger, G.R., Price, L.H.: Effects of acute tryptophan depletion in lithium remitted manic patients. Abstr Amer Coll

Neuropsychopharm, p. 238, 1996.

A91. Carpenter, L.L., Anderson, G., **McDougle, C.J.**, Kirwin, P.D., Price, L.H., Heninger, G.R.: Tryptophan depletion during continuous CSF sampling via indwelling lumbar catheter in healthy human subjects. Amer. Psychiatr. Assoc. New Research Abstract #NR72, p. 85, May 19, 1997.

A92. Haroon, E., Vegso, S.J., Fayad, P.B., Malison, R.T., **McDougle, C.J.**, Heninger, G.R.: Post-stroke depression and location of lesion: A systematic review. Amer. Psychiatr. Assoc. New Research Abstract #NR75, p. 85, May 19, 1997.

A93. Epperson, C.N., Anderson, G.M., **McDougle, C.J.**: Infant whole blood serotonin levels before and after exposure to sertraline through breast milk. Soc Neurosci Abstr 23(2):1221(#483.21), October 1997.

A94. Carpenter, L.L., Anderson, G., Pelton, G., Gudin, J., Kirwin, P.D.S., Price, L.H., Heninger, G.R., **McDougle, C.J.**: Tryptophan depletion during continuous CSF sampling via indwelling lumbar catheter in healthy human subjects. Soc Neurosci Abstr 23(2):1220(#483.16), October 1997.

A95. Pelton, G.H., **McDougle, C.J.**, Carpenter, L., Anderson, G.M., Gudin, J.A., Price, L.H., Malison, R.T., Kirwin, P., Heninger, G.R.: Cerebrospinal fluid levels of interleukin-1 and interleukin-6 increase after intravenous lipopolysaccharide in healthy humans. Soc Neurosci Abstr 23(1):992(#393.5), October 1997.

A96. **McDougle**, C.J., Epperson, C.N., Price, L.H., Gelernter, J.: Evidence for linkage disequilibrium between serotonin transporter protein and obsessive compulsive disorder. American Society of Human Genetics Abstr, October, 1997.

A97. Price, L.H., Pelton, G.H. **McDougle, C.J.**, Malison, R.T., Jatlow, P., Carpenter, L., Kirwin, P.D., O'Brien, D.W., Nadim, H., Heninger, G.R.: Effects of acute pretreatment with risperidone on responses to cocaine in cocaine addicts. Abstr Amer Coll Neuropsychopharm, p. 208, 1997.

A98. **McDougle, C.J.**: Neuropsychopharmacology of autism-spectrum disorders, In Panel, Neurobiology of Autism (**McDougle, C.J.,** Chair). Abstr Amer Coll Neuropsychopharm, p. 52, 1997.

A99. **McDougle, C.J.**: Neuropsychopharmacology of autism-spectrum disorders, In Symposium, Neurobiology and Treatment of Autism. Biol Psychiatry 43:4S (#11), 1998.

A100. George , T.P., Potenza, M.N., Degen, K., Sernyak, M.J., **McDougle, C.J.**, Woods, S.W.: Effects of acute tryptophan depletion on clozapine-responsive schizophrenic subjects. Amer. Psychiatr. Assoc. New Research Abstract #NR451, p. 190, June 3, 1998.

A101. Potenza, M.N., Holmes, J.P., Kanes, S.J., **McDougle, C.J.**: Olanzapine in pervasive developmental disorders. Amer. Psychiatr. Assoc. New Research Abstract #NR711, p.260, June 4, 1998.

A102. **McDougle, C.J.**: Psychopharmacology of autism, In Symposium #S.20, Developmental Psychopharmacology: New Approaches to Autism. European Psychopharmacology 8 (suppl.2): S107 (#S.20.04) Paris, France, November 3, 1998.

A103. Charney, D., Shore, D., Bowden, C., **McDougle, C.**, Hirschfeld, R., Kraemer, H., Gorman, J., Schatzberg, A., Kane, J., Ross, J., Lieber, C., Hall, L., Lewis, L.: Study Group - The Use of Placebo in Clinical Trials: What Changes Are Necessary? Abstr Amer Coll Neuropsychopharm, p. 15, 1999.

A104. Zimolo, Z., Pelton, G.H., **McDougle, C.J.**, Price, L.H., Heninger, G.R.: Serum leptin changes after lipopolysaccharide induced stress in humans. Abstr Amer Coll Neuropsychopharm, p.289, 1999.

A105. Posey, D.J., Guenin, K.D., Kohburn, A., Swiezy, N.B., **McDougle, C.J.**: A systematic open-label trial of mirtazapine in autism and related pervasive developmental disorders. Amer. Psychiatr. Assoc, New Research Abtract #NR 187, p. 106, May 15, 2000.

A106. **McDougle, C.J.**: The diagnosis and pharmacotherapy of autism spectrum disorders. In symposium, Adaptive/Maladaptive Behaviors and Strategies for Treatment, 8th International Professional Conference on Williams Syndrome, Williams Syndrome: Genetics, Cognitive Studies, Clinical Care, Program and Abstracts, p. 35, Dearborn, MI, July 22, 2000.

A107. Posey, D.J., Guenin, K., Kohburn, A., Swiezy, N., **McDougle, C.**: An open-label trial of Mirtazapine in autism and related disorders. 47th Annual Meeting of the American Academy of Child and Adolescent Psychiatry, Scientific Proceedings, Poster Session E, P5, p. 127, 2000.

A108. Posey, D.J., Guenin, K., Kohburn, A., Swiezy, N.B., **McDougle, C.J.**: An open-label trial of mirtazapine in autism and related disorders. Abstr Amer Coll Neuropsychopharm, p. 121, 2000.

A109. Posey, D.J., Decker, J., Sasher, T.M., Kohn, A., Swiezy, N.B., **McDougle, C.J.**: A retrospective analysis of guanfacine treatment of autism. Amer. Psychiat. Assoc. New Research Abstract #816, May, 2001.

A110. Heiligenstein, J.H., Dunn, D.W., Busner, J., Stein, M., **McDougle, C.J.**: Efficacy of tomoxetine versus placebo in school-age children with ADHD who failed psychostimulant treatment. Amer. Psychiat. Assoc. New Research #550, May, 2001.

A111. Carpenter, L.L., Kirwin, P.D., Pelton, G.H., **McDougle, C.J.**, Malison, R.T., Owens, M.J.,

Nemeroff, C.B., Price, L.H.: Tryptophan depletion increases CSF corticotropin releasing factor in healthy adult humans. Abstr Amer Coll Neuropsychopharm, p. 137, 2001.

A112. Carpenter, L.L., Pelton, G.H., Heninger, G.R., **McDougle, C.J.**, Malison, R.T., Owens, M.J., Nemeroff, C.B., Price, L.H.: Relationship between CSF corticotropin releasing factor and perceived early life stress in depressed patients and healthy controls. Abstr Amer Coll Neuropsychopharm, p. 137, 2001.

A113. Posey, D.J., Decker, J., Kohn, A., Swiezy, N.B., **McDougle, C.J.**: A retrospective analysis of guanfacine in the treatment of autism and related pervasive developmental disorders. Abstr Amer Coll Neuropsychopharm, p. 302, 2001.

A114. **McDougle, C.J.**, Aman, M., McCracken, J.T., Scahill, L., Tierney, E., Vitiello, B., and the RUPP Autism Network: A double-blind placebo-controlled trial of risperidone in autistic disorder. Abst Amer Coll Neuropsychopharm, p. 303, 2001.

A115. Bangs, M., **McDougle, C.J.**: A double-blind placebo-controlled study of valproate in children and adolescents with mood disorders. Poster #6, Emory University School of Medicine Department of Psychiatry and Behavioral Sciences Future Leaders in Psychiatry Conference, p. 12, April 2002.

A116. Posey, D.J., Swiezy, N.B., Sweeten, T., Kem, D., Zaphiriou, M., **McDougle, C.J.**: A pilot study of D-cycloserine in the treatment of autism. Poster #65, Emory University School of Medicine Department of Psychiatry and Behavioral Sciences Future Leaders in Psychiatry Conference, pp. 64-65, April 2002.

A117. Research Units on Pediatric Psychopharmacology Autism Network: A placebo-controlled study of risperidone in the treatment of children with autistic disorder. Pediatric Research 51(4):458A, 2002.

A118. Research Units on Pediatric Psychopharmacology Autism Network. A placebo-controlled study of risperidone in the treatment of children with autistic disorder. Pediatric Research 2002, 51 (4): 458A. Presented at the Pediatric Academic Societies' (PAS) Annual Meeting, Baltimore, MD, May 7, 2002.

A119. **McDougle, C.J.**: Testing the efficacy of risperidone in autism: Rationale, experimental design, and methods. In Workshop #9 Therapeutic Use of Atypical Antipsychotics in Children with Autism, Society of Biological Psychiatry Annual Meeting, Philadelphia, PA, May 16, 2002, Biol Psychiatry 2002; 51:3S.

A120. **McDougle, C.J.**: Atypical antipsychotics in pediatric psychiatry: efficacy in well-designed trials. In symposium, Breaking the Silence of Children's Mental Illness: National Initiatives, Early Detection, and New Pharmacotherapies, Amer Psychiatr Assoc Annual Meeting, Proceedings Abstract No. 30B, pp. 282-283, May 20, 2002.

A121. Carpenter, L., Pelton, G., Heninger, G., **McDougle, C.**, Owens, M.J., Nemeroff, C.B.: CSF corticotropin releasing factor and perceived early life stress in depressed patients and healthy controls. Amer Psychiatr Assoc New Research Abstract #NR 480, p. 130, May 22, 2002.

A122. Research Units on Pediatric Psychopharmacology Autism Network: Risperidone treatment of autistic disorder: Longer term benefits and blinded discontinuation after six months. J of Developmental and Behavioral Pediatrics, Presented at the Society for Developmental and Behavioral Pediatarics 20th Annual Meeting, Seattle, WA, September 29, 2002.

A123. **McDougle, C.J.** (CHAIR): Symposium, Diagnostic and Treatment Advances in Pediatric Psychotic and Behavioral Disorders, 49th Annual Meeting of the American Academy of Child and Adolescent Psychiatry, Scientific Proceedings, pp. 26-27, October 23, 2002.

A124. Arnold, L.E., Vitiello, B., **McDougle, C.**, Davies, M., Gonzales, N., and the RUPP Autism Network: Target symptoms respond sensitively to risperidone in autism RUPP trial. In Symposium, The RUPP Network: Recent Findings and New Directions, 49th Annual Meeting of the American Academy of Child and Adolescent Psychiatry, Scientific Proceedings, p. 44, October 24, 2002.

A125. Martin, A., Anderson, G., Scahill, L., McCracken, J., and the RUPP Autism Network: Risperidone treatment in autism: Weight and neuroendocrine effects. In Symposium, The RUPP Network: Recent Findings and New Directions, 49th Annual Meeting of the American Academy of Child and Adolescent Psychiatry, Scientific Proceedings, p. 44, October 24, 2002.

A126. **McDougle, C.J.**, Posey, D.: Recent advances in the pharmacotherapy of pervasive developmental disorders. In Institute IV: Psychopharmacologic Treatment of Externalizing Disorders in Youth, 49th Annual Meeting of the American Academy of Child and Adolescent Psychiatry, Scientific Proceedings, p. 7, October 25, 2002.

A127. Shekhar, A., Sajdyk, T.J., Fitz, S., **McDougle, C.J.**: Over stimulation of amygdala results in behavioral deficits similar to autistic disorders. Soc Neurosci Abstr, Program No. 496.13, November, 2002.

A128. Fitz, S., **McDougle, C.J.**, Sajdyk, T.J., Shekhar, A.: Effects of ziprasidone and D-cycloserine treatment on the behavioral deficits resembling autistic disorder in rats with disrupted basolateral amygdala. Soc Neurosci Abstr, Program No. 707.1, November, 2002.

A129. Shekhar, A., Sajdyk, T.J., Fitz, S.D., **McDougle, C.J.**: Over-stimulation of the basolateral amygdala of rats results in behavioral deficits similar to autism spectrum disorders. Abstr Amer Coll Neuropsychopharm, p. 156, 2002.

A130. **McDougle, C.J.**, Aman, M., McCracken, J.T., Scahill, L., Tierney, E., Vitiello, B., and the RUPP Autism Network: Risperidone treatment of autistic disorder: Longer-term benefits

and blinded discontinuation after six months. Abstr Amer Coll Neuropsychopharm, p. 245, 2002.

A131. **McDougle, C.J.**, Posey, D.J.: Recent advances in the pharmacotherapy of pervasive developmental disorders. In Symposium, Treatment of Comorbidity in Neuropsychiatric Disorders in Children and Adolescents, Amer Psychiatr Assoc Annual Meeting, Proceedings Abstract No. 26 D, May 18, 2003.

A132. Stigler, K.A., Desmond, L.A., Posey, D.J., **McDougle, C.J.**: A naturalistic restrospective analysis of psychostimulants in pervasive developmental disorders. Poster #74, Emory University School of Medicine, Department of Psychiatry and Behavioral Sciences Future Leaders in Psychiatry Conference, May 31, 2003.

A133. Posey, D.J., Swiezy, N.B., Kem, D.L., Sweeten, T.L., **McDougle, C.J.**: A pilot study of D-cycloserine in the treatment of autistic disorder. Biol Psychiatry 53:170S, #484, 2003.

A134. **McDougle, C.J.**, Posey, D., Stigler, K.: Evidence-based treatment of target symptoms associated with pervasive developmental disorders. In Symposium, Targeted Treatment of Psychiatric Spectrum Disorders, 50th Annual Meeting of the American Academy of Child and Adolescent Psychiatry, Scientific Proceedings, p. 89, October 18, 2003.

A135. Posey, D.J., Stigler, K., **McDougle, C**.: PDD-NOS: Psychopharmacological treatment. In Symposium, Pervasive Developmental Disorder-Not Otherwise Specified: Prevalence, Genetics, Evaluation, and Treatment, 50th Annual Meeting of the American Academy of Child and Adolescent Psychiatry, Scientific Proceedings, p. 97, October 18th, 2003.

A136. Vitiello, B., McCracken, J., Aman, A., **McDougle, C.,** Scahill, L., Tierney, E., Arnold, E., Davies, M.: Research knowledge among parents of children in a clinical trial. 50th Annual Meeting of the American Academy of Child and Adolescent Psychiatry, Scientific Proceedings, Abstract #C12, p. 134, October 2003.

A137. Posey, D.J., Swiezy, N., Kem, D., Sweeten, T., **McDougle, C.:** A pilot study of D-cycloserine in autistic disorder. 50th Annual Meeting of the American Academy of Child and Adolescent Psychiatry, Scientific Proceedings, Abstract #E7, p. 155, October 2003.

A138. Stigler, K.A., Posey, D., Desmond, L., **McDougle, C.:** A naturalistic retrospective analysis of psychostimulants in pervasive developmental disorders. 50th Annual Meeting of the American Academy of Child and Adolescent Psychiatry, Scientific Proceedings, Abstract #E11, p. 156, October, 2003.

A139. **McDougle, C.J.**: Beyond stimulants: Evidence-based treatment using atypical antipsychotics. In Symposium, More Than ADHD, More Than Stimulants: Management of Severe Behavioral Problems, American Academy of Pediatrics Annual Meeting Proceedings Abstract, New Orleans, LA, November, 2003.

A140. Yoder, K.K., Morris, E.D., Wang, C., **McDougle, C.J.**, Shekhar, A.: Elevation of striatal dopamine transporter binding potential in a subgroup of obsessive-compulsive disorder. Soc Neurosci Abstr, Program No. 416.13, November, 2003.

A141. **McDougle, C.J.**, Aman, M., McCracken, J., Scahill, L., Tierney, E., Vitiello, B.: Controlled acute, longer term, and blinded discontinuation treatment trial of risperidone in children and adolescents with autism, In Panel, New Data From Randomized Controlled Trials of Efficacy in Autism (McDougle, C.J.- Co-Chair with Hollander, E.). Abstr Amer Coll Neuropsychopharm, Scientific Abstracts, p. 58, 2003.

A142. Posey, D.J., Swiezy, N., Kem, D., Sweeten, T., **McDougle, C.J.**: Treating social impairment: A pilot study of D-cycloserine in autistic disorder, In Panel, New Data From Randomized Controlled Trials of Efficacy in Autism (McDougle, C.J.- Co-Chair with Hollander, E.). Abstr Amer Coll Neuropsychopharm, Scientific Abstracts, p. 59, 2003.

A143. Stigler, K.A., Desmond, L.A., Posey, D.J., Wiegand, R.E., **McDougle, C.J.**: A naturalistic retrospective analysis of psychostimulants in pervasive developmental disorders. Abstr Amer Coll Neuropsychopharm, Scientific Abstracts, p. 196, 2003.

A144. Carpenter, W.T., Penn, D., **McDougle, C.J.**, Conley, R.R.: Novel therapies for the Treatment of deficits in social competence in neuropsychiatric disorders - Workshop, Biol Psychiatry, 55:4S, #11, 2004.

A145. **McDougle, C.J.**: Pharmacotherapy of autism. (SP.34.01) In Symposium, Child Psychopharmacology(SP.34). International Journal of Neuropsychopharmacology Volume 7, Supplement 1, S42, June, 2004.

A146. **McDougle, C.J.**: Atypical antipsychotics in patients with severe developmental disabilities (SP.57.02). In Symposium, Psychopharmacological treatment of aggressive, self-injurious and destructive/disruptive behaviors in autism in mental retardation – Exploration of a parallel universe (SP.57). International Journal of Neuropsychopharmacology Volume 7, Supplement 1, S70, June, 2004.

A147. **McDougle, C.J.**: Pharmacological management of behavioral disturbances in autistic spectrum disorders. In Symposium 33, A Multidisciplinary Approach Toward The Assessment and Treatment of Autism (Co-Chairs: C.J. McDougle, L.Scahill), 51st Annual Meeting of the American Academy of Child and Adolescent Psychiatry, Scientific Proceedings, Abstract #33C, p. 64, October, 2004.

A148. Aman, M.G., McCracken, J., **McDougle, C.**, Scahill, L., Tierney, E., Vitiello, B., Lam, K.: Previous research on stimulants in children with developmental disabilities. In Symposium 48, Treatment of Hyperactivity in Pervasive Developmental Disorders: RUPP Autism Network, 51st Annual Meeting of the American Academy of Child and Adolescent Psychiatry, Scientific Proceedings, Abstract # 48A, p. 82, October, 2004.

A149. Arnold, L.E., Aman, M., Scahill, L., McCracken, J., **McDougle, C.**, Tierney, E., Vitiello, B.: Background, rationale and design of RUPP Autism Network methylphenidate study. In Symposium 48, Treatment of Hyperactivity in Pervasive Developmental Disorders: RUPP Autism Network, 51st Annual Meeting of the American Academy of Child and Adolescent Psychiatry, Scientific Proceedings, Abstract # 48B, p. 82, October, 2004.

A150. Posey, D.J., **McDougle, C.**, Swiezy, N., Davies, M., Kohn, A., Witner, A.: Methylphenidate in autism: Results from the RUPP Autism Network. In Symposium 48, Treatment of Hyperactivity in Pervasive Developmental Disorders: RUPP Autism Network, 51st Annual Meeting of the American Academy of Child and Adolescent Psychiatry, Scientific Proceedings, Abstract # 48C, p. 83, October, 2004.

A151. McCracken, J.T., Aman, M., Scahill, L., **McDougle, C.**, Lindsay, R., Tierney, E., Lee, S.: Pharmacogenetic analyses from the RUPP Autism Network Risperidone Study. In Symposium 48, Treatment of Hyperactivity in Pervasive Developmental Disorders, 51st Annual Meeting of the American Academy of Child and Adolescent Psychiatry, Scientific Proceedings, Abstract # 48D, p. 83, October, 2004.

A152. **McDougle, C.J.**, Davies, M., Gonzalez, N., McGough, J., Nash, P., Scahill, L., Swiezy, N.: Risperidone for the core symptom domains of autism. In Symposium 53, New Findings From the RUPP Autism Network Study of Risperidone (C.J. McDougle-Chair), 51stAnnual Meeting of the American Academy of Child and Adolescent Psychiatry, Scientific Proceedings, Abstract # 53A, p. 88, October, 2004.

A153. Martin, A., Andersan, G., Carpenter, T., Ghuman, J., Lindsay, R., McGough, J., Posey, D., RUPP Autism Network: Impact of risperidone on prolactin levels in children with autism. In Symposium 53, New Findings From the RUPP Autism Network Study of Risperidone, 51stAnnual Meeting of the American Academy of Child and Adolescent Psychiatry, Scientific Proceedings, Abstract 53B, p. 88, October, 2004.

A154. Corson, A.H., Barkenbus, J.E., Posey, D.J., Stigler, K.A., **McDougle, C.J.**: Retrospective analysis of quetiapine in the treatment of pervasive developmental disorders (#47). Neuropsychopharmacology, Volume 29, Supplement 1, S142, 2004.

A155. Posey, D.J., **McDougle, C.J.**, Aman, M.G., Arnold, L.E., Scahill, L., McCracken, J.T., Tierney, E., Vitiello, B., Chuang, S., and RUPP Autism Network: A randomized, double-blind, placebo-controlled, crossover trial of methylphenidate in children with hyperactivity associated with pervasive developmental disorders (#48). Neuropsychopharmacology, Volume 29, Supplement 1, S142, 2004.

A156. Posey, D.J., Stigler, K.A., **McDougle, C.J**.: The unmet treatment needs of youth with severe behavioral problems. In Symposium, Management of Disruptive Behavioral and Pervasive Developmental Disorders (Chair: Christopher J. McDougle, M.D.), 158th American Psychiatric Association Annual Meeting, Program-page 2, May 21, 2005.

A157. **McDougle, C.J.**, Posey, D.J., Stigler, K.A.: Pharmacotherapy of behavioral symptoms in pervasive developmental disorders. In Symposium, Management of Disruptive Behavioral and Pervasive Developmental Disorders (Chair: Christopher J. McDougle, M.D.), 158th American Psychiatric Association Annual Meeting, Program-page 2, May 21, 2005.

A158. **McDougle, C.J.**: Pharmacological interventions for symptom clusters in ASD. In Workshop, Developing Targeted Interventions for Autistic Spectrum Disorders (Collaborative Session with The National Institute of Mental Health, Chair: Ann Wagner, Ph.D.), 158th American Psychiatric Association Annual Meeting, Program-pages 87-88, May 26, 2005.

A159. **McDougle, C.J.**: Pharmacologic management of behavioral symptoms in pervasive developmental disorders. In Symposium 17, Symptom Management in Pediatric Disruptive Behavioral and Pervasive Developmental Disorders (C.J. McDougle–Chair), 52nd Annual Meeting of the American Academy of Child and Adolescent Psychiatry, Scientic Proceedings, Abstract # 17C, p. 45, October 2005.

A160. **McDougle, C.J.**, Stigler, K.A., Posey, D.J.: Pharmacological treatment of behavioral symptoms in autism. In Panel, Drug Development: Novel Insights into the Neurobiology and Treatment of Autism Spectrum Disorders. Neuropsychopharmacology. Volume 30, Supplement 1, S72, 2005.

A161. Posey, D.J., Wiegand, R.E., Wilkerson, J., Maynard, M., Stigler, K.A., **McDougle, C.J.**: A prospective, open-label study of atomoxetine for ADHD symptoms associated with higher-functioning pervasive developmental disorders (#36). Neuropsychopharmacology Volume 30, Supplement 1, S156-S157, 2005.

A162. Kryzhanovskaya, L., Schulz, C., **McDougle, C.J.**, Frazier, J.A., Shen, J., Dittman, R., Robertson-Plouch, C., Bauer, T., Xu, W., Wang, W.V., Carlson, J., Corya, S., Tohen, M.: A double-blind, placebo-controlled study of olanzapine in adolescents with schizophrenia (#129). Neuropsychopharmacology Volume 30, Supplement 1, S258-S259, 2005.

A163. Jahromi, L.B., Lee, L.L., Kasari, C., McCracken, J., and RUPP Autism Network: Self-regulation, compliance, and joint attention in children with autistic disorder and hyperactivity treated with methylphenidate. International Meeting for Autism Research, 2006.

A164. Kryzhanovskaya, L., Schulz C., **McDougle C.J.**, Frazier J.A., Dittmann R.W., Robertson-Plough C., Bauer T., Xu W., Wang W.V., Carlson J., Tohen M.: A double-blind, placebo-controlled study of olanzapine in adolescents with schizophrenia. Schizophrenia Research, 81 (Supplement 1), S44-45, 2006.

A165. Kryzhanovskaya, L., Schulz C., **McDougle C.J.**, Frazier J.A., Dittmann R.W., Robertson-Plough C., Bauer T., Xu W., Wang W.V., Carlson J., Tohen M.: A double-blind, placebo-controlled study of olanzapine in adolescents with schizophrenia. European Psychiatry, 21

(Supplement 1), S104-105, 2006.

A166. Kryzhanovskaya, L., Schulz C., **McDougle C.J.**, Frazier J.A., Dittmann R.W., Robertson-Plough C., Bauer T., Xu W., Wang W.V., Carlson J., Tohen M.: A double-blind, placebo-controlled study of olanzapine in adolescents with schizophrenia. Biological Psychiatry, *59* (8, Supplement 1), S44, 2006.

A167. Kryzhanovskaya, L., Schulz C., **McDougle C.J.**, Frazier J.A., Dittmann R.W., Robertson-Plough C., Bauer T., Xu W., Wang W.V., Carlson J., Tohen M.: A double-blind, placebo-controlled study of olanzapine in adolescents with schizophrenia. 168th Annual Meeting of the American Psychiatric Association, Toronto, Canada, 2006.

A168. Erickson, C.A., Posey, D.J., Stigler, K.A., Mullett, J., Katschke, A.R., **McDougle, C.J.**: Open-label memantine in children and adolescents with pervasive developmental disorders. Poster Presentation at the American Psychiatric Association Eleventh Annual Research Colloquium for Junior Investigators, Toronto, Ontario, May 21, 2006.

A169. Posey, D.J., Erickson, C.A., Stigler, K.A., Mullett, J., **McDougle, C.J.**: Open-label memantine in children and adolescents with pervasive developmental disorders. Poster Presentation at the New Clinical Drug Evaluation Unit (NCDEU) 46th Annual Meeting, Boca Raton, Florida, June 12-15, 2006.

A170. Kryzhanovskaya, L., Schulz, C., **McDougle, C.J.,** Frazier, J.A., Dittman, R., Robertson-Plouch, C., Bauer, T., Xu, W., Wang, W.V., Carlson, J., Tohen, M.: Olanzapine versus placebo in adolescents with schizophrenia. 53rd Annual Meeting of the American Academy of Child and Adolescent Psychiatry, Scientific Proceedings, Abstract C26, p. 74, October 2006.

A171. Stigler, K.A., Diener, J., Kohn, A., Posey, D., **McDougle, C.**: Open-label study of aripiprazole in youth with Asperger's disorder and pervasive developmental disorder not otherwise specified. 53rd Annual Meeting of the American Academy of Child and Adolescent Psychiatry, Scientific Proceedings, Abstract F2, p. 213, October 2006.

A172. Scahill, L., Aman, M., Arnold, L., McCracken, J., **McDougle, C.,** Tierney, E., and RUPP Autism Network: Hyperactivity in autism: Nosological tangles and meager evidence. In Symposium, Pharmacological Management of ADHD Symptoms in Autism Spectrum Disorders. 53rd Annual Meeting of the American Academy of Child and Adolescent Psychiatry, Scientific Proceedings, Abstract 25A, p. 73, October 2006.

A173. Posey, D.J., Aman, M., Arnold, L., McCracken, J., **McDougle, C.,** Scahill, L., Tierney, E., and RUPP Autism Network: Comparison of risperidone and methylphenidate effects on hyperactivity in autism. In Symposium, Pharmacological Management of ADHD Symptoms in Autism Spectrum Disorders. 53rd Annual Meeting of the American Academy of Child and Adolescent Psychiatry, Scientific Proceedings, Abstract 25B, p. 73, October 2006.

A174. **McDougle, C.J**.: Pharmacologic treatment of autism spectrum disorders: Maximizing treatment options. In Symposium, Translating Neurobiology to Clinical Applications: Untangling the Complexities of Autism Spectrum Disorders. (Chair: **C.J. McDougle**). 53rd Annual Meeting of the American Academy of Child and Adolescent Psychiatry, Scientific Proceedings, Abstract 39A, p. 93, October 2006.

A175. Posey, D.J., Aman, M.G., McCracken, J.T., Scahill, L., Tierney, E., Arnold, L.E., Vitiello, B., Chuang, S.Z., Davies, M., Ramadan, Y., Witwe, A., Swiezy, N.B., Cronin, P., Shah, B., Carroll, D., Young, C., Courtney, W., **McDougle, C.J.**: Methylphenidate in pervasive developmental disorders: An analysis of secondary measures (#161). Neuropsychopharmacology Volume 31, Supplement 1, S134, 2006.

A176. Stigler, K.A., Diener, J.T., Kohn, A.E., Erickson, C.A., Posey, D.J., **McDougle, C.J.**: A prospective, open-label study of aripiprazole in youth with Asperger's Disorder and Pervasive Developmental Disorder Not Otherwise Specified (#147). Neuropsychopharmacology Volume 31, Supplement 1, S194, 2006.

A177. Stigler, K.A., Diener, J.T., Kohn, A.E., Erickson, C.A., Posey, D.J., **McDougle, C.J.**: A prospective, open-label study of aripiprazole in youth with Asperger's disorder and pervasive developmental disorder not otherwise specified. Poster presentation at the New Clinical Drug Evaluation Unit (NCDEU) 47th Annual Meeting, Boca Raton, FL, June 11-14, 2007.

A178. Robertson-Plouch, C., Kryzhanovskaya, L., Schulz, C., **McDougle, C.J.**, Frazier, J.A., Xu, W., Carlson, J., Tohen, M.: Olanzapine efficacy and tolerability in adolescents with schizophrenia: Results from an open-label extension phase. Poster presentation at the New Clinical Drug Evaluation Unit (NCDEU) 47th Annual Meeting, Boca Raton, FL, June 11-14, 2007.

A179. Robertson-Plouch, C., Kryzhanovskaya, L., Schulz, C., **McDougle, C.J.**, Frazier, J.A., Xu, W., Carlson, J., Tohen, M.: Olanzapine efficacy and tolerability in adolescents with schizophrenia: results from an open-label extension phase. Pharmacoepidemiology and Drug Safety, 16:S215-S216, 2007.

A180. Posey, D.J., Stigler, K., Erickson, C., **McDougle, C.**: Pharmacotherapy of pervasive developmental disorders. In Institute 1, Advanced Psychopharmacology for Clinical Practice. 54th Annual Meeting of the American Academy of Child and Adolescent Psychiatry, Scientific Proceedings, Abstract G., p. 10, October 2007.

A181. **McDougle, C.J.**: Atypical antipsychotics in autism and other pervasive developmental disorders. In Symposium #29, Update on the Use of antipsychotics in Children and Adolescents. 54th Annual Meeting of the American Academy of Child and Adolescent Psychiatry, Scientific Proceedings, Abstract 29C., pp. 91-92, October 2007.

A182. Posey, D.J., Stigler, K.A., Erickson, C.A., Azzouz, F., Wilkerson, J., Mullett, J., **McDougle, C.J.**: A double-blind, placebo-controlled study of D-cycloserine in children with autistic disorder. American College of Neuropsychopharmacology 46th Annual Meeting Abstracts, Boca Raton, FL, December 9-13, 2007.

A183. Stigler, K.A., Diener, J.T., Kohn, A.E., Erickson, C.A., Posey, D.J., **McDougle, C.J.**: Aripiprazole in Asperger's disorder and pervasive developmental disorders: A 14-week prospective, open-label study. American College of Neuropsychopharmacology 46th Annual Meeting Abstracts, Boca Raton, FL, December 9-13, 2007.

A184. Jahromi, L.B., McCracken, J.T., Lee, L.S-Y., and the RUPP Autism Network: Positive effects of methylphenidate on social communication and self-regulation in children with pervasive developmental disorders and hyperactivity. Gatlinburg Conference, Gatlinburg, TN, 2008.

A185. Melmed, R., Handen, B., Hansen, R.L., Aman, M., Bruss, J., Burnham, D., **McDougle, C.**, Ober-Reynolds, S.E., Jones, J., Kirwan, J., Brautigam, S.E., Stephens, S.M., Smith, C.J.: A placebo-controlled trial of oral human immunoglobulin for gastrointestinal dysfunction in children with autistic disorder. International Meeting for Autism Research, Abstract # 1843, London, England, May 2008.

A186. Posey, D.J., Erickson, C.A., **McDougle, C.J.**: Treating attention-deficit/hyperactivity disorder symptoms in pervasive developmental disorders. American Psychiatric Association 2008 Annual Meeting Syllabus & Proceedings Summary, Washington, DC., p. 215, May 3-8, 2008.

A187. **McDougle, C.J.**: Psychopharmacology of autism and other pervasive developmental disorders. In Institute 1, Advanced Psychopharmacology Institute: Translating Recent Psychopharmacological Research Findings Into Clinical Care. 55th Annual Meeting of the American Academy of Child and Adolescent Psychiatry, Scientific Proceedings, Abstract I 1.5, p. 10, October 2008.

A188. Posey, D.J., Stigler, K.A., Erickson, C.A., Azzouz, F., Mullett, J., Diener, J.T., **McDougle, C.J.**: A double-blind, placebo-controlled study of D-Cycloserine in children with autistic disorder. 55th Annual Meeting of the American Academy of Child and Adolescent Psychiatry, Scientific Proceedings, Abstract P3.53, p. 219, October 2008.

A189. **McDougle, C.J.** (Chair) Symposium 24, RUPP-PI Autism Network: Risperidone With or Without Parent Management Training in Children and Adolescents With Pervasive Developmental Disorders. 55th Annual Meeting of the American Academy of Child and Adolescent Psychiatry, Scientific Proceedings, Abstract S24, p. 86, October 2008.

A190. Erickson, C.A., Mullett, J.E., Diener, J.T., Kohn, A.E., Peay, K.I., Stigler, K.A., Posey, D.J., **McDougle, C.J.**: A prospective 12-week open-label study of aripiprazole in Fragile-

X Syndrome. 55th Annual Meeting of the American Academy of Child and Adolescent Psychiatry, Scientific Proceedings, Abstract P6.11, p. 269, November, 2008.

A191. Posey, D., Erickson, C., Stigler, K., Mullet, J., Katschke, A., **McDougle, C.**: Open-label memantine in children and adolescents with pervasive developmental disorders. American College of Neuropsychopharmacology 47th Annual Meeting Abstract, Scottsdale, AZ, December 7-11, 2008.

A192. Farmer, C.A., Arnold, L.E., Witwer, A., Disilvestro, R., Aman, M.G., McCracken, J., **McDougle, C.**, Scahill, L., Tierney, E.: Moderators, mediators, and other predictors of risperidone response in children with autistic disorder and irritability. International Meeting for Autism Research, Abstract # 4004, Chicago, IL, May 2009.

A193. Erickson, C.A., Mullett, J.E., Diener, J.T., Kohn, A.E., Stigler, K.A., Posey, D.J., **McDougle, C.J.**: Open-label, aripiprazole in fragile X syndrome. Poster Presentation at National Clinical and Translational Research Education Annual Meeting, Washington, DC, April 14-15, 2009.

A194. Posey, D., Stigler, K., **McDougle, C.**: Antipsychotic agents in the treatment of autism. 9th World Congress of Biological Psychiatry Abstracts, Paris, France, June 28 – July 2, 2009.

A195. **McDougle, C.J.**: Psychopharmacology of autism. In Institute 1, Advanced Psychopharmacology Update: Evidence-Based Treatment and Beyond. 56th Annual Meeting of the American Academy of Child and Adolescent Psychiatry, Scientific Proceedings, Abstract I1.2, p. 7, October 2009.

A196. McCracken, J.T., Aman, M.G., **McDougle, C.J.**, Scahill, L., Tierney, E., Arnold, L.E., Whelan, F., Vitiello, B.: Dopamine genes and weight gain in autistic children treated with Risperidone. 56th Annual Meeting of the American Academy of Child and Adolescent Psychiatry, Scientific Proceedings, Abstract P32.3, p. 101, October 2009.

A197. **McDougle, C.J.**: Psychopharmacology of adults with autism. In Institute 8, Autism Spectrum Disorders: Review of Basic Sciences, Diagnosis, and Treatment. 56th Annual Meeting of the American Academy of Child and Adolescent Psychiatry, Scientific Proceedings, Abstract I 8.6, p. 26, October 2009.

A198. Posey, D., Erickson, C., Stigler, K., Diener, J., Kieffer, E., Kohn, A., Mathieu-Frazier, L., Mullett, J., **McDougle, C.**: A double-blind, placebo-controlled trial of N-acetylcysteine in children with autism spectrum disorders. American College of Neuropsychopharmacology, 48th Annual Meeting, Abstract # 204, page 208, 2009.

A199. Stigler, K., Aman, M., McDougle, C., Scahill, L., Handen, B., Arnold, L.E., Johnson, C., Dziura, J., Vitiello, B., Wagner, A.: Medication and parent training in children with pervasive developmental disorders and serious behavior problems. American College of Neuropsychopharmacology, 48th Annual Meeting, Abstract # 208, page 208, 2009.

A200. Boorin, S., Scahill, L., Jeon, S., Caprio, S. and the Research Units on Pediatric Psychopharmacology Autism Network (RUPP). Metabolic consequences of risperidone in children with autism. Poster presentation: International Society of Psychiatric-Mental Health Nurses 12th Annual Conference, St Louis, Missouri, USA, April 14-17, 2010.

A201. Erickson, C.A., Mullett, J.E., Kohn, A.E., Stigler, K.A., Plawecki, M.H., Miller, A.M., **McDougle, C.J.**: Open-label acamprosate in fragile x-associated and idiopathic autistic disorder. Indiana Clinical and Translational Sciences Institute 2nd Annual Meeting, Indianapolis, IN, April 19, 2010.

A202. **McDougle, C.J.**: Psychopharmacology of Autism, In Master Course 01 Update on Pediatric Psychopharmacology, American Psychiatric Association Course Brochure, p. 12, New Orleans, LA, May 22, 2010.

A203. **McDougle, C.J.:** Pharmacological Approaches to Autism Spectrum Disorders for Clinicians, American Psychiatric Association Syllabus and Proceedings Book, Workshop 58, p. 33, New Orleans, LA, May 24, 2010.

A204. Stigler, K.A., Erickson, C.A., Posey, D.J., Mullett, J.E., Diener, J.T., Kohn, A.E., **McDougle, C.J.**: Paliperidone for irritability in adolescents and young adults with autistic disorder. American Psychiatric Association New Research Abstract No. NR5-29, P. 174, New Orleans, LA, May 25, 2010.

A205. Stigler, K.A., Wang, Y., Dzemidzic, M., McDonald, B., **McDougle, C.**, Anand, A., Saykin, A.: Effects of aripiprazole on brain circuitry in youth with autism spectrum disorders. 16th Annual Meeting of the Organization for Human Brain Mapping, Barcelona, Spain, June, 2010.

A206. **McDougle, C.J.**: Advanced pharmacological approaches to treating autism spectrum disorders. In Institute 1, Advanced Psychopharmacology for Clinical Practice. 57th Annual Meeting of the American Academy of Child and Adolescent Psychiatry, Scientific Proceedings, Abstract 1.7, p. 9, October 2010.

A207. Geraghty, M., Arnold, L.E., Taylor, C.A., Young, G.S., De Pasquale, G.M., Aman, M.G., Scahill, L.D., **McDougle, C.J.**: Comparison of bone nutrient levels in children with and without autism. 57th Annual Meeting of the American Academy of Child and Adolescent Psychiatry, Scientific Proceedings, Abstract 1.22, p. 226, October 2010.

A208. Nurmi, E.L., Spilman, S.L., Badashova, K.K., McCracken, J.T., and the RUPP Autism Network: Genetic predictors of antipsychotic-induced weight gain in autism. 57th Annual Meeting of the American Academy of Child and Adolescent Psychiatry, Scientific Proceedings, Abstract 1.57, p. 241, October 2010.

A209. Goddard, A., Dydak, A., Long, Z., Medlock, C., Shekhar, A., **McDougle, C.**: The effect of

family history of panic on cortical GABA deficits in panic disorder: a prospective 1H-MRS Study. American College of Nueropsychopharmacology, 49th Annual Meeting, Poster Session I, #121, page 200, 2010.

A210. Stigler, K., Wang, Y., McDonald, B., Saykin, A., Anand, A., **McDougle, C.**: Effects of aripiprazole on brain circuitry in youth with pervasive developmental disorders. American College of Neuropsychophamacology, 49th Annual Meeting, Poster Session III, #147, page 284, 2010.

GRANTS:

COMPLETED:

FEDERAL GRANTS:

1991-1994 NIDA Grant, Clinical Research Center for Opioid and Cocaine Abuse (Thomas R. Kosten, P.I., $1,407,294/yr, 25% of salary.

1991-1994 RO1 MH45803, Neurobiology and Treatment of OCD (Wayne K. Goodman, (P.I.), $124,020/yr, 10% of salary.

07/01/95-06/30/98 5PO1 HD 03008-28 Program Project Grant, Mental Retardation and Developmental Psychopathology (Donald J. Cohen, P.I., $881,380/yr, 15% of salary.

1996-1997 RO3 MH53304, Dopamine Transporter Imaging in Tourette's Syndrome (Robert T. Malison, P.I.), $49,150/yr, 10% of salary.

1996-1998 Supplement to Yale Clinical Science Research Center in Psychiatry, Venlafaxine vs. Placebo in Adolescents With Major Depression, $100,000 (P.I.).

1996-1998 Yale Clinical Science Research Center in Psychiatry, Core Director, Experimental Therapeutics Core, $45,00/yr, (P.I.).

07/01/96-06/30/99 PO1 MH49351 Program Project Grant, Pathogenesis and Treatment of TS, OCD and Related Disorders (James F. Leckman, P.I.) $1,432,980/yr, C.J. McDougle, P.I. of Project 5, Pharmacological Treatment of OCD, $120,000/yr.

10/01/97-09/30/03 Research Units on Pediatric Psychopharmacology: Autism and Other Pervasive Disorders, National Institute of Mental Health. A Double-Blind, Placebo-Controlled Investigation of Risperidone in Children, Adolescents, and Young Adults with Autistic Disorder, total costs for the entire project = $1,236,009 (P.I.)

10/01/01 - Housing and Urban Development, To expand the services of the James Whitcomb

09/30/05	Riley Hospital for Children Autism Treatment Center, total costs = $860,000, (P.I.)
09/15/02 - 07/31/07	Research Units on Pediatric Psychopharmacology-Psychosocial Intervention at Indiana University School of Medicine, National Institute of Mental Health, total costs for the entire project = $2,435,810 (P.I.)
09/15/02 - 07/31/07	Research Units on Pediatric Psychopharmacology-Psychosocial Intervention at Indiana University School of Medicine, National Institute of Mental Health, Genetics of Autism Support, Administrative Supplement, total costs for the entire project = $200,000 (P.I.)
08/01/03 - 04/30/08	NIH/NIMH K23 MHO68627, Psychopharmacology of Autism and Related Disorders, total costs for the entire project = $881,282 (Mentor to David Posey, M.D. for Career Developmental Award)
08/01/08 - 06/30/10	NIH KL1 RR02570, Indiana University Clinical and Translational Sciences Institute, total costs for the entire project = $50,000 per year (Mentor to Craig Erickson, M.D., for Career Development Award)

FOUNDATION GRANTS:

1990-1991	Lilly Psychiatric Research Fellowship, The Pharmacotherapy of Treatment-Refractory Obsessive Compulsive Disorder, $35,000 (P.I.)
1990-1992	NARSAD Young Investigator Award, The Role of Serotonin in Depression, $60,000 (P.I.)
1994-1996	NARSAD Young Investigator Award, The Pharmacotherapy of Autism, $60,000 (P.I.)
1995-1998	Korczak Foundation for Autism and Related Disorders, $20,000/yr, (Co-P.I.)
10/01/97- 09/30/99	Theodore and Vada Stanley Foundation Research Award, A Double-Blind, Placebo-Controlled Study of Risperidone in Adults With Autistic Disorder, total costs for the entire project = $97,000 (P.I.)
09/15/97 03/14/00	NARSAD Independent Investigator Award, A Double-Blind, Placebo-Controlled Study of Risperidone in Children and Adolescents with Autistic Disorder, total costs for the entire project = $100,000 (P.I.)
08/01/00- 07/31/00	Indiana University Intercampus Research Fund, Immunologic Function in Children and Adolescents with Autism, total costs = $10,000 (P.I.)
04/17/01 -	NARSAD Young Investigator Award, A Double-Blind Placebo Controlled Study

06/30/01 of Valproate with Children and Adolescents With Mood Disorder, total costs = $60,000 (Co-P.I.)

11/01/06 - 10/31/09 FRAXA Fragile X Research Foundation, Aripiprazole in Fragile X Syndrome, total costs for the entire project = $30,000 (P.I.)

12/15/06 - 12/14/09 National Alliance for Autism Research – Autism Speaks Research Award, A Pilot Study of Oral N-Acetylcysteine in Children with Autism Spectrum Disorders, total costs for the entire project = $60,000 (Co-I)

01/01/07 - 12/31/08 Autism Speaks Research Award, Subcontract through Ohio State University Research Foundation, Risperidone and Behavior Therapy in Children with Pervasive Developmental Disorder: Long Term Follow-up, total costs for the entire project = $22,500 (Co-P.I.)

INDUSTRY-SPONSORED GRANTS:

INVESTIGATOR-INITIATED TRIAL (IIT)

1992 IIT - Solvay/UpJohn, Fluvoxamine in Adults with Autism, $25,000 (P.I.)

1992-1996 Pfizer, Sertraline vs. Desipramine in OCD, Multicenter Study (Co-P.I.)

1992-1996 Miles, Ipsapirone vs. Placebo in Major Depression, Multicenter Study (Co-P.I.)

1996 IIT - Solvay/UpJohn, Fluvoxamine vs. Placebo in Children and Adolescents with Autism, $25,000 (P.I.)

1996 IIT - Pfizer, Sertraline vs. Placebo in Adults with Autism, $15,000 (P.I.)

06/11/98- 06/10/00 Eli Lilly and Co., Randomized, Double-Blind, Placebo-Controlled, Variable Discontinuation Study in Children with Attention-Deficit/Hyperactivity Disorder, total costs for the entire project = $208,440 (P.I.)

06/11/98- 06/10/00 Eli Lilly and Co., Long-Term, Open-Label, Safety Study of Tomoxetine Hydrochloride in Patients 6 Years and Older, total costs for the entire project = $220,300 (P.I.)

01/01/99- 12/31/99 Eli Lilly and Co., Fluoxetine Versus Placebo in Childhood/Adolescent Depression, total costs for the entire project = $240,000 (Co-P.I.)

01/01/99- 12/31/99 Eli Lilly and Co., Fluoxetine Versus Placebo in Children and Adolescents with OCD, total costs for the entire project = $120,000 (Co-P.I.)

01/01/99- Eli Lilly and Co., Randomized, Double-Blind Study of Tomoxetine

06/30/00	Hydrochloride, Methylphenidate Hydrochloride, and Placebo in Pediatric Outpatients with Attention-Deficit/Hyperactivity Disorder, total costs for the entire project = $250,000 (P.I.)
06/01/00 - 05/31/01	Eli Lilly and Co., A Phase III Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Comparison of Fixed-Dose Ranges of Tomoxetine with Placebo in Child and Adolescent Outpatients, Aged 8 to 18 years, total costs for The entire project = $300,726 (Co-P.I.)
06/01/00 - 05/31/01	Eli Lilly and Co., Long Term, Open-Label, Safety Study of Tomoxetine in Patients, 6 Years and Older, total costs for the entire project = $535,193 (Co-P.I.)
10/10/02 06/30/05	Pfizer, Inc., A Multicenter, 10-week, Randomized, Double-Blind, Placebo-Controlled, Flexible Dose Outpatient Study of Sertraline in Children and Adolescents with Major Depressive Disorder, total costs for the entire project = $65,000 (Co-P.I.)
06/01/00- 07/01/00	Pfizer, Inc., A Multicenter, 24-week, Open-Label Extension Study of Sertraline in Children and Adolescent Outpatients Previously Diagnosed with Major Depressive Disorder, total costs for the entire project = $44,000 (Co-P.I.)
12/15/00- 06/30/01	Eli Lilly and Co., Efficacy, Tolerability, and Safety of Once-daily Tomoxetine Hydrochloride versus Placebo in Children with Attention-Deficit/Hyperactivity Disorder, total costs for the entire project = $143,258 (P.I.)
06/15/01 - 07/01/02	Eli Lilly and Co., A Randomized, Double-Blind Study of Tomoxetine Hydrochloride and Placebo in Pediatric Outpatients with Attention-Deficit/ Hyperactivity Disorder and Comorbid Tic Disorders, total costs for the entire project = $185,873 (Co-P.I.)
04/17/00 - 03/20/02	IIT - Abbott Laboratories, A Double-Blind, Placebo-Controlled Study of Valproate With Children and Adolescents With Mood Disorder, total costs for the entire project= $44,484 (Co-P.I.)
02/15/00 - 02/14/01	Pfizer, Inc. A Multicenter, 10- week, Randomized, Double-Blind, Placebo Controlled, Flexible dose Outpatient Study of Sertraline in Children and Adolescents with Major Depression Disorder, total costs = 65,188 (Co-P.I.)
12/15/98 09/15/00	Eli Lilly and Co., Fluoxetine Versus Placebo in Childhood/Adolescent Depression, total costs = $245,096 (Co-P.I.)
01/12/01 - 12/31/01	Wyeth-Ayerst, A Double-Blind, Placebo-Controlled Study of Venlafaxine ER in Children and Adolescents with Generalized Anxiety Disorder, total costs for the entire project = $74,440 (Co-P.I.)

05/04/01 - 05/01/02	Wyeth-Ayerst, A Double-Blind, Placebo-Controlled, Parallel-Group, flexible-Dose Study of Venlafaxine ER in Children and Adolescent Outpatients with Social Anxiety Disorder, total costs for the entire project = $80,350 (Co-P.I.)
08/01/02 - 07/31/04	Repligen, A Phase III, Randomized, DB, PC, Multiple Dose Study to Assess the Efficacy, Safety, and Tolerability of RG1068 (Synthetic Human Secretin) in Children with Autism, total costs for the entire project = $131,750 (P.I.)
10/01/02 - 06/30/05	Pfizer, Inc., A Multicenter 10-week, Randomized, Double-Blind Study of Sertraline and Placebo in Children and Adolescents with Post Tramatic Stress Disorder (PTSD), total costs for the entire project = $71,500 (P.I.)
10/01/03 - 09/30/05	IIT - AstraZeneca, A Retrospective Analysis of Quetiapine in the Treatment of Autism, total costs for the entire project = $15,875 (P.I.)
07/01/03 - 06/30/05	Eli Lilly and Co., Guiding Dose Increases in Patients Incompletely Responsive to Usual Doses of Atomoxetine Concentrations: A Randomized Double-Blind Study (LYCL), total costs for the entire project = $139,250 (Co-P.I.)
07/15/02 - 04/30/04	Eli Lilly and Co., Comparison of Atomoxetine HCI, Extended-Release Methyphenidate HCI (Concerta) and Placebo in Pediatric Outpatients with DSM-IV ADHD (LYBI), total costs for the entire project = $253,111 (Co-P.I.)
06/01/00 - 06/30/05	Eli Lilly and Co., Long Term, Open-Label, Safety Study of Tomoxetine in Patients, 6 years and Older (LYAI), total costs for the entire project = $860,472 (Co-P.I.)
10/01/01 - 12/01/03	Eli Lilly and Co., A Phase 4, Double-Blind, Placebo-Controlled Trial of Atomoxetine to Evaluate Efficacy in the School in Children Ages 8-12 with ADHD (LYAW), total costs for the entire project = $219,715 (Co-P.I.)
03/01/03 - 08/30/04	Shire Pharmaceutical Development, Inc., A Phase III, Randomized, Multi-Center, Double-Blind, Parallel-Group, Placebo-Controlled, Safety and Efficacy Study of SPD503 in Children and Adolescents Aged 6-17 with Attention Deficit Hyperactivity Disorder (ADHD), total costs for the entire project = $89,681 (Co-P.I.)
03/01/03 - 07/30/04	Shire Pharmaceutical Development, Inc., A Phase III Open-Label Study of SPD503 in Children and Adolescents (Aged 6-17) with Attention Deficit Hyperactivity Disorder, total costs for the entire project = $54,500 (Co-P.I.)
07/01/03 - 06/30/04	Eli Lilly and Co., Guiding Dose Increases in Patients Incompletely Responsive to Usual Doses of Atomoxetine Concentrations: A Randomized Double-Blind Study (LYCL), total costs for the entire project = $99,360 (Co-P.I.)

07/15/02 - ongoing	Eli Lilly and Co., Comparison of Atomoxetine HCI, Extended-Release Methyphenidate HCI (Concerta) and Placebo in Pediatric Outpatients with DSM-IV ADHD (LYBI), total costs for the entire project = $449,066 (Co-P.I.)
06/01/00 - ongoing	Eli Lilly and Co., Long Term, Open-Label, Safety Study of Tomoxetine in Patients, 6 years and Older (LYAI), total costs for the entire project = $535,193 (Co-P.I.)
10/01/01 - 06/30/03	Eli Lilly and Co., A Phase 4, Double-Blind, Placebo-Controlled Trial of Atomoxetine to Evaluate Efficacy in the School in Children Ages 8-12 with ADHD (LYAW), total costs for the entire project = $263,358 (Co-P.I.)
03/01/03 - 08/30/03	Shire Pharmaceutical Development, Inc., A Phase III, Randomized, Multi-Center, Double-Blind, Parallel-Group, Placebo-Controlled, Safety and Efficacy Study of SPD503 in Children and Adolescents Aged 6-17 with Attention Deficit Hyperactivity Disorder (ADHD), total costs for the entire project = $67,750 (Co-P.I.)
03/01/03 - 07/30/04	Shire Pharmaceutical Development, Inc., A Phase III Open-Label Study of SPD503 in Children and Adolescents (Aged 6-17) with Attention Deficit Hyperactivity Disorder, total costs for the entire project = $89,681 (Co-P.I.)
10/01/03 - 10/31/04	IIT - AstraZeneca, An Open-Label Pilot Study of Quetiapine Addition to Oros Methylphenidate in the Treatment of ADHD and High-Aggression Disruptive Behavior Disorders, total costs for the entire project = $122,858 (Co-P.I.)
07/01/03 - 06/30/05	Repligen Corporation, Open Label Extension Protocol for the Treatment of Children Previously Enrolled in Repligen Protocol RG 1068-03 or RG 1068-04, total costs of entire project = $155,400 (P.I.)
09/01/03 - 08/31/05	Johnson & Johnson Pharmaceutical, Provide Data from a NIMH Sponsored Trial Involving Risperdal in Pediatric Autism, total costs for the entire project = $30,000 (P.I.)
11/01/03 - 12/31/04	IIT - Eli Lilly and Co., A Pilot Study of Atomoxetine for the Treatment of Inattention, Hyperactivity, and Impulsivity in Children and Adolescents with Pervasive Developmental Disorders, total costs for the entire project = $60,000 (Co-P.I.)
03/01/04 - 02/28/06	IIT - Bristol-Myers Squibb, An Open-Label Study of Aripiprazole in Children and Adolescents with Autistic Disorder, total costs for the entire project = $75,094 (P.I.)
10/01/04 - 09/03/07	Repligen Corporation, An Open-Label, Dose-Escalation, Pilot Study to Assess the Safety and Efficacy of Subcutaneous RG106B (synthetic human secretin) in

Patients with Obsessive Compulsive Disorder, total costs for the entire project = $103,510 (Co-P.I.)

05/09/05 – 05/08/08 Pediamed, Oral Human Immunoglobulin in Autism, total cost for entire project = $53,940. (P.I.)

ACTIVE:

FEDERAL GRANTS:

07/01/05 - 06/30/11 NIMH RO1 MH072964, Novel Pharmacological Strategies in Autism, total costs for the entire project = $1,609,690 (P.I.)

04/01/07 - 03/31/12 NIMH R01 MH077600, Targeted Pharmacologic Interventions for Autism, total costs for the entire project = $1,853,683 (P.I.)

09/24/08 - 06/30/13 NIH/NIMH K23 MH082119-01A1, Pharmacotherapy of Pervasive Developmental Disorders, total costs for the entire project = $921,545 (Mentor to Kimberly Stigler, M.D. for Career Development Award)

03/01/09 - 03/31/14 Department of Defense W81XWH-09-1-0091, A Randomized, Placebo-Controlled Trial of D-Cycloserine for the Enhancement of Social Skills Training in Pervasive Developmental Disorders, total costs for the entire project = $1,786,961 (Co-P.I.)

08/07/08 - 06/30/11 KL2RR025760-01, Indiana CTSI Career Development Award, Riluzole in Fragile X Syndrome: A Pilot Study Incorporating Biomarker Assay, total costs = $7,645 (Co-I)

12/01/09 - 11/30/14 NIMH R01 MH081221, Randomized Trial of Parent Training for Young Children with Autism, total costs for the entire project = $1,212,753 (Co-I)

02/11/10 - 02/09/11 KL2RR025760-01, Indiana CTSI Pilot Research Award, Acamprosate in Fragile X Syndrome: Pilot Study Incorporating Biomarker and Psychophysiological Measures Including Baseline Comparison to Idiopathic Autism Spectrum Disorders, total costs = $17,156 (Co-I)

07/01/10 - 06/30/13 NIMH R01 MH083739, RUPP Autism Network: Guanfacine for the Treatment of Hyperactivity in PDD (1/4), total costs for the entire period = $1,112,283 (P.I.)

07/01/10 - 05/31/14 American Academy of Child & Adolescent Psychiatry/NIDA K12 DA000357, Neural Correlates of Emotion Dysregulation in Youth at Risk for Substance Abuse, total costs for the entire period = $860,305 (Mentor to Leslie Hulvershorn, M.D. for Career Development Award)

FOUNDATION GRANTS:

07/01/97- Indiana Division of Mental Health, Riley Child Psychiatry Clinic, total costs for the entire project = $152,996 per year (P.I.)

05/01/07 - 04/30/11 Clarian Health Partners Values Grant VFR-235, Effects of Aripiprazole on Brain Circuitry in Children and Adolescents with Autism, total costs for the entire project = $80,000 (Co-I)

06/01/10 - 05/31/13 Autism Speaks Research Award, Mirtazapine Treatment of Anxiety in Children and Adolescents with Pervasive Developmental Disorders, total costs = $300,000 (P.I.)

07/01/10 06/30/11 Showalter Trust, Effects of Memantine on Brain Circuitry in Adolescents and Young Adults with Asperger's Disorder, total costs for the entire period = $60,000 (Co-I)

07/01/10 06/30/12 American Academy of Child & Adolescent Psychiatry, Acamprosate in Youth with Autistic Disorder, total costs for the entire period = $60,000 (Co-I and Primary Mentor to Craig Erickson, M.D., for Jr. Investigator Award)

07/01/10 06/30/12 Klingenstein Depression Fellowship, The Impact of Methylphenidate Treatment on Emotion Regulation in ADHD: A Functional Connectivity Analysis, total costs for the entire period = $60,000 (Primary Mentor to Leslie Hulvershorn, M.D.)

INDUSTRY-SPONSORED GRANTS:

05/01/07 - 04/30/11 IIT - Janssen Pharmaceutica, A Prospective, Open-Label Study of Paliperidone ER in Adolescents and Adults with Autism, total costs for entire project = $149,106 (Co-I)

09/01/08 - 08/31/13 Seaside Therapeutics, A Double-Blind, Placebo-Controlled, Crossover, Flexible-Dose Evaluation of the Efficacy, Safety, and Tolerability of STX209 in the Treatment of Irritability in Subjects with Fragile X Syndrome, total costs = $146,013 (Co-I)

12/01/08 - 11/30/13 Forest Research Institute, An Open-Label (Part One) and a Randomized, Double-Blind, Placebo-Controlled (Part Two) Study of the Pharmacokinetics, Safety, Efficacy and Tolerability of Memantine in Pediatric Patients with Autism, total costs = $64,138 (Co-I)

12/01/08 - 11/30/13 Seaside Therapeutics, An Open-Label, Flexible-Dose Evaluation of the Safety and Tolerability of STX209 for the Treatment of Irritability in Subjects with Autism Spectrum Disorders, total costs = $100,125 (Co-I)

09/01/09 - F. Hoffman-LaRoche, Inc. (Roche), A Randomized, Double-Blind, Placebo-

01/20/11 Controlled, Pharmacokinetic, Safety and Tolerability Study of R044917523 in Adult Patients with Fragile X Syndrome in Two Segments: A) Multiple Ascending Dose and, (B) Parallel Group Fixed Dose, NP22578 (the "Study") with the compound known as R044917523 (The "Compound"), total costs = $409,020 (Co-I)

12/01/09 - 11/30/14 Ortho McNeil Janssen Scientific Affairs, Evaluation of Growth, Sexual Maturation, and Prolactin-Related Adverse Events in the Pediatric Population Exposed to Atypical Antipsychotic Drugs (RIS-NAP-4022), total costs = $49,438 (Co-I)

PENDING:

FEDERAL GRANTS:

07/01/11 06/30/16 NIMH R01 MH094318, Novel Pharmacotherapy of Social Impairment in Autism Spectrum Disorder, total costs for the entire period = $2,937,624 (Co-P.I. with Craig Erickson, M.D.)

09/30/11 09/29/16 Department of Defense PR 100957, Aripiprazole in Fragile X Syndrome, total costs for the entire period = $2,956,364 (Co-P.I. with Craig Erickson, M.D.)

PRESENTATIONS:

ACADEMIC:

1. "MHPG and Depression: A Naturalistic Clinical Evaluation," (with Milstein, V.), Indiana University School of Medicine, Indianapolis, Indiana, Fall, 1983.

2. "Neuroleptic Addition in Fluvoxamine Refractory Obsessive Compulsive Disorder," Seymour Lustman Award Presentation, Department of Psychiatry, Yale University, New Haven, Connecticut, June 2, 1989.

3. "Psychotherapies and Obsessive Compulsive Disorder," (with Price, L.H., Rifkin, B., Hills, O.). Grand Rounds, Department of Psychiatry, Yale University, New Haven, CT, October 20, 1989.

4. "The Clinical Neurobiology of Cocaine Withdrawal: The Dopamine System," Biological Sciences Training Program, Department of Psychiatry, Yale University, New Haven, CT, January 29, 1990.

5. "Pathophysiological Differences Between PTSD, Melancholia, and Panic Disorder: Novel Pharmacotherapeutic Approaches for a Unique Disorder," (with Krystal, J., Southwick, S., Charney, D.), Regional Meeting of the Society for Traumatic Stress Studies, April 26, 1990.

6. "Fluvoxamine and the Mechanism of Anti-Obsessive Compulsive Disorder Action," Goodman, W.K., Price, L.H., Delgado, P.L., McDougle, C.J., Charney, D.S., Heninger, G.R., Symposium #1, Amer. Psychiat. Assoc., New York, NY, May 1990.

7. "Phenelzine and Imipramine in the Treatment of PTSD," Frank, J.B., Kosten, T.R., Giller, E.L., Dan, E., McDougle, C.J., Symposium #115, Amer. Psychiat. Assoc., New York, NY, May, 1990.

8. "Obsessive Compulsive Disorder: New Perspectives - Part II (with Goodman, W.K. and Leckman, J.F.), Grand Rounds, Department of Psychiatry, Yale University, New Haven, CT, May 25, 1990.

9. "Lithium Augmentation in Fluvoxamine-Refractory Obsessive Compulsive Disorder," Seymour Lustman Award Presentation, Department of Psychiatry, Yale University, New Haven, CT, June 1, 1990.

10. "The Role of Antidepressant Medication in General Psychiatry," Yale University Graduate Students in Psychology, New Haven, CT, August 16, 1990.

11. "The Pharmacotherapy of Treatment-Resistant Obsessive Compulsive Disorder," Grand Rounds, Department of Psychiatry, Wayne State University, Lafayette Clinic, Detroit, MI, September 18, 1990.

12. "The Acute Tryptophan Depletion Test as a Predictor of Depressive Relapse," NARSAD Research Symposium, Washington, D.C., October 5-6, 1990.

13. "Autistic Disorder: Recent Neurobiological Developments," 18th Annual Northeast Regional Conference on Autism, Ascutney Mountain Resort, Brownsville, VT, October 27, 1990.

14. "Post Traumatic Stress Syndromes," State University of New York Health Science Center, College of Medicine, Department of Psychiatry and Behavioral Sciences, Grand Rounds, Syracuse, NY, February 7, 1991.

15. "Haloperidol Addition in Fluvoxamine-Refractory Obsessive Compulsive Disorder," Biological Sciences Training Program, Department of Psychiatry, Yale University, New Haven, CT, March 18, 1991.

16. Goodman, W.K., McDougle, C.J., Price, L.H.: Pharmacotherapy of OCD, Symposium #IS12: OCD: Integrating Theory and Practice, APA Annual Meeting, New Orleans, LA, May 12, 1991.

17. Goodman, W.K., McDougle, C.J., Price, L.H., Charney, D.S., Heninger, G.R.: Serotonin Reuptake Inhibitors in OCD. Symposium #20: Serotonin Hypothesis of OCD: A Critical Review, APA Annual Meeting, New Orleans, LA, May 13, 1991.

18. "The Pharmacotherapy of Treatment-Resistant Obsessive Compulsive Disorder," Lilly Psychiatric Research Fellowship Award Presentation, Indianapolis, IN, June 3, 1991.

19. "Studies of Fluvoxamine in OCD," 5th World Congress of Biological Psychiatry, Florence, Italy, June 11, 1991.

20. "Serotonin Function and Major Depressive Disorders," National Depressive and Manic-Depressive Association 7th Annual Convention, Brown University Department of Psychiatry and Human Behavior, Providence, RI, July 27, 1991.

21. "The Pharmacotherapy of Affective Disorders," Yale University Graduate Students in Psychology, New Haven, CT, August 15, 1991.

22. "Advances in the Diagnosis and Treatment of Obsessive Compulsive Disorder," Chicago Medical School, Department of Psychiatry, Grand Rounds, North Chicago, IL, September 5, 1991.

23. "The Neurobiology and Pharmacotherapy of Autistic Disorder," Grand Rounds, The University of Connecticut, Department of Psychiatry, Farmington, CT, November 8, 1991.

24. "The Neurobiology and Pharmacotherapy of Autistic Disorder," Autism: Humanizing a Complex Disability, Course 94, American Psychiatric Association, 145th Annual Meeting, Washington, D.C., May 5, 1992.

25. "The Pharmacotherapy of Obsessive Compulsive Disorder," Grand Rounds, Yale Child Study Center, New Haven, CT, February 5, 1993.

26. "Treatment of Nonresponders to Serotonin Reuptake Inhibitors," Obsessive Compulsive Disorder: Clinical Frontiers, University of Chicago, Chicago, IL, April 21, 1993.

27. "The Treatment of Refractory OCD," Clinical Aspects of OCD Spectrum Disorders, American Society of Clinical Psychopharmacology, San Francisco, CA, May 23, 1993.

28. "Managing Psychotic or Schizotypal OCD Patients," in OCD: Comorbidity and Management Dilemmas, 146th Annual Meeting of the APA, San Francisco, CA, May 23, 1993.

29. "Noradrenergic Dysregulation During Cocaine Abstinence in Cocaine Addicts: Biochemical, Behavioral, and Cardiovascular Correlates," Biological Sciences Training Program, Department of Psychiatry, Yale University, New Haven, CT, January 10, 1994.

30. "Childhood Psychiatric Disorders Grown-Up," Grand Rounds, Department of Psychiatry, Yale University School of Medicine, New Haven, CT, February 18, 1994.

31. "The Role of Serotonin in Autistic Disorder," Grand Rounds, Department of Psychiatry, University of Florida College of Medicine, Gainesville, FL, February 22, 1994.

32. "The Diagnosis and Treatment of OCD," Cornell-Westchester Psychiatry Residents, White Plains, NY, March 15, 1994.

33. "The Diagnosis and Treatment of Depression," Grand Rounds, Department of Medicine, Medical College of Pennsylvania, Philadelphia, PA, March 23, 1994.

34. "The Diagnosis and Treatment of OCD," Grand Rounds, Department of Psychiatry, New York Medical College, Valhalla, NY, April 14, 1994.

35. "The Differential Diagnosis of OCD," presented at an Industry Supported Breakfast Symposia, "The Anxiety Kaleidoscope," Annual Meeting of the American Psychiatric Association, Philadelphia, PA, May 24, 1994.

36. Goodman WK, McDougle CJ, Barr LC, Leckman JF, Price LH. Serotonin/dopamine interaction in Tourette's syndrome related OCD. In Symposium 40, "The Neurobiology and Treatment of Human Anxiety: Recent Advances. Proc Amer Psychiatric Assoc, Philadelphia, PA, p. 88, May 24, 1994.

37. "Psychopharmacological Therapy of Autism," as part of "The Challenge of Autism: Neurobiological, Clinical and Educational Perspectives," North Shore University Hospital, Manhasset, NY, October 21, 1994.

38. "The Pharmacotherapy of OCD," in "TS and OCD: Neurobiological Approaches to Childhood Psychiatric Disorders," American Academy of Child and Adolescent Psychiatry Annual Meeting, New York, NY, October 30, 1994.

39. "Serotonin in the Pathophysiology and Pharmacotherapy of Autism," Grand Rounds, Yale Child Study Center, New Haven, CT, November 22, 1994.

40. "Tourette's Disorder: Clinical Features, Treatment Strategies, and Relationship to OCD," In symposium, "Obsessive Compulsive Disorder & OCD Spectrum Disorders," Butler Hospital, Department of Psychiatry, Brown University, School of Medicine, Providence, RI, January 25, 1995.

41. "The Diagnosis and Pharmacotherapy of Social Phobia," Grand Rounds, Department of Psychiatry, Albany Medical College, Albany, NY, April 14, 1995.

40. "Pharmacology of Obsessive Compulsive Disorder," In Symposium Obsessive-Compulsive Disorder: Diagnosis and Treatment, University of Chicago, Chicago, IL, April 26, 1995.

41. "Pharmacological Treatment of OCD," in Symposium: New Developments in Obsessive Compulsive Disorder, Academic Hospital, Utrecht, The Netherlands, May 12, 1995.

42. "SSRIs in the Treatment of Autism," in Symposium, "SSRIs in Children and Adolescents," NCDEU 35th Annual Meeting, Orlando, FL, June 3, 1995.

43. "OCD in Children," in Symposium: The Obsessive Compulsive Spectrum, Maine Medical Center, Portland, ME, October 3, 1995.

44. "Suicidality in Obsessive Compulsive Disorder: Prevalence and Prediction," Grand Rounds, Yale Child Study Center, New Haven, CT, October 17, 1995.

45. "The Role of Serotonin in Pervasive Developmental Disorders," Biological Sciences Training Program, Department of Psychiatry, Yale University, New Haven, CT, November 27, 1995.

50. "Risperidone in Pervasive Developmental Disorders," Grand Rounds Discussant for Wendy S. Levine, M.D., Yale Child Study Center, New Haven, CT, January 9, 1996.

51. "The Treatment of Repetitive Disorders: Tics, OCD, and Autism Across the Life Cycle," Academic Conference Series, Westwood Lodge Hospital, Westwood, MA, January 16, 1996.

52. "The Role of Serotonin in the Neurobiology and Treatment of Autistic Disorder," Grand Rounds, Department of Psychiatry, Division of Child and Adolescent Psychiatry, Mt. Sinai School of Medicine, New York, NY, February 22, 1996.

53. "The Diagnosis and Pharmacotherapy of OCD," Grand Rounds, Department of Psychiatry, Highland Drive Veterans Administration Hospital, Pittsburgh, PA, March 20, 1996.

54. "Autism," In Symposium, Obsessive-Compulsive Spectrum Disorders: New Dimensions and Practical Management, Mount Sinai Medical Center, New York, NY, March 30, 1996.

55. "Neurobiology and Pharmacotherapy of Obsessive Compulsive Disorder," In Symposium, New Knowledge of Stress and Anxiety Disorders: Promises for the Future, Department of Psychiatry, Yale University School of Medicine, New Haven, CT, April 2, 1996.

56. "The Role of Serotonin in Repetitive Behavior," Grand Rounds, Department of Psychiatry, State University of New York Health Science Center at Brooklyn, Brooklyn, NY, April 10, 1996.

57. "Pervasive Developmental Disorder and Risperidone," Grand Rounds. Discussant for Wendy S. Levine, M.D., Riverview Hospital for Children, Middletown, CT, April 17, 1996.

58. "The Role of Serotonin in Repetitive Behavior," Grand Rounds, Carrier Foundation, Belle Mead, NJ, May 2, 1996.

59. "Update on Pharmacological Management: Agents and Augmentation," In Symposium - OCD New Perspectives and Practical Management, American Psychiatric Association Annual Meeting, New York, NY, May 7, 1996.

60. "Relationship of Autism to Obsessive Compulsive Disorder," In Symposium, Autism and Related Disorders, 17th Annual TEACCH Conference, Chapel Hill, NC, May 24, 1996.

61. "The Diagnosis and Pharmacotherapy of Obsessive Compulsive Disorder," Grand Rounds, Department of Psychiatry, University of Medicine and Dentistry of New Jersey, Newark, NJ, September 18, 1996.

62. "Treatment Strategies for Refractory OCD," in Symposium: Refractory Obsessive Compulsive Disorder, European College of Neuropsychopharmacology 9th Annual Congress, Amsterdam, The Netherlands, September 25, 1996.

63. "The Pharmacotherapy of Treatment-Refractory Obsessive Compulsive Disorder," Grand Rounds, Department of Psychiatry, University of Minnesota School of Medicine, Minneapolis, MN, October 22, 1996.

64. "The Diagnosis and Pharmacotherapy of Obsessive Compulsive Disorder," Grand Rounds, Department of Psychiatry, North Shore University Hospital, Cornell University Medical College, Manhasset, NY, November 1, 1996.

65. "The Role of Serotonin in the Neurobiology and Pharmacotherapy of Autism-Spectrum Disorders," Grand Rounds, Department of Psychiatry, Vanderbilt University School of Medicine, Nashville, TN, November 12, 1996.

66. "The Diagnosis and Treatment of Obsessive Compulsive and Chronic Tic Disorders," Grand Rounds, Department of Psychiatry, St. Vincent's Medical Center, New York, NY, January 16, 1997.

67. "The Role of Serotonin in the Neurobiology and Pharmacotherapy of Autism-Spectrum Disorders," Grand Rounds, Department of Psychiatry, Mt. Sinai School of Medicine, New York, NY, January 28, 1997.

68. "Management and Treatment of OCD and Tic-Related Conditions Including Tourette's Syndrome," In Symposium, Diagnosis and Treatment of Obsessive Compulsive Disorder Through the Life Cycle, Department of Psychiatry and Behavioral Neurosciences, Wayne State University School of Medicine, Detroit, MI, March 8, 1997.

69. "The Diagnosis and Pharmacotherapy of Obsessive Compulsive Disorder," Grand Rounds, Department of Psychiatry, Brockton Veterans Administration Medical Center, Brockton, MA, March 20, 1997.

70. "The Pharmacotherapy of Treatment-Refractory Obsessive Compulsive Disorder," Grand Rounds, Department of Psychiatry, The Mayo Clinic, Rochester, MN, March 25, 1997.

71. "Studies on Serotonin Function in Autism," In Symposium, New Insights in the Diagnosis, Neurobiology, Genetics, and Treatment of Autism, Mt. Sinai School of Medicine, New York, NY, April 5, 1997.

72. "The Diagnosis and Pharmacotherapy of Obsessive Compulsive Disorder," Grand Rounds, Department of Psychiatry, University of Medicine and Dentistry of New Jersey, Newark, NJ, April 25, 1997.

73. "The Diagnosis and Pharmacotherapy of Obsessive Compulsive Disorder," Grand Rounds, Department of Psychiatry, St. Elizabeth's Hospital, Washington, D.C., May 15, 1997.

74. "The Diagnosis and Pharmacotherapy of Obsessive Compulsive Disorder, Grand Rounds, Department of Psychiatry, Howard University School of Medicine, Washington, D.C., May 16, 1997.

75. "Recent Advances in the Neuropsychopharmacology of Autism Spectrum Disorders," Grand Rounds, Department of Psychiatry, Yale University School of Medicine, New Haven, CT, May 30, 1997.

76. "The Role of Serotonin Reuptake Inhibitors in the Treatment of Patients with Pervasive Developmental Disorders," In Symposium IV: Pharmacotherapy of Major Psychiatric Disorders in Developmental Disabilities, American Psychological Association Annual Meeting, Chicago, IL, August 17, 1997.

77. “The Pharmacotherapy of Treatment-Refractory Obsessive Compulsive Disorder,” Grand Rounds, Department of Psychiatry, University of Cincinnati School of Medicine, Cincinnati, OH, January 14, 1998.

78. ”The Role of Serotonin in the Neuropsychopharmacology of Autism-Spectrum Disorders,” Grand Rounds, Department of Psychiatry, Indiana University School of Medicine, Indianapolis, IN, January 30, 1998.

79. “The Diagnosis and Pharmacotherapy of Obsessive Compulsive Disorder,” Grand Rounds, Department of Psychiatry, Dartmouth Medical School, Hanover, NH, September 1, 1998.

80. “The Diagnosis and Pharmacotherapy of Obsessive Compulsive Disorder,” Grand Rounds, Department of Psychiatry, Case Western Reserve University School of Medicine, Cleveland, OH, September 11, 1998.

81. “The Role of Serotonin in the Neurobiology and Psychopharmacology of Autism,” Grand Rounds, Department of Psychiatry, Columbia University College of Physicians and Surgeons, New York State Psychiatric Institute, New York, NY, October 9, 1998.

82. "Pharmacotherapy of Treatment - Refractory Obsessive Compulsive Disorder," Grand Rounds, Section of Child and Adolescent Psychiatry, Department of Psychiatry, Wayne State University School of Medicine, Detroit, MI, December 8, 1998.

83. "The Diagnosis and Pharmacotherapy of Obsessive Compulsive Disorder," Grand Rounds, Department of Psychiatry, Indiana University School of Medicine, Indianapolis, IN, February 12, 1999.

84. "The Diagnosis and Treatment of Obsessive Compulsive Disorder in Children and Adolescents," Presentation to General Psychiatry Residents, Department of Psychiatry, Michigan State University School of Medicine, East Lansing, MI, March 11, 1999.

85. "The Diagnosis and Pharmacotherapy of Autistic-Spectrum Disorders," Grand Rounds, Section of Child and Adolescent Psychiatry, Department of Psychiatry, University of Michigan School of Medicine, Ann Arbor, MI, March 12, 1999.

86. "Advances in Psychopharmacologic Therapies," In Symposium, Autism/PDD Today and Tomorrow: A Comprehensive View Across the Life Span, 22nd Annual Arthur B. Richter Conference in Child Psychiatry, Indiana University School of Medicine, Indianapolis, IN April 15-16, 1999.

87. "The Role of Serotonin in the Neurobiology and Pharmacotherapy of Autistic-Spectrum Disorders," Indiana University, Department of Psychology, Neuroscience Colloquium, Bloomington, IN, April 23, 1999.

88. "The Role of Serotonin in the Neurobiology and Pharmacotherapy of Autism," Grand Rounds, Department of Pediatrics, Indiana University School of Medicine, Indianapolis, IN, April 28, 1999.

89. "Neurobiology and Pharmacotherapy of Autism," Grand Rounds, Department of Psychiatry and Behavioral Sciences, Finch University of Health Sciences/The Chicago Medical School, North Chicago, IL, May 6, 1999.

90. "Psychopharmacology of Autism," In Symposium, Pediatric Psychopharmacology, American Psychiatric Association Annual Meeting, Washington, D.C., May 19, 1999.

91. "The Diagnosis and Treatment of Autistic-Spectrum Disorders," Grand Rounds, Department of Psychiatry and Behavioral Science, State University of New York-Syracuse, Upstate Medical Center, Syracuse, NY, June 3, 1999.

92. "The Use of Antipsychotics in Children and Adolescents With Neuropsychiatric Disorders," In Regional Psychiatric Symposium: Psychosis Across the Life Span, Department of Psychiatry, Wright State University School of Medicine, Dayton, OH, September 21, 1999.

93. "Treatment of Depression in Children and Adolescents," In Symposium, Treating Depression: A Comprehensive Review for Clinicians, Department of Psychiatry, Yale University School of Medicine, New Haven, CT, October 2, 1999.

94. "The Diagnosis and Treatment of Depression in the Primary Care Setting," Residents' Lecture Series, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, October 4, 1999.

95. "The Phenomenology and Clinical Neurobiology of Autism," for Indiana University Undergraduate Course entitled "The Biology of Mental Illness," Department of Biology, Indianapolis, IN, October 12, 1999.

96. "Diagnosis and Treatment of Obsessive-Compulsive Disorder in Children and Adolescents," In Symposium "Anxiety Disorders: An Update," Department of Psychiatry, Indiana University School of Medicine, Indianapolis, IN, October 15, 1999.

97. "Psychopharmacology of Pervasive Developmental Disorders," In Institute I "Targets of Pharmacotherapy: From Signs and Symptoms to Synapses (Chair - Christopher J. McDougle, M.D.), 46th Annual Meeting, American Academy of Child and Adolescent Psychiatry, Chicago, IL, October 19, 1999.

98. "Treatment of Compulsions and Stereotypies," In Workshop, Treatments for People with Autism and Other Pervasive Developmental Disorders: Research Perspectives, National Institutes of Health, Neuroscience Center, Bethesda, MD, November 8-9, 1999.

99. "The Diagnosis and Pharmacotherapy of Autistic-Spectrum Disorders," Grand Rounds, Section of Child and Adolescent Psychiatry, Department of Psychiatry, Wayne State University School of Medicine, Detroit, MI, December 7, 1999.

100. "Treatment-Refractory Obsessive-Compulsive Disorder," for Child and Adolescent Psychiatry Fellows, Department of Psychiatry, University of Michigan School of Medicine, Ann Arbor, MI, December 7, 1999.

101. "The Diagnosis and Pharmacotherapy of Autistic-Spectrum Disorders," Grand Rounds, Department of Psychiatry, Medical College of Ohio, Toledo, OH, January 20, 2000.

102. "Clinical Neurobiology and Psychopharmacology of Autism," Grand Rounds, Department of Psychiatry, Michigan State University, Kalamazoo Center for Medical Studies, Kalamazoo, MI, March 14, 2000.

103. "Diagnosis and Treatment of Child and Adolescent Depression," Pediatric Residents Forum, Albany Medical College, Albany, NY, March 28, 2000.

104. "The Pharmacological Management of Derpession and Anxiety in Children and

Adolescents," In symposium Child and Adolescent Psychopharmacology Update, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY, March 30, 2000.

105. "The Pharmacological Management of Aggression in Children and Adolescents," In symposium Child and Adolescent Psychopharmacology Update, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY, March 30, 2000.

106. "The Pharmacological Treatment of Aggression in Children and Adolescents," Child and Adolescent Psychiatry Residents' Forum, Department of Psychiatry, Medical College of Wisconsin, Milwaukee, WI, April 11, 2000.

107. "The Psychopharmacology of Post-Traumatic Stress Disorder," 23rd Annual Arthur B. Richter Conference in Child Psychiatry, Early Trauma and Post-Traumatic Stress: A Developmental Perspective, Department of Psychiatry, Indiana University School of Medicine, Indianapolis, IN, April 14, 2000.

108. "Childhood-Onset Schizophrenia," In Symposium, Treatment Practice and Promise for Schizophrenia in the New Millennium, American Psychiatric Association 2000 Annual Meeting, Chicago, IL, May 14, 2000.

109. "New Advances in Pharmacotherapy of Treatment-Refractory Obsessive Compulsive Disorder Patients," In Symposium, New Advances in the Assessment and Treatment of Pediatric Obsessive Compulsive Disorders, Wayne State University School of Medicine, Department of Psychiatry, Children's Hospital of Michigan, Detroit, MI, June 16, 2000.

110. "Diagnosis and Treatment of Depression in Children and Adolescents," In Conference, Update on Common Pediatric Issues for Primary Care Physicians, Department of Pediatrics, Indiana University School of Medicine, Fort Wayne, IN, June 21, 2000.

111. "Pediatric Psychopharmacology," Grand Rounds, Department of Pediatrics, Indiana University School of Medicine, Indianapolis, IN, August 2, 2000.

112. "Developmental Disorders - Medication and Side Effects Management," In Course, Clinical Pediatric Psychopharmacology: State-of-the-Art, Albert Einstein College of Medicine and Montefiore Medical Center, New York Academy of Medicine, New York, NY, September 15, 2000.

113. "The Diagnosis and Pharmacotherapy of Autistic and Other Pervasive Developmental Disorders." Grand Rounds, Department of Psychiatry, Indiana University School of Medicine, Indianapolis, IN, September 22, 2000.

114. "Pediatric Psychopharmacology," Pediatric Residents' Lecture Series, Department of Pediatrics, Riley Hospital for Children, Indianapolis, IN, October 9, 2000.

115. "The Diagnosis and Pharmacotherapy of Obsessive-Compulsive Disorder," Grand Rounds, Department of Psychiatry, Cleveland Clinic, Cleveland, OH, October 12, 2000.

116. "Obsessive-Compulsive Disorder," Indiana University School of Medicine Medical Student Interest Group in Psychiatry, Indianapolis, IN, October 13, 2000.

117. "Pediatric Psychopharmacology," Pediatric Residents' Lecture Series, Department of Pediatrics, Methodist Hospital, Indianapolis, IN, October 18, 2000.

118. "Introduction," In Symposium "Atypical Antipsychotics in Children and Adolescents: Real World Considerations," (Chair, Christopher J. McDougle, M.D.), 47th Annual Meeting, American Academy of Child and Adolescent Psychiatry, New York, NY, October 28, 2000.

119. "The Role of Atypical Antipsychotic Agents in Child and Adolescent Psychiatry," Third Annual Psychiatric Symposium, "Psychosis: At the Forefront of Discovery," Wright State University School of Medicine, Dayton, OH, October 31, 2000.

120. "Autism and Related Pervasive Developmental Disorders," Lecture for Indiana University Undergraduate Course, The Biology of Mental Illness, Indianapolis, IN, November 14, 2000.

121. "The Diagnosis and Pharmacotherapy of Autistic and Other Pervasive Developmental Disorders," Grand Rounds, Department of Psychiatry and Behavioral Science, Division of Child and Adolescent Psychiatry, Wayne State University School of Medicine, Detroit, MI, December 5, 2000.

122. "An Update on Autism and Related Pervasive Developmental Disorders," Section of Developmental Pediatrics, Department of Pediatrics, Indiana University School of Medicine, Indianapolis, IN, February 6, 2001.

123. "The Diagnosis and Pharmacotherapy of Autism and Related Pervasive Developmental Disorders," Grand Rounds, Department of Psychiatry, University of Florida College of Medicine, Gainesville, FL, May 22, 2001.

124. "Recent Advances in the Diagnosis and Pharmacotherapy of Autism and Related Pervasive Developmental Disorders," Grand Rounds, Division of Child and Adolescent Psychiatry, Department of Psychiatry, University of Cincinnati College of Medicine, Children's Hospital Medical Center, Cincinnati, OH, June 13, 2001.

125. "The Diagnosis and Pharmacotherapy of Treatment-Refractory Obsessive-Compulsive Disorder," Grand Rounds, Department of Psychiatry, University of Cincinnati College of Medicine, Cincinnati, OH, June 13, 2001.

126. "Pediatric Aggression: Treatment Considerations," In Symposium, "Aggression Across the

Life Cycle: A Symptom-Based Approach to Management," 14th Annual U.S. Psychiatric Mental Health Congress, Boston, MA, November 17, 2001.

127. "The Genetics of Autism," (with James Trofatter, Ph.D.), Department of Medical and Molecular Genetics, Seminar Series, Indiana University School of Medicine, Indianapolis, IN, December 5, 2001.

128. "The Diagnosis and Pharmacotherapy of Autism and Other Pervasive Developmental Disorders," Grand Rounds, Department of Psychiatry, Wright State University School of Medicine, Dayton, OH, March 5, 2002.

129. "The Diagnosis and Pharmacotherapy of Autism," University of Michigan School of Medicine, Department of Psychiatry, Division of Child and Adolescent Psychiatry, Ann Arbor, MI, April 24, 2002.

130. "The Diagnosis and Pharmacotherapy of Autism," University of Pittsburgh School of Medicine, Department of Psychiatry, Section of Child and Adolescent Psychiatry, Pittsburgh, PA, June 24, 2002.

131. "The Diagnosis and Pharmacotherapy of Autism and Other Pervasive Developmental Disorders," Grand Rounds, Department of Psychiatry, Case Western Reserve University School of Medicine, Cleveland, OH, September 27, 2002.

132. "The Diagnosis and Pharmacotherapy of Mood and Anxiety Disorders in the Primary Care Setting," Grand Rounds, Department of Obstetrics and Gynecology, Indiana University School of Medicine, Indianapolis, IN, October 9, 2002.

133. "The Diagnosis and Pharmacotherapy of Autism and Other Pervasive Developmental Disorders," Grand Rounds, Department of Psychiatry and Behavioral Neurobiology, The University of Alabama at Birmingham, Birmingham, AL, April 15, 2003.

134. "The Diagnosis and Pharmacotherapy of Autism and Other Pervasive Developmental Disorders," Child and Adolescent Psychiatry Grand Rounds, University of Illinois-Chicago School of Medicine, Chicago, IL, July 30, 2003.

135. "The Diagnosis and Pharmacotherapy of Autism and Other Pervasive Developmental Disorders," Child and Adolescent Psychiatry Morning Report, Rush College of Medicine, Chicago, IL, August 1, 2003.

136. "The Diagnosis and Pharmacotherapy of Autism," In "Fall Neurosciences Symposium," Department of Neuropsychiatry and Behavioral Science, University of South Carolina School of Medicine, Greenville, SC, September 20, 2003.

137. "The Diagnosis and Pharmacotherapy of Autism and Other Pervasive Developmental Disorders," Grand Rounds, Department of Psychiatry, Vanderbilt University School of

Medicine, Nashville, TN, October 28, 2003.

138. "Neurobiology and Potential Etiologies," In Symposium, A Multidisciplinary View of Autism Spectrum disorders, The Christian Sarkine Autism Treatment Center First Annual Conference, Department of Psychiatry, Indiana University School of Medicine, Indianapolis, IN, November 14, 2003.

139. "Effective Medication Treatment of Individuals with Autism", (with K. Stigler, M.D.), In Symposium, A Multidisciplinary View of Autism Spectrum disorders, The Christian Sarkine Autism Treatment Center First Annual Conference, Department of Psychiatry, Indiana University School of Medicine, Indianapolis, IN, November 14, 2003.

140. "The Diagnosis and Pharmacotherapy of Autism and Other Pervasive Developmental Disorders," Grand Rounds, Department of Psychiatry and Behavioral Sciences, Northwestern University School of Medicine, Chicago, IL, November 19, 2003.

141. "The Diagnosis and Pharmacotherapy of Autism," Grand Rounds, Department of Pediatrics, Indiana University School of Medicine, Indianapolis, IN, March 24, 2004.

142. "The Diagnosis and Pharmacotherapy of Autism," Grand Rounds, Department of Psychiatry, University of Illinois at Chicago School of Medicine, Chicago, IL, April 14, 2004.

143. "The Diagnosis and Pharmacotherapy of Autism," Grand Rounds, Department of Psychiatry, Metro Health Medical Center, Cleveland, OH, April 22, 2004.

144. "The Diagnosis and Pharmacotherapy of Autism," Grand Rounds, Department of Psychiatry, Case Western Reserve University School of Medicine, Cleveland, OH, April 23, 2004.

145. "The Diagnosis and Pharmacotherapy of Autism," Grand Rounds, Department of Psychiatry, University of Kentucky School of Medicine, Lexington, KY, April 28, 2004.

146. "The Pharmacotherapy of Treatment-Refractory Obsessive-Compulsive Disorder," Grand Rounds, Bethesda Naval Medical Center, Bethesda, MD, May 19, 2004.

147. "Pharmacotherapy of Autism," In Symposium, Child Psychopharmacology (Chair: Christopher Gillberg), CINP Congress, Paris, France, June 22, 2004.

148. "Atypical Antipsychotics in Patients with Severe Developmental Disabilities," In Symposium, Psychopharmacological Treatment of Aggressive Self-Injurious and Destructive/Disruptive Behaviors in Autism and Mental Retardation: Exploration of a Parallel Universe (Co-Chairs: David Janowsky and Christopher J. McDougle), CINP Congress, Paris, France, June 24, 2004.

149. "The Diagnosis and Pharmacotherapy of Autism," Grand Rounds, Department of Psychiatry, University of Florida College of Medicine, Gainesville, FL, August 20, 2004.

150. "The Pharmacotherapy of Autism," Grand Rounds, Department of Psychiatry, Medical College of Georgia, Augusta, GA, August 26, 2004.

151. "Psychopharmacological Interventions for Individuals with Autism and Autism Spectrum Disorders," For IU Bloomington Psychology Student Course: Autism: A Research Seminar K-780 (27865), Indianapolis, IN, September 28, 2004.

152. "Diagnosis and Pharmacotherapy of Autism and Other Pervasive Developmental Disorders, Grand Rounds, Department of Child and Adolescent Psychiatry, Columbia University College of Physicians and Surgeons, New York, NY, September 29, 2004.

153. "The Diagnosis and Pharmacotherapy of Autism and Other Pervasive Developmental Disorders," Grand Rounds, Division of Child and Adolescent Psychiatry, Schneider Children's Hospital and Hillside Hospital of Long Island Jewish Medical Center, New Hyde Park, NY, September 30, 2004.

154. "Update on Neurobiology and Potential Etiologies," In, The Christian Sarkine Autism Treatment Center: Second Annual Conference, Department of Psychiatry, Indiana University School of Medicine, Indianapolis, IN, November 12, 2004.

155. "The Diagnosis and Pharmacotherapy of Autism and Other Pervasive Developmental Disorders," Grand Rounds, Department of Psychiatry and Behavioral Neurosciences, Wayne State University School of Medicine, Detroit, MI, April 12, 2005.

156. "Psychopharmacology of Autism," Grand Rounds, Department of Psychiatry and Behavioral Sciences, University of Louisville School of Medicine, Louisville, KY, September 29, 2005.

157. "Principles of Medication Management," In, The Christian Sarkin Autism Treatment Center: Third Annual Conference – Autism: A Lifetime of Learning, Department of Psychiatry, Indiana University School of Medicine, Indianapolis, IN, November 11, 2005.

158. "Pharmacology of Autism," In, Recent Advances in Autism and Related Disorders – 85th Annual Conference (Christopher J. McDougle, M.D. – Conference Co-President), Association for Research in Nervous and Mental Disease with The New York Academy of Medicine, New York, NY, December 2, 2005.

159. "The Diagnosis and Pharmacotherapy of Autism and Related Disorders," Glenwood Honorary Lectureship, University of Alabama at Birmingham, School of Public Health, Birmingham, AL, April 12, 2006.

160. "The Diagnosis and Pharmacotherapy of Autism and Related Disorders," Grand Rounds,

Department of Psychiatry and Behavioral Neurosciences, Wayne State University School of Medicine, Detroit, MI, June 13, 2006.

161. "The Psychopharmacology of Autism," In, Psychopharmacology Update 2006, Baylor College of Medicine, Houston, TX, October 13, 2006.

162. "The Diagnosis and Pharmacotherapy of Autism and Related Disorders," Grand Rounds, Department of Psychiatry, Division of Child and Adolescent Psychiatry, Columbia University College of Physicians and Surgeons, New York, NY, October 18, 2006.

163. "The Diagnosis and Pharmacotherapy of Autism and Other Pervasive Developmental Disorders", Grand Rounds, Department of Psychiatry, University of Texas Health Science Center at San Antonio, San Antonio, TX, April 17, 2007.

164. "Pharmacotherapy of Autism," In 5th Annual Christian Sarkine Autism Treatment Center Conference, Collaborative Systems at Work: Improving Service Delivery to Children with an Autism Spectrum Disorder, Indianapolis, IN, November 16, 2007.

165. "Atypical Antipsychotics in Autism Spectrum and Disruptive Behavior Disorders," In Symposium Treatment of Children and Adolescents with Psychiatric Disorders: The Rising Use of Antipsychotics, Annual Meeting of the American Psychiatric Association, Washington, D.C., May 4, 2008.

166. "The Pharmacotherapy of Autism and Other Pervasive Developmental Disorders," Distinguished Lecturer Series, University of California Davis M.I.N.D. Institute, Sacramento, CA, May 21, 2008.

167. "Practical Aspects of Medication Treatment in Autism for Parents and Other Providers," Distinguished Lecturer Series, University of California Davis M.I.N.D. Institute, Sacramento, CA, May 21, 2008.

168. "The Diagnosis and Pharmacotherapy of Autism and Other Pervasive Developmental Disorders," Grand Rounds, Department of Psychiatry and Behavioral Neurosciences, Wayne State University School of Medicine, Detroit, MI, June 10, 2008.

169. "The Diagnosis and Pharmacotherapy of Autism," Grand Rounds, Department of Psychiatry, Yale University School of Medicine, New Haven, CT, October 17, 2008.

170. "The Psychopharmacology of Autism," Master Clinician Clinical Consultation Breakfast, 55th Annual Meeting of the American Academy of Child and Adolescent Psychiatry, Chicago, IL, October 30, 2008.

171. "Pharmacology and Beyond: Transition Issues in Autism Spectrum Disorders," In 6th Annual Christian Sarkine Autism Treatment Center Conference, A Time for Transition: Autism Spectrum Disorders in Adolescence and Adulthood, Department of Psychiatry,

Indiana University School of Medicine, Indianapolis, IN, December 5, 2008.

172. "Psychopharmacology of Autism," In High Functioning Autism and Asperger's Disorder: Assessment and Treatment, 32nd Annual Arthur B. Richter Conference in Child Psychiatry, Department of Psychiatry, Indiana University School of Medicine, Indianapolis, IN, February 20, 2009.

173. "The Diagnosis and Pharmacotherapy of Autism and Other Pervasive Developmental Disorders," Grand Rounds, New York University Child Study Center, New York, NY, May 1, 2009.

174. "The Diagnosis and Pharmacotherapy of Autism," Distinguished Lecture Series, UCLA Center for Autism Research and Treatment, Los Angeles, CA, June 5, 2009.

175. "The Diagnosis and Pharmacotherapy of Autism," Frank J. Menolascino Award Lecture, Institute on Psychiatric Services, New York, NY, October 8, 2009.

176. "Psychopharmacology of Autism," 10th National Autism Congress, Rotterdam, The Netherlands, March 12, 2010.

177. "Psychopharmacology of Autism," 1st Autism Congress, Frankfurt, Germany, March 13, 2010.

178. "The Diagnosis and Pharmacotherapy of Autism and Other Pervasive Developmental Disorder," Special Guest Lecturer, Johns Hopkins Medical Institutions, Department of Psychiatry and Behavioral Sciences, Baltimore, MD, July 6, 2010.

179. "Psychopharmacology of Autism," 2010 Indianapolis Society for Neuroscience Annual Meeting, Indianapolis, IN, October 29, 2010.

180. "Pharmacotherapy of Irritability in Autism Spectrum Disorders," In Session 7: Pharmacological Interventions for Autism Spectrum Disorders (**C. McDougle**, Chair), of Symposium "A Brain Research Meeting: The Emerging Neuroscience of Autism Spectrum Disorders: Etiologic Insights; Treatment Opportunities," San Diego, CA, November 12, 2010.

181. "Psychopharmacology of Autism," M.I.N.D. Institute, University of California-Davis, Sacramento, CA, November 30, 2010.

COMMUNITY:

1. "The Neurobiology of Obsessive Compulsive Disorder," Obsessive Compulsive Disorder Foundation, North Haven, CT, December 13, 1989.

2. "Obsessive Compulsive Disorder: Phenomenology, Diagnosis, and Treatment," Mental

Health Association of Greater Springfield, Springfield, MA, March 28, 1990.

3 "Assessment and Clinical Management of Patients with Obsessive Compulsive Disorder," Danbury Hospital, Danbury, CT, May 8, 1990.

4. "Obsessive Compulsive Disorder: Clinical Assessment and Treatment," Human Services, East Haven, CT, July 3, 1990.

5. "Post-Traumatic Stress Disorder: Diagnosis and Pharmacotherapeutic Strategies," Albany County Mental Health Clinic, Albany, NY, November 14, 1990.

6. "New Concepts in the Treatment of Post-Traumatic Stress Disorder," Greater Albany Area Psychiatric Speaker Forum, Albany, NY, November 14, 1990.

7. "Recent Advances in Treatment for the OCD Patient," Fairfield County Private Practice Psychiatrists, Westport, CT, November 15, 1990.

8. "Autistic Disorder and Serotonin: Is There a Connection?," South Central Connecticut Chapter of the Autism Society of America, Hamden, CT, November 26, 1990.

9. "Autism and Obsessive Compulsive Disorders," Consultant's Forum, Department of Mental Retardation, Region 1, State of Connecticut, Danbury Hospital, Danbury, CT, January 7, 1991.

10. "Post Traumatic Stress Disorder: Diagnosis, Pathophysiology, and Treatment," Central New York District Branch, American Psychiatric Association, Syracuse, NY, February 7, 1991.

11. "Recent Treatment Advances for Obsessive Compulsive Disorder Patients: Special Emphasis on Autistic and Retarded Patients, Ella Grasso Center, Stratford, CT, February 27, 1991.

12. "Pharmacotherapy of Obsessive Compulsive Disorders," Fifth Annual Symposium on Psychiatric Medicine, Florida Hospital, Center for Psychiatry, Lake Buena Vista, Florida, March 26, 1991.

13. "Autistic Disorder, Obsessive Compulsive Disorder, and Serotonin Function," Department of Mental Retardation, Region 2, State of Connecticut, Glastonbury, CT, April 23, 1991.

14. "OCD with Autism and Mental Retardation," Sigmund Freud "Fragments from a Buried Past" Art Exhibit Tour, New Orleans, LA, April 27, 1991.

15. "Autistic Disorder and Serotonin Function," Naugatuck Valley Chapter of the Autism Society of America, Waterbury, CT, May 22, 1991.

16. "The Diagnosis, Treatment, and Pathophysiology of Post-Traumatic Stress Disorder," American Psychiatric Association Chapter, Binghamton, NY, June 5, 1991.

17. "Contributions of Serotonin Function to the Neurobiology and Treatment of Autistic Disorder," Autism Society of America Conference, Indianapolis, IN, July 10, 1991.

18. "The Biology and Medication Treatment of Autistic Disorder," Community Integration: Challenges and Strategies Conference, Holyoke Community College, Holyoke, Massachusetts, September 28, 1991.

19. "The Neurobiology and Pharmacotherapy of Autistic Disorder," Institute of Professional Practice, North Haven, CT, October 11, 1991.

20. "Depression in the Primary Care Setting," St. Vincent's Hospital, Bridgeport, CT, October 17, 1991.

21. "The Pharmacotherapy of Impulse Control Disorders," Fairfield Hills Hospital, Newtown, CT, November 22, 1991.

22. "Obsessive Compulsive Disorder and Autism in Children," Grand Rounds, Department of Psychiatry, Danbury Hospital, Danbury, CT, November 27, 1991.

23. "Obsessive Compulsive Disorder and Comorbid Illness," Grand Rounds, Department of Psychiatry, Morristown Memorial Hospital, Morristown, NJ, January 24, 1992.

24. "The Pharmacotherapy and Pathophysiology of Adults with Autism," National Alliance for the Mentally Ill, Children and Adolescents Network, Woodbridge, CT, February 12, 1992.

25. "Serotonin Function and Neuropsychiatric Disorders," Grand Rounds, Connecticut Valley Hospital, Middletown, CT, February 26, 1992.

26. "The Diagnosis, Pathophysiology, and Pharmacotherapy of Post-Traumatic Stress Disorder," Southern Tier Psychiatric Group, Elmira, NY, March 5, 1992.

27. "The Role of Serotonin in Impulsivity and Aggressivity," Grand Rounds, Department of Psychiatry, Morristown Memorial Hospital, Morristown, NJ, March 27, 1992.

28. "The Neurobiology of Fragile-X Syndrome," Fragile-X Society of Connecticut, Cheshire, CT, March 30, 1992.

29. "Bipolar Disorder in Patients With Developmental Disabilities," Consultant's Forum, Department of Mental Retardation, Region 1, State of Connecticut, Charlotte-Hungerford Hospital, Torrington, CT, April 23, 1992.

30. "The Role of Serotonin in Impulsivity and Aggressivity," Grand Rounds, Department of

Psychiatry, Elizabeth General Medical Center, Elizabeth, NJ, April 28, 1992.

31. "Serotonin Function in Neuropsychiatric Disorders," Grand Rounds, Four Winds Hospital, Katona, NY, May 14, 1992.

32. "Serotonin Function in Neuropsychiatric Disorders," Grand Rounds, Fairfield Hills Hospital, Newtown, CT, June 11, 1992.

33. "The Pathophysiology and Pharmacotherapy of Autistic Disorder," Southbury Training School, Southbury, CT, June 16, 1992.

34. "The Pathophysiology and Pharmacotherapy of Post-Traumatic Stress Disorder," Grand Rounds, Charter Hospital, Miami, FL, June 19, 1992.

35. "The Diagnosis and Treatment of Depression for the Primary Care Physician," New Haven, CT, August 25, 1992.

36. "Serotonin Function in Neuropsychiatric Disorders," Grand Rounds, Hartford Hospital, Hartford, CT, October 8, 1992.

37. "Serotonin Function in Neuropsychiatric Disorders," Danbury Psychiatric Group, Danbury, CT, October 19, 1992.

38. "The Diagnosis and Treatment of Depression for the Primary Care Physician," Community Health Care Plan, New Haven, CT, October 22, 1992.

39. "The Diagnosis and Treatment of Post-Traumatic Stress Disorder," Central Florida Psychiatric Society, Orlando, FL, December 3, 1992.

40. "Serotonin and Aggression and Impulsivity," Grand Rounds, Bergen Pines County Hospital, Paramus, NJ, January 28, 1993.

41. "Serotonin and Aggression and Impulsivity," Grand Rounds, Hackensack Medical Center, Hackensack, NJ, January 28, 1993.

42. "Serotonin Function in Neuropsychiatric Disorders," Grand Rounds, Bridgeport Mental Health Center, Bridgeport, CT, February 17, 1993.

43. "The Diagnosis and Treatment of Post-Traumatic Stress Disorder," Grand Rounds, St. Vincent's Hospital, Harrison, NY, March 10, 1993.

44. "The Diagnosis and Treatment of Depression in the Medical Setting," Grand Rounds, Department of Medicine, Griffin Hospital, Derby, CT, March 18, 1993.

45. "Obsessive Compulsive Disorders in Children and Adolescents," Grand Rounds,

Department of Psychiatry, Morristown Memorial Hospital, Morristown, NJ, March 26, 1993.

46. "The Diagnosis and Treatment of Post-Traumatic Stress Disorder," Grand Rounds, Brattleboro Retreat, Brattleboro, VT, June 3, 1993.

47. "The Role of Serotonin Uptake Inhibitors in the Treatment of Depression," Grand Rounds, Department of Medicine, Community Health Care Plan, New Haven, CT, July 22, 1993.

48. "The Diagnosis and Treatment of OCD," APA Regional Meeting, Princeton, NJ, October 13, 1993.

49. "The Pharmacotherapy of Depression," APA Regional Meeting, Syracuse, NY, October 26, 1993.

50. "The Pharmacotherapy of Pervasive Developmental Disorders," Grand Rounds, Department of Psychiatry, Waterbury Hospital, Waterbury, CT, November 3, 1993.

51. "The Diagnosis and Treatment of Depression for Primary Care Physicians," Atlantic City, NJ, November 13, 1993.

52. "The Diagnosis and Treatment of Depression for Primary Care Physicians," Local Primary Care Group, New Haven, CT, November 20, 1993.

53. "The Role of Pharmacotherapy in Mental Retardation Syndromes," Grand Rounds, Department of Psychiatry, Norwich Hospital, Norwich, CT, January 12, 1994.

54. "The Diagnosis and Treatment of OCD," Grand Rounds, Greater Bridgeport Mental Health Center, Bridgeport, CT, January 18, 1994.

55. "The Diagnosis and Treatment of Depression," Grand Rounds, Department of Psychiatry, Newington V.A. Hospital, Newington, CT, January 19, 1994.

56. "The Diagnosis and Treatment of OCD," APA Regional Meeting, Providence, R.I., January 20, 1994.

57. "The Diagnosis and Treatment of Depression," Grand Rounds, Department of Medicine, Underwood Hospital, Underwood, NJ, January 25, 1994.

58. "The Diagnosis and Treatment of Depression in the Primary Care Setting," Grand Rounds, Department of Medicine, Austen Clinic, Trenton, NJ, January 26, 1994.

59. "The Diagnosis and Treatment of OCD," Grand Rounds, Trenton State Psychiatric Hospital, Trenton, NJ, January 26, 1994.

60. "The Diagnosis and Treatment of OCD," Grand Rounds, Marlboro State Psychiatric Hospital, Marlboro, NJ, January 27, 1994.

61. "The Diagnosis and Treatment of Depression in the Primary Care Setting," Grand Rounds, Department of Medicine, Union Hospital, Union, NJ, January 28, 1994.

62. "The Diagnosis and Treatment of PTSD," APA Regional Meeting, Tuxedo, NY, January 30, 1994.

63. "The Diagnosis and Pharmacotherapy of PTSD in Patients with Eating Disorders," Annual Meeting of the Anorexia and Bulimia Society, New York, NY, February 5, 1994.

64. "The Role of Serotonin in Repetitive Behaviors," Grand Rounds, Department of Psychiatry, Bergen Pines County Hospital, Paramus, NJ, February 10, 1994.

65. "The Diagnosis and Treatment of Depression," Grand Rounds, Department of Medicine, Griffin Hospital, Derby, CT, February 17, 1994.

66. "The Diagnosis and Treatment of Depression," Grand Rounds, Department of Medicine, Lawrence Memorial Hospital, Bronxville, NY, March 8, 1994.

67. "The Diagnosis and Treatment of OCD," Grand Rounds, Department of Psychiatry, Backus Hospital, Norwich, CT, March 11, 1994.

68. "The Diagnosis and Treatment of OCD," Grand Rounds, Department of Psychiatry, Kings County Hospital, Brooklyn, NY, March 14, 1994.

69. "The Diagnosis and Treatment of Panic Disorder, OCD, and Chronic Fatigue Syndrome," Grand Rounds, Department of Medicine, Roxborough Hospital, Philadelphia, PA, March 22, 1994.

70. "The Diagnosis and Treatment of Depression," Grand Rounds, Department of Medicine, Pennsylvania Hospital, Philadelphia, PA, March 23, 1994.

71. "The Diagnosis and Treatment of Depression in the Primary Care Setting," Grand Rounds, Department of Medicine, Windham Hospital, Willimantic, CT, March 28, 1994.

72. "The Role of Serotonin in the Pathophysiology and Treatment of Autistic Disorder," South Central Connecticut Chapter of the Autism Society of America, Wallingford, CT, March 28, 1994.

73. “The Diagnosis and Treatment of PTSD," Grand Rounds, Department of Psychiatry, Montrose V.A. Hospital, Montrose, N.Y., April 15, 1994.

74. "The Diagnosis and Pharmacotherapy of PTSD," Grand Rounds, Department of Psychiatry,

Nassau County Medical Center, East Meadow, NY, April 29, 1994.

75. "The Neurobiology and Psychopharmacology of Pervasive Developmental Disorder Across the Lifespan," National Alliance for the Mentally Ill, Woodbridge, CT, June 8, 1994.

76. "The Recognition and Treatment of Depression in the Primary Care Setting," Grand Rounds, Department of Medicine, Bergen Pines County Hospital, Bergen Pines, NJ, September 14, 1994.

77. "The Diagnosis and Treatment of Pervasive Developmental Disorder," Lower Fairfield County Regional Center, Norwalk, CT, September 21, 1994.

78. "The Diagnosis and Rational Pharmacotherapy of Mental Retardation Syndromes," Connecticut Behavior Therapy Association, New Haven, CT, October 19, 1994.

79. "The Diagnosis, Pathophysiology, and Pharmacotherapy of PTSD," Grand Rounds, Department of Psychiatry, Waterbury Hospital, Waterbury, CT, December 7, 1994.

80. "The Pathophysiology and Pharmacotherapy of Mental Retardation Syndromes," Connecticut Nurses Association for Developmental Disabilities, Quarterly Meeting, Trumbull, CT, December 8, 1994.

81. "Diagnosis and Treatment of Depression in the Primary Care Setting," Grand Rounds, Department of Medicine, Morristown Memorial Hospital, Morristown, NJ, December 21, 1994.

82. "Pharmacotherapy of Depression and Anxiety in the Primary Care Setting," Grand Rounds, Department of Medicine, Union Hospital, Union, NJ, January 11, 1995.

83. "Obsessive Compulsive Disorder," Grand Rounds, Manhattan Psychiatric Hospital, Ward's Island, New York, NY, March 10, 1995.

84.. "Other Uses of Antidepressants and Anxiolytics," Psychopharmacology Course, State of Connecticut Department of Mental Health, Mental Health and Education Resource Center and Certificate Program, Connecticut Mental Health Center, March 13, 1995, New Haven, CT.

85. "The Role of Serotonin in Repetitive Behavior," Grand Rounds, Department of Psychiatry, Metropolitan Hospital, New York, NY, March 30, 1995.

86. "The Diagnosis and Pharmacotherapy of Social Phobia," Dr. Newton Bigelow Psychiatric Teaching Day, Central New York Academy of Medicine, New Hartford, NY, April 13, 1995.

87. "The Role of Serotonin in Repetitive Behavior," Grand Rounds, Greystone Psychiatric

Hospital, Morris Plains, NJ, April 19, 1995.

88. "The Recognition and Treatment of Depression in the Primary Care Setting, Grand Rounds, Department of Medicine, St. Peter's Hospital, New Brunswick, NJ, April 20, 1995.

89. "Recognition and Treatment of OCD," Grand Rounds, Westwood Lodge Hospital, Westwood, MA, April 24, 1995.

90. "The Diagnosis and Treatment of OCD," Grand Rounds, Department of Medicine, Middlesex Hospital, Middletown, CT, May 4, 1995.

91. "Repetitive Thoughts and Behavior in Neurodevelopmental Disorders," Annual Staff Teaching Day, The Kennedy Center, Bridgeport, CT, May 8, 1995.

92. "Depression and Anxiety in the Primary Care Setting," Grand Rounds, Department of Medicine, Windham Hospital, Willimantic, CT, May 15, 1995.

93. "The Neurobiology of Aggression," Grand Rounds, Department of Psychiatry, Bristol Hospital, Bristol, CT, June 20, 1995.

94. "Obsessive Compulsive Disorder," Grand Rounds, Department of Psychiatry, Natchaug Hospital, Mansfield Center, CT, June 29, 1995.

95. "Obsessive Compulsive Disorder," Connecticut Psychiatric Residents' Association, Middletown, CT, July 28, 1995.

96. "Obsessive Compulsive Disorder in Children," New York State Coalition of Nurse Practitioners 11th Annual Conference, Rye, NY, October 13, 1995.

97. "Diagnosis and Treatment of Obsessive Compulsive Disorder," in Symposium, "Mental Health Aspects of Mental Retardation: Diagnosis and Treatment," National Association for the Dually Diagnosed Regional Conference, East Windsor, CT, October 20, 1995.

98. Chair - "Issues in Combined and Novel Drug Treatments," In Symposium, "Treatment-Refractory Obsessive Compulsive Disorder," New England Conference Center, Durham, NH, October 23-25, 1995.

99. “The Diagnosis and Pharmacotherapy of OCD," Grand Rounds, Department of Psychiatry, Veterans Administration Medical Center, Wilkes-Barre, PA, November 2, 1995.

100. "Diagnosis and Pharmacotherapy of OCD," The Connecticut Psychological Association Annual Convention, Rocky Hill, CT, November 3, 1995.

101. "Diagnosis and Treatment of Depression in the Primary Care Setting," Grand Rounds, Department of Medicine, United Hospital, Portchester, NY, November 21, 1995.

102. "The Diagnosis and Treatment of Depression in the Primary Care Setting," Grand Rounds, Department of Medicine, Bridgeport Hospital, Bridgeport, CT, January 18, 1996.

103. "The Diagnosis and Treatment of OCD in Children and Adolescents," Grand Rounds, Department of Psychiatry, Brookdale Hospital, Brooklyn, NY, February 7, 1996.

104. "The Role of Serotonin in Repetitive Behavior," Grand Rounds, Department of Psychiatry, South Beach Psychiatric Center, Staten Island, NY, February 7, 1996.

105. "The Diagnosis and Pharmacotherapy of OCD," Grand Rounds, Department of Psychiatry, Four Winds Hospital, Katona, NY, February 13, 1996.

106. "The Diagnosis and Pharmacotherapy of OCD in Children and Adolescents," Grand Rounds, Hall-Brooke Hospital, Westport, CT, March 6, 1996.

107. "The Diagnosis and Pharmacotherapy of Obsessive Compulsive Disorder," Grand Rounds, Department of Psychiatry, Beth Israel Hospital, Newark, NJ, March 26, 1996.

108. "The Role of Serotonin in Repetitive Behavior," Grand Rounds, Department of Psychiatry, Overlook Hospital, Summit, NJ, March 27, 1996.

109. "The Diagnosis and Pharmacotherapy of Obsessive Compulsive Disorder," Grand Rounds, Department of Psychiatry, Brooklyn Veteran's Administration Hospital, Brooklyn, NY, March 29, 1996.

110. "The Diagnosis and Pharmacotherapy of Obsessive Compulsive Disorder," Grand Rounds, Department of Psychiatry, Waterbury Hospital, Waterbury, CT, April 3, 1996.

111. "The Diagnosis and Treatment of Obsessive Compulsive Disorder," Grand Rounds, Department of Psychiatry, Lincoln Hospital, Bronx, NY, April 9, 1996.

112. "The Diagnosis and Pharmacotherapy of Obsessive Compulsive Disorder," Grand Rounds, Department of Psychiatry, Newton Hospital, Newton, NJ, May 2, 1996.

113. "The Diagnosis and Pharmacotherapy of Depression in the Elderly," Grand Rounds, Department of Psychiatry, Griffin Hospital, Derby, CT, May 15, 1996.

114. "Anxiety and Depression in Children," American Academy of Physician Assistants 24th Annual Physician Assistant Conference, New York, NY, May 28, 1996.

115. "The Role of Serotonin in the Neurobiology and Psychopharmacology of Autistic Disorder," Grand Rounds, Department of Psychiatry, Newton Hospital, Newton, NJ, September 19, 1996.

116. "The Role of Serotonin in Repetitive Behavior," Grand Rounds, Hudson River Psychiatric Center, Poughkeepsie, NY, September 19, 1996.

117. "Diagnosis and Treatment of Depression in the Primary Care Setting," Grand Rounds, Department of Medicine, Bayshore Community Hospital, Holmedel, NJ, October 18, 1996.

118. "The Psychopharmacology of Patients with Mental Retardation," The Kelly Hayes Memorial Lecture, State of Connecticut, Department of Mental Retardation - South Central Region, New Haven, CT, October 29, 1996.

119. "The Diagnosis and Pharmacotherapy of Obsessive Compulsive Disorder," Grand Rounds, Department of Medicine, Pascack Valley Hospital, Westwood, NJ, November 8, 1996.

120. "Recent Advances in Child and Adolescent Psychopharmacology," Connecticut Chapter of Child and Adolescent Psychiatry, Quarterly Meeting, Hamden, CT, November 13, 1996.

121. "The Role of Serotonin in the Neurobiology and Pharmacotherapy of Autism-Spectrum Disorders," Atypical P.D.D./Asperger Support Group, Inc., Fairfield, CT, December 2, 1996.

122. "The Diagnosis and Treatment of Depression and Anxiety in the Primary Care Setting," Grand Rounds, Department of Medicine, Griffin Hospital, Derby, CT, January 9, 1997.

123. "The Diagnosis and Pharmacotherapy of Obsessive Compulsive Disorder," Grand Rounds, Department of Medicine, St. Francis Hospital, Jersey City, NJ, January 14, 1997.

124. "The Diagnosis and Pharmacotherapy of Obsessive Compulsive Disorder," Grand Rounds, Department of Medicine, St. Mary Hospital, Hoboken, NJ, January 15, 1997.

125. "The Diagnosis and Treatment of Obsessive Compulsive Disorder," Grand Rounds, Department of Psychiatry, Monmouth Medical Center, Long Branch, NJ, January 23, 1997.

126. "The Diagnosis and Treatment of Depression in the Primary Care Setting," Grand Rounds, Department of Medicine, Helene Fuld Hospital, Trenton, NJ, January 24, 1997.

127. "The Diagnosis and Pharmacotherapy of Obsessive Compulsive Disorder," Grand Rounds, Department of Psychiatry, Cooper Hospital, Camden, NJ, January 24, 1997.

128. "Depression in the Elderly," Grand Rounds, Department of Medicine, Community Medical Center, Toms River, NJ, February 20, 1997.

129. "The Diagnosis and Pharmacotherapy of OCD," Grand Rounds, Belmont Behavioral Health, Albert Einstein Medical Center, Philadelphia, PA, March 3, 1997.

130. "Recent Advances in Pediatric Psychopharmacology," Connecticut Psychiatric Residents

Annual Meeting, Berlin, CT, March 12, 1997.

131. "Diagnosis, Treatment and Neuropsychopharmacology of Attention-Deficit Hyperactivity Disorder, Autism, and Pervasive Developmental Disorders," State of Connecticut, Department of Mental Retardation, North Central Region, Newington, CT, April 9, 1997.

132. "Recent Advances in the Neuropharmacology of Autism Spectrum Disorders," In Symposium, Behavioral Intervention in Autism: Stepping into the Future III, Foundation for Educating Children with Autism, Inc., Third Annual Conference for Parents, Educators and Professionals, Purchase College, Purchase, NY, April 12, 1997.

133. "The Diagnosis and Pharmacotherapy of Obsessive Compulsive Disorder," Grand Rounds, Department of Psychiatry, Newark Beth Israel Medical Center, Newark, NJ, April 23, 1997.

134. "The Diagnosis and Pharmacotherapy of Obsessive Compulsive Disorder," Grand Rounds, Department of Psychiatry, Elizabeth General Medical Center, Elizabeth, NJ, April 24, 1997.

135. "The Diagnosis and Pharmacotherapy of Obsessive Compulsive Disorder," Grand Rounds, Department of Psychiatry, Mount Carmel Guild Medical Center, Newark, NJ, April 24, 1997.

136. "The Diagnosis and Treatment of Obsessive Compulsive Disorder in the Primary Care Setting," Grand Rounds, Department of Medicine, Jersey Shore Medical Center, Neptune, NJ, April 29, 1997.

137. "Psychiatric Disorders in Adolescents," 1997 Charter Oak Conference, Connecticut Academy of Physician Assistants, Southbury, CT, May 1, 1997.

138. "The Treatment of Geriatric Depression," Grand Rounds, Eleanor Slater Hospital, Cranston, RI, May 22, 1997.

139. "The Diagnosis and Treatment of Depression in the Primary Care Setting," Grand Rounds, Department of Medicine, Nassau County Medical Center, East Meadow, NY, May 29, 1997.

140. “OCD Spectrum Disorders in Children and Adolescents,” Indiana Council of Child and Adolescent Psychiatry, Indianapolis, IN, October 23, 1997.

142. “The Diagnosis and Treatment of Depression and Anxiety in the Primary Care Setting,” Grand Rounds, Department of Medicine, DeKalb Hospital, Auburn, IN, March 31, 1998.

143. “The Diagnosis and Pharmacotherapy of Obsessive Compulsive Disorder,” Grand Rounds, Department of Psychiatry, Crownsville Hospital, Crownsville, MD, April 8, 1998.

144. “Obsessive Compulsive Disorder: A Disease Common in Private Practice,” Grand Rounds, Department of Medicine, Saint Joseph’s Medical Center, South Bend, IN, April 29, 1998.

145. “The Diagnosis and Pharmacotherapy of Obsessive Compulsive Disorder,” Grand Rounds, Department of Psychiatry, Park Center, Fort Wayne, IN, May 5, 1998.

146. “Autism,” In Symposium: Unlocking the Mysteries of Mental Health: From Research to Treatment, First Annual Indiana University Mental Health Symposium for Consumers and Professionals, Indiana University School of Medicine, Indianapolis, IN, June 10, 1998.

147. “The Diagnosis and Treatment of Autistic-Spectrum Disorders and Depression Disorders in Children and Adolescents,” 27th Annual Graduate Course in Pediatrics, James Whitcomb Riley Hospital for Children, Indianapolis, IN, July 15, 1998.

148. ”The Diagnosis and Pharmacotherapy of Obsessive Compulsive Disorder,” Mid-Town Mental Health Center, Indianapolis, IN, July 30, 1998.

149. ”The Diagnosis and Pharmacotherapy of Obsessive Compulsive Disorder,” Grand Rounds, Northcoast Behavioral Healthcare System, Northfield Campus, Ohio Department of Mental Health, Northfield, OH, September 11, 1998.

150. “The Diagnosis and Pharmacotherapy of Obsessive Compulsive Disorder,” Grand Rounds, Department of Psychiatry, Brecksville Veterans Administration MedicalCenter, Brecksville, OH, September 11, 1998.

151. “The Diagnosis and Treatment of Autism and Related Conditions,” Pediatric Lecture Series, Department of Pediatrics, Ball Memorial Hospital, Muncie, IN, September, 22, 1998.

152. “SSRIs in Neuropsychiatric Disorders, Grand Rounds, Department of Psychiatry, Behavior Corp, Carmel, IN, September 23, 1998.

153. “The Diagnosis and Treatment of Depression and Panic Disorder,” Grand Rounds, Department of Medicine, Lutheran Hospital, Ft. Wayne, IN, October 6, 1998.

154. “Panic Disorder and Obsessive Compulsive Disorder,” Grand Rounds, Department of Medicine, Home Hospital, Lafayette, IN, October 14, 1998.

155. “Depression,” Grand Rounds, Department of Medicine, Community Hospitals of Williams County, Bryan, OH, October 20, 1998.

156. “The Diagnosis and Treatment of Depression in the Primary Care Setting,” Grand Rounds, Department of Medicine, Parkview Hospital, Ft. Wayne, IN, October 20, 1998.

157. "Autism," Grand Rounds, Department of Medicine, Union Hospital, Terre Haute, IN, October 22, 1998.

158. "Pharmacotherapy of Anxiety Disorders," Grand Rounds, Department of Psychiatry, Marion Veterans Administration Medical Center, Marion, IN, October 28, 1998.

159. "The Diagnosis and Treatment of Anxiety Disorders in the Primary Care Setting," Grand Rounds, Department of Medicine, Ball Memorial Hospital, Muncie, IN, January 13, 1999.

160. "The Role of Atypical Antipsychotics in Non-Psychotic Disorders," Grand Rounds, Department of Psychiatry, Dover Community Mental Health Center, Dover, OH, January 19, 1999.

161. "Obsessive Compulsive Disorder in Children and Adolescents," Grand Rounds, Department of Psychiatry, Parkview Hospital, Ft. Wayne, IN, February 22, 1999.

162. "The Diagnosis and Pharmacotherapy of Obsessive Compulsive Disorder," Grand Rounds, Huron Valley Center, Ypsilanti, MI, March 12, 1999.

163. "The Diagnosis and Pharmacotherapy of Autistic-Spectrum Disorders," Central Indiana Branch, Autism Society of America, Indianapolis, IN, March 14, 1999.

164. "Child and Adolescent Obsessive Compulsive Disorder", Grand Rounds, Shoreline Behavioral Health, Toms River, NJ, March 17, 1999.

165. "The Use of Atypical Antipsychotics in Non-Psychotic Disorders," In Symposium, Contemporay Issues in Psychiatry, Huron Valley Center, Ypsilanti, MI, March 25, 1999.

166. "Child and Adolescent Depression and Anxiety Disorders," 34th Annual Indiana Multidisciplinary Child Care Conference, Indianapolis, IN, May 26, 1999.

167. "Diagnosis and Treatment of Autism and Other Pervasive Developmental Disorders," Grand Rounds, Mohawk Valley Psychiatric Center, Utica, NY, June 1, 1999.

168. "Diagnosis and Treatment of Obsessive-Compulsive Symptoms in Elderly Patients," Grand Rounds, Syracuse Veteran's Administration Medical Center, Syracuse, NY, June 2, 1999.

169. "The Diagnosis and Pharmacotherapy of Obsessive Compulsive Disorder," Central Branch-State of New York - American Psychiatric Association Meeting, Syracuse, NY, June 3, 1999.

170. "The Diagnosis and Treatment of Child and Adolescent Depression," Indiana Chapter of the American Academy of Pediatrics, Annual Presentations, Indianapolis, IN, June 8, 1999.

171. "The Diagnosis and Treatment of Mood and Anxiety Disorders in Adolescents," Grand

Rounds, Department of Medicine, St. Joseph's Hospital, Ft. Wayne, IN, June 16, 1999.

172. "The Diagnosis of Mood and Anxiety Disorders in the Primary Care Setting," Grand Rounds, Department of Medicine, Lutheran Hospital, Ft. Wayne, IN, August 31, 1999.

173. "The Diagnosis and Treatment of Depression and Panic Disorder in the Primary Care Setting," Grand Rounds, Department of Medicine, Reid Hospital, Richmond, IN, October 27, 1999.

174. "The Diagnosis and Pharmacotherapy of Autistic-Spectrum Disorders," Grand Rounds, Mt. Pleasant Center for Developmental Disabilities, Mt. Pleasant, MI, November 3, 1999.

175. "Treatment-Refractory Obsessive-Compulsive Disorder," Quarterly Meeting, Michigan Council of Child and Adolescent Psychiatry, Novi, MI, December 6, 1999.

176. "The Diagnosis and Treatment of Obsessive-Compulsive Disorder," Grand Rounds, Hawthorn Center, Northville, MI, December 8, 1999.

177. "Advancements in the Treatment of Depression," Howard County Medical Society Lecture Series, Kokomo, IN, January 4, 2000.

178. "The Role of Atypical Antipsychotics in Non-Psychotic Disorders," Midtown Mental Health Center, Indianapolis, IN, January 11, 2000.

179. "The Diagnosis and Treatment of Autism and Other Pervasive Developmental Disorders," Ft. Wayne Community School System, Department of Special Education, Ft. Wayne, IN, January 13, 2000.

180. "The Pharmacological Treatment of Aggressive Children with Conduct Disorder," Northwest Ohio Council of Child and Adolescent Psychiatry Quarterly Meeting, Toledo, OH, January 20, 2000.

181. "Pediatric Depression," Grand Rounds, Bloomington Hospital, Bloomington, IN, February 16, 2000.

182. "The Diagnosis of Autism and Other Pervasive Developmental Disorders," Psychiatry Residents' Forum, Erie County Medical Center, Buffalo, NY, March 8, 2000.

183. "Treatment of Children with Developmental Disorders," New York State Office of Mental Health, Spring Psychopharmacology Training Program, Albany, NY, March 27, 2000.

184. "Diagnosis and Treatment of Child and Adolescent Depression," In Symposium, The Mother and Child Continuum: Treatment of Depression, Four Winds-Saratoga Hospital, Saratoga Springs, NY, March 28, 2000.

185. "Psychopharmacology of Children and Adolescents," Grand Rounds, Department of Psychiatry, Lutheran General Hospital, Chicago, IL, April 12, 2000.

186. "The Diagnosis and Treatment of Mood and Anxiety Disorders in the Primary Care Setting," Grand Rounds, Department of Medicine, Columbus Regional Hospital, Columbus, IN, May 10, 2000.

187. "Autistic Characteristics in Individuals with Williams Syndrome," Driving Toward a Millennium of Endless Opportunities, Williams Syndrome Association, Convention 2000, Dearborn, MI, July 21, 2000.

188. "Medical Updates," NAMI Indiana 2000 State Conference and Annual Meeting, Mission Possible: Recovery, Reclaiming a Life, Larue D. Carter Memorial Hospital, Indianapolis, IN, September 16, 2000.

189. Program: "Fighting the Stigma of Mental Illness," National Mental Illness Awareness Week, Panel Member, Larue D. Carter Memorial Hospital, Indianapolis, IN, October 4, 2000.

190. "Psychopharmacology of Autism and Related Pervasive Developmental Disorders," Keynote Speaker, In The Autism Society of Indiana Annual Statewide Conference - "New Century, New Hope," Indianapolis, IN, November 3, 2000.

191. "The Diagnosis and Treatment of Depression and Anxiety Disorders in the Primary Care Setting," Grant County Medical Society, Marion, IN, November 28, 2000.

192. "Contemporary Issues in the Treatment of Depression and Anxiety Disorders," Grand Rounds, Marion Veteran's Administration Medical Center, Marion, IN, November 29, 2000.

193. "Chairman's Vision for the Department of Psychiatry at Indiana University School of Medicine," Indiana Psychiatric Society, Indianapolis, IN, February 15, 2001.

194. "Diagnosis and Pharmacotherapy of Mood and Anxiety Disorders in the Primary Care Setting," Grand Rounds, Terre Haute Regional Hospital, Terre Haute, IN, February 20, 2001.

195. "The Pharmacotherapy of Autism and Related Pervasive Developmental Disorders," In Conference, "The Road Less Traveled: Supporting Individuals With High-Functioning Autism and Asperger's," MAAP Services/Indiana Resource Center for Autism, Indianapolis, IN, April 6, 2001.

196. "An Update on Atypical Antipsychotics," Grand Rounds, Columbus Regional Hospital, Columbus, IN, May, 30, 2001.

197. "Recent Developments in Child Psychpharmacology," Fourth Annual Mental Health Symposium entitled "A New Century for Mental Health: Exploring the Brain, Treating the Person," Indiana University School of Medicine Department of Psychiatry and the Mental Health Association of Indiana, Inc., Indianapolis, IN, June 1, 2001.

198. "Update on the Management of Schizophrenia: New Therapeutic Options," Grand Rounds, Department of Internal Medicine, St. Vincent Hospital, Indianapolis, IN, June 19, 2001.

199. "Pharmacotherapy of Pervasive Developmental Disorders," Annual Pediatric Psychiatry Advisory Board, "Child and Adolescent Psychopharmacology: Planning for the Future," Janssen Pharmaceutica, New York, NY, June 21-22, 2001.

200. "Role of Atypical Antipsychotics in Non-Psychotic Disorders," Grand Rounds, Department of Psychiatry, Marion Veteran's Administration Medical Center, Marion, IN, July 17, 2001.

201. "Autism and Asperger's Disorder: An Update," State of Indiana Division of Mental Health and Addictions Children's Bureau Advisory Committee, Larue D. Carter Memorial Hospital, Indianapolis, IN, September 7, 2001.

202. "An Update on Autism," Premedical Arts Annual Lecture, Valparaiso University, Valparaiso, IN, October 12, 2001.

203. "The Diagnosis and Treatment of Mood and Anxiety Disorders in the Primary Care Setting," Carroll County Medical Society, Flora, IN, February 27, 2002.

204. "Autism, Target Symptoms, and Medication Treatment," 50th Year Anniversary Lecture, Gertrude A. Barber Center, Erie, PA, April 17, 2002.

205. "A Psychiatrist's Perspective on Dual Diagnosis," Workgroup on Dual Diagnosis, Division of Mental Health, State of Indiana, Indianapolis, IN, April 19, 2002.

206. "Treatment-Refractory Obsessive-Compulsive Disorder," St. Vincent-Mercy Medical Center, Department of Medicine, Residents' Lecture Series, Toledo, OH, April 23, 2002.

207. "The Diagnosis and Pharmacotherapy of Autism," Pittsburgh Regional Organization of Child and Adolescent Psychiatry, Pittsburgh, PA, June 24, 2002.

208. "Challenges in Diagnosing and Treating Children and Adolescents with Comorbid Mental Retardation and Mental Illness," Summer Quarterly Meeting and Child and Adolescent Conference, Indiana Council of Community Mental Health Centers, Inc. and Child and Adolescent Committee, Bloomington, IN, July 17, 2002.

209. "Practical Psychopharmacologic Treatment of Symptoms Associated with Autism," Champions and Challenges: 2002 National Conference on Autism Spectrum Disorders,

Autism Society of America, Indianapolis, IN, July 20, 2002.

210. "The Diagnosis and Treatment of Depression and Anxiety in the Primary Care Setting," Grant Rounds, Terre Haute Regional Hospital, Terre Haute, IN, August 20, 2002.

211. "The Diagnosis and Pharmacotherapy of Mood and Anxiety Disorders in the Primary Care Setting," Grand Rounds, Department of Medicine, Ball Memorial Hospital, Muncie, IN, March 12, 2003.

212. "The Diagnosis and Treatment of Mood and Anxiety Disorders in the Primary Care Setting," Connersville Medical Society, Connersville, IN, April 24, 2003.

213. "The Diagnosis and Pharmacotherapy of Mood and Anxiety Disorders," Purdue University Student Health Center, West Lafayette, IN, April 29, 2003.

214. "The Diagnosis and Pharmacotherapy of Autism and Other Pervasive Developmental Disorders," Grand Rounds, Howard Community Hospital, Kokomo, IN, May 12, 2003.

215. "The Diagnosis and Pharmacotherapy of Mood and Anxiety Disorders in the Primary Care Setting," Grand Rounds, Reid Hospital, Richmond, IN, May 14, 2003.

216. "The Diagnosis and Pharmacotherapy of Autism and Other Pervasive Developmental Disorders," Grand Rounds, Terre Haute Regional Hospital, Terre Haute, IN, August 19, 2003.

217. "The Diagnosis and Pharmacotherapy of Autism and Other Pervasive Developmental Disorders," Pediatric Conference, Lafayette Home Hospital, Lafayette, IN, August 23, 2003.

218. "The Pharmacotherapy of Treatment-Refractory Obsessive-Compulsive Disorder," Cherokee Mental Health Institute, Cherokee, IA, September 23, 2003.

219. "The Diagnosis and Pharmacotherapy of Autism and Other Pervasive Developmental Disorders," Broadlawns Mental Health Center, Des Moines, IA, September, 23, 2003.

220. "The Diagnosis and Pharmacotherapy of Mood and Anxiety Disorders," Richmond State Hospital, Richmond, IN, November 24, 2003.

221. "The Diagnosis and Pharmacotherapy of Autism," Grand Rounds, Reid Memorial Hospital, Richmond, IN, December 3, 2003.

222. "The Safety and Efficacy of Aripiprazole in Neuropsychiatric Disorders, Grand Rounds, Wabash Valley Hospital, Lafayette, IN, May 21, 2004.

223. "Pharmacological Management of Children and Adolescents with Autism," In Conference,

2nd Annual Child and Adolescent Psychiatry: The Place of Pharmacotherapy and Psychotherapy, Chicago, IL, May 22, 2004.

224. "The Safety and Efficacy of Aripiprazole in Neuropsychiatric Disorders, Grand Rounds, Richmond State Hospital, Richmond, IN, July 20, 2004.

225. "The Use of Medications for Interfering Symptoms in Individuals with Developmental Disabilities," Keynote Address, Symposium on Dual Diagnosis, Collaboration Across Systems: Promoting Mental Wellness in People with Developmental Disabilities, Indianapolis, IN, November 10, 2004.

226. "The Pharmacotherapy of Treatment-Refractory Obsessive-Compulsive Disorder," Grand Rounds, Memorial Hospital, South Bend, IN, March 9, 2005.

227. "The Diagnosis and Pharmacotherapy of Autism," Grand Rounds, Hawthorn Center, Northville, MI, March 16, 2005.

228. "Neurobiology and Treatment of Autism," In Symposium Current Issues in Psychiatry 2005, Arizona Psychiatric Society Annual Spring Meeting, Scottsdale, AZ, April 16, 2005.

229. "The Use of Medications for Interfering Symptoms in Individuals with Developmental Disabilities," In Symposium Dual Diagnosis as it Pertains to Promoting Mental Wellness in People with Developmental Disabilities, Easter Seals ARC of Northeast Indiana Conference, Ft. Wayne, IN, May 3, 2005.

230. "Pharmacological Management of Autism," In Third Annual Child and Adolescent Psychiatry Conference: The Place of Pharmacotherapy and Psychotherapy, Secaucus, NJ, May 6, 2005.

231. "Psychopharmacology of Autism,"Autism Treatment Network Emerging Medical Practices in Autism Care and Treatment (EMPACT) Conference, Chicago, IL, September 13, 2005.

232. "Pediatric Autism/PDD," Grand Rounds, Department of Pediatrics, Community Hospital, Munster, IN (Indiana University Visiting Professor Program), October 26, 2005.

233. "Autism: Diagnosis and Treatment," In, Eighth Annual Symposium: Mental Health Issues in Children and Adolescents, Macomb County Community Mental Health Services, Troy, MI, November 4, 2005.

234. "The Diagnosis and Pharmacotherapy of Autism," Grand Rounds, Columbus Regional Hospital, Columbus, IN, Indiana University Visiting Professor Program, November 9, 2005.

235. "The Diagnosis and Pharmacotherapy of Autism and Related Disorders," Lanterman

Developmental Center, Pomona, CA, May 23, 2006.

236. "The Diagnosis and Pharmacotherapy of Autism and Related Disorders", Fairview Developmental Center, Costa Mesa, CA, May 24, 2006.

237. "State of the Department Address," Department of Psychiatry, Indiana University School Of Medicine, Indianapolis, IN, June 9, 2006.

238. "The Diagnosis and Pharmacotherapy of Autism and Related Disorders," Grand Rounds, St. Joseph Hospital, Fort Wayne, IN (Indiana University Visiting Professor Program), January 17, 2007.

239. "The Diagnosis and Pharmacotherapy of Autism and Related Pervasive Developmental Disorders," Indiana Academy of Family Physicians Family Medicine Update, Indianapolis, IN, January 26, 2007.

240. "The Psychopharmacology of Autism and Related Disorders," In 6th Annual Alabama Autism Conference, Social Understanding in Autism and Asperger Syndrome, The University of Alabama and the Autism Society of Alabama, Tuscaloosa, AL, February 9, 2007.

241. "Pharmacological approaches to Treating Target Symptoms in Pervasive Developmental Disorders," In Conference, Caring Solutions for Adolescents: Improving Mental Health Care and Outcomes, Carrier Clinic, Bridgewater, NJ, March 9, 2007.

242. "The Management and Treatment of Adults with Autism," In Symposium, Autism Through the Lifespan, Sheppard Pratt Health System, Baltimore, MD, October 5-6, 2007.

243. "The Diagnosis and Pharmacotherapy of Autism and Other Pervasive Developmental Disorders," Grand Rounds, Department of Pediatrics, Community Hospital, Munster, IN (Indiana University Visiting Professor Program), October 24, 2007.

244. "An Update on the Indiana University School of Medicine Department of Psychiatry," Indiana Psychiatric Society, Indianapolis, IN, April 17, 2008.

245. "Autism," In Symposium The Spectrum of Mental Health Disorders, 11th Annual Mental Health Symposium, Department of Psychiatry, Indiana University School of Medicine and Mental Health America of Indiana, Indianapolis, IN, May 16, 2008.

246. "Atypical Antipsychotics in Children and Adolescents: An Evidence-Based Update," In Symposium, 1st Annual Chairs in Psychiatry Summit: The Master Class for Psychiatric Professional Development, Hilton Head Island, SC, June 29, 2008.

247. "Autism – What Is It and Is It Increasing?," Grand Rounds, Department of Medical Education, St. Francis Hospital and Health Centers, Indianapolis, IN (Indiana University

Visiting Professor Program), August 5, 2008.

248. National Alliance for Research on Schizophrenia and Depression, Healthy Minds Across America, Moderator, Department of Psychiatry, Indiana University School of Medicine, Indianapolis, IN, September 14, 2008.

249. "The Diagnosis and Pharmacotherapy of Autism," Pediatric Grand Rounds, Home Hospital, Lafayette, IN (Indiana University Visiting Professor Program), November 11, 2008.

250. "The Diagnosis and Pharmacotherapy of Autism," Grand Rounds, Bloomington Hospital, Bloomington, IN (Indiana University Visiting Professor Program), July 10, 2009.

251. "The Diagnosis and Pharmacotherapy of Autism," Riverview Hospital, Noblesville, IN (Indiana University Visiting Professor Program), March 23, 2010.

252. "The Diagnosis and Pharmacology of Autism," Grand Rounds, Hawthorne Center, Northville, MI, April 28, 2010.

253. "Update on Autism," Grand Rounds, Blanchard Valley Hospital, Findlay, OH, April 30, 2010.

254. National Alliance for Research on Schizophrenia and Depression, Healthy Minds Across America, "Diagnosis and Treatment of Autism," and Program Moderator, Department of Psychiatry, Indiana University School of Medicine, Indianapolis, IN, May 1, 2010.

255. "Practical Aspects of Medication Treatment in Autism," Kentucky Autism Training Center, College of Education and Human Development, University of Louisville, Louisville, KY, May 14, 2010.

256. "State of the Art Psychopharmacology for Persons with Dual Dianosis," Keynote Address in "Racing Toward Awareness," The 2nd Annual Dual Diagnosis Conference – ID: M4 Intellectual Disabilities: Mental Health Challenges, Indianapolis, IN, May 20, 2010.